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Abstract 
Thromboembolic disorders are a major cause of morbidity and mortality. Therapeutic 
intervention with anticoagulants and antiplatelets greatly reduces the risk of arterial and 
venous thrombosis. However, the observed large interindividual variation in responsiveness 
to these drugs indicates that subsets of patients are not attaining optimal therapy, resulting in 
either lack of antithrombotic effect or elevated bleeding risk. Recently, single nucleotide 
polymorphisms (SNPs) have been linked to the variation observed in efficacy and toxicity for 
many cardiovascular drugs.  
 
Warfarin has been the gold standard anticoagulant for prevention of stroke and 
thromboembolism in atrial fibrillation (AF) and venous thromboembolism (VTE) patients. 
SNPs in genes that affect warfarin metabolism (CYP2C9) and response (VKORC1) have an 
important influence on response and dose, particularly during initiation. Accordingly, we 
developed and evaluated the clinical utility of a pharmacogenetics-based initiation nomogram 
in AF and VTE patients which provides safe and optimal anticoagulation therapy irrespective 
of genetic variation.  
 
The new oral anticoagulant (NOAC) rivaroxaban is highly dependent on the kidney for 
elimination through glomerular filtration and active tubular secretion. Importantly, 
interindividual variation in exposure and response to rivaroxaban has been reported. Using 
cell-based and animal models, we demonstrated that rivaroxaban is a dual substrate of the 
 iii 
 
efflux transporters MDR1 and BCRP, which played a synergistic role in modulating 
rivaroxaban clearance and brain accumulation. The contribution of interindividual variation 
in transport and metabolism to the efficacy of rivaroxaban as well as other NOACs requires 
to be addressed in patients.   
 
Clopidogrel has been the gold standard antiplatelet for prevention of acute coronary 
syndromes and stent thrombosis following percutaneous coronary intervention. Two 
enzymes, CYP2C19 and PON1, have been proposed to affect clopidogrel bioactivation and 
efficacy. We showed that CYP2C19 but not PON1 is capable of bioactivating clopidogrel to 
its active metabolite. This is in line our finding that CYP2C19 genetic variation is a predictor 
of clopidogrel pharmacokinetics and antiplatelet response while PON1 is not.  
 
Taken together, these studies demonstrate the contribution of SNPs to the variation in 
efficacy and toxicity of cardiovascular drugs, enabling personalized medicine for patients, 
where an individual’s genetic makeup is used to guide drug selection and dosing.  
 
Keywords 
Oral anticoagulant therapy, antiplatelet therapy, warfarin, clopidogrel, rivaroxaban, 
cytochrome P450 enzymes, single nucleotide polymorphisms, pharmacogenomics, 
pharmacogenetics, metabolism, pharmacokinetics, pharmacodynamics, thromboembolic 
disorders, efflux drug transporters 
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1 THROMBOEMBOLIC DISORDERS: PATHOGENESIS 
AND RATIONALE FOR ANTICOAGULANT AND 
ANTIPLATELET THERAPY 
2 
 
 
1.1 Introduction 
Maintenance of blood fluidity within the vasculature is an important human physiological 
process. Under normal conditions, there is a fine equilibrium between pathological states 
of hypocoagulability and hypercoagulability. Hemostasis refers to a series of normal 
physiological processes that confine blood to the vascular spaces, maintain blood fluidity, 
and importantly, clot formation to limit hemorrhage following vascular injury. 
Thrombosis is pathological clot formation when hemostasis is inappropriately activated 
in the absence of a bleeding event. In the 1800s, Rudolf Virchow postulated a triad of 
causes for thrombosis formation: changes in the composition of blood, alterations in the 
vessel wall, and disruption of blood flow (1). Indeed, in the event of a vascular vessel 
injury, a sequence of events is generated in response: vessel constriction to reduce blood 
flow, hemostatic platelet plug formation at the trauma site following platelet adhesion, 
activation, and aggregation, formation of a fibrin clot to stabilize the platelet plug by 
activation of a series of proteins in the coagulation cascade. As such, a thrombus forms in 
the presence of alterations in the hemostatic system leading to inappropriate platelet 
aggregation and coagulation. A thrombus in a large blood vessel will decrease blood flow 
through that vessel while a thrombus in a small blood vessel may completely cut-off 
blood flow resulting in an occlusive thrombus. An embolism is the dislodging of the 
thrombus from the site of formation that travels to a distal vessel leading to blood flow 
blockage in a distant part of the body.  
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Thromboembolic disorders are a significant source of mortality and morbidity. There are 
two types of thrombosis, arterial and venous thrombosis, whereby the clinical and 
therapeutic management differs, reflecting the distinct pathogenesis of the two 
classifications. Arterial thrombosis usually occurs after the erosion or rupture of an 
atherosclerotic plaque, potentially leading to ischemic events. Cardiac ischemia and 
stroke are the most devastating clinical manifestations of atherothrombosis. Venous 
thromboembolism (VTE) is represented by two main manifestations, deep venous 
thrombosis (DVT) and pulmonary embolism (PE). The most devastating clinical 
consequence of VTE is PE where majority of PEs result from DVT that have dislodged 
from site of formation in the lower extremities and traveled to the pulmonary circulation. 
 
Understanding the pathogenic processes leading to either arterial or venous thrombosis is 
crucial for selecting effective and safe antithrombotic agents for management of patients 
with thromboembolic disorders. While arterial thrombosis undoubtedly involves the 
coagulation cascade, platelet activation and aggregation plays a more prominent role in 
the rapidly flowing arteries. As such, arterial thrombosis is often referred to as white clot, 
rich in platelets and little red blood cells. On the other hand, venous thrombosis is 
associated with venous stasis and hypercoagulability. Thus, the coagulation cascade plays 
a prominent role in formation of a venous thrombus, often referred to as red clot due to 
the abundance of red blood cells and little platelets.  
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1.2 Hemostasis  
The endothelium of blood vessel walls plays an important role in maintaining vasculature 
integrity. Vessel wall damage or disruption of the endothelium leads to exposing the 
collagen present in the subendothelial matrix, resulting in platelet activation, aggregation, 
and formation of a primary platelet plug. Concurrently, subendothelial tissue factor (TF) 
is also exposed on the damaged endothelium leading to activation of the coagulation 
cascade, resulting in formation of a fibrin mesh to stabilize the platelet plug  (2).  
 
1.2.1 Platelet activation 
Platelets are small disk shaped colorless cells present in the blood that play a vital role in 
hemostasis and are the key factor in the pathogenesis of arterial thrombosis. Vascular 
injury may cause the rupture of an atherosclerotic plaque and denudation of the 
endothelium (Figure 1.1). The exposure of subendothelial collagen bound to a protein 
known as von Willebrand factor (vWF) facilitates platelet adhesion to the vessel wall. At 
the site of injury, vWF binds platelets via the glycoprotein Ib/IX/V receptor complex on 
the platelet membrane (3). At low shear rates, platelets can also bind to subendothelial 
collagen through other receptors such as the glycoprotein IV, VI, and Ia/IIa. Upon 
adhering to the vessel wall, platelets release the granules of platelet agonist thromboxane 
A2 and adenosine diphosphate (ADP), initiating an autocrine/paracrine signaling cascade 
of platelet activation. Activated platelets undergo a change in morphology from smooth 
disks to irregular spheroids with filopodia, allowing platelets to bind to one another for 
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platelet aggregation. The formation of this hemostatic plug is essential for wound healing. 
However, formation of a thrombotic occlusion in coronary arteries can cause tissue 
ischemia leading to conditions known as acute coronary syndromes (ACS), in the form of 
either unstable angina or myocardial infarction (MI).  
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Figure 1.1 Schematic representation of arterial thrombosis. 
An atherosclerosis plaque develops through the accumulation of lipid deposits. The 
rupture of an atherosclerotic plaque is the primary trigger for arterial thrombosis by 
promoting platelet activation and fibrin generation.   
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1.2.2 Coagulation cascade 
The coagulation cascade plays a pivotal role in forming the fibrin mesh to reinforce the 
hemostatic platelet plug. The ultimate formation of fibrin is dependent on two distinct 
pathways: the extrinsic and intrinsic pathway. It was previously thought that both 
pathways were equally crucial to hemostasis. However, it is evident now that the 
extrinsic pathway is the predominant pathway for initiation and activation of the 
coagulation cascade during hemostasis and response to vascular injury. The intrinsic and 
extrinsic pathways are activated by distinct factors but merge into a common pathway to 
activate thrombin and form fibrin. The ultimate generation of fibrin is governed by 
initiation, amplification, and propagation of coagulation (4). The ability to form a fibrin 
clot is dependent on a series of serine proteases that are clotting factors and/or cofactors 
(Figure 1.2). These clotting factors are chronologically activated producing thrombin by 
stepwise activation of a series of proenzymes.  
 
During initiation phase, the extrinsic cascade is activated by tissue injury or trauma 
triggering the exposure of TF on subendothelial cells, an essential cofactor for factor VII 
(4). Activated factor VII, a serine protease will subsequently cleave factor X and factor V 
to Xa and Va, respectively, to combine with phospholipid and calcium to form the 
prothrombinase complex. The complex then cleaves a small amount of prothrombin 
(factor II) to active thrombin (factor IIa). In addition to activating platelets, this small 
amount of thrombin amplifies the coagulation reactions by positive feedback. Thrombin 
activates factor V and VIII on the platelet surface leading to a burst of activated clotting 
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factors ready to generate thrombin. On activated platelets, factor XIa activates IX to IXa, 
which forms the tenase complex with factor VIIIa to activate factor X. Finally, factor Xa 
and factor Va forms the prothrombinase complex in abundance to produce the thrombin 
burst. The propagation of thrombin generation converts fibrinogen to fibrin for forming 
the mesh.  
 
The intrinsic pathway begins with the formation of a primary complex of coagulation 
factors, including high molecular weight kininogen, prekallikrein, and factor XII, driven 
by the collagen exposed on the damaged blood vessel wall (4). Prekallikrein is converted 
to kallikrein and factor XII is activated to factor XIIa through a process called 
autoactivation, resulting in the activation of factor XI to factor XIa. Subsequently, factor 
XIa activates factor IX to factor IXa, which associates with factor VIIIa to form the 
tenase complex to activate factor X to factor Xa. Lastly, the intrinsic pathway merges 
with the extrinsic pathway in the common pathway where factor Xa activates 
prothrombin to thrombin to form fibrin. The minor role that the intrinsic pathway plays in 
hemostasis is evident in the fact that patients with deficiencies in primary proteins 
prekallikrein, high molecular weight kininogen, and factor XII do not have life-
threatening bleeding disorders. 
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Figure 1.2 Schematic representation of the coagulation cascade. 
The coagulation cascade can be activated by intrinsic and extrinsic factors to ultimately 
generate thrombin and fibrin.   
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1.3 Thrombosis 
1.3.1 Arterial thrombosis 
Arterial thrombosis (Table 1.1) typically occurs in conjunction with vascular 
abnormalities that are the result of atherosclerosis (buildup of cholesterol and fatty 
plaques on the inner walls of arteries), leading to coronary artery disease (CAD). ACS 
reflects the clinical manifestations attributed to CAD, thrombus formation, and occlusion 
of the coronary arteries. It has been suggested that thrombotic coronary occlusion 
accounts for 50 - 70% of sudden deaths caused by ischemic heart disease (5). The three 
types of ACS are unstable angina, non-ST segment elevation MI (NSTEMI), and ST 
segment elevation MI (STEMI). An arterial thrombus that is fibrin-rich is often fully 
occlusive, results in STEMI as characterized by clinically significant changes on an 
electrocardiogram (ECG). Platelet-rich thrombus is likely partially occlusive, resulting in 
unstable angina and NSTEMI, with little change on an ECG. Antiplatelet therapy is the 
primary therapy for prevention of ACS recurrence.  
 
1.3.2 Atrial fibrillation  
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting a significant 
portion of the elderly population. Statistics show that there are currently 5.2 million 
individuals with AF in North America and this number is expected to increase 
substantially by 2050 as a consequence of the aging population (6). The incidence of AF 
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increases from 2.3% among individuals over age 40 to 5.9% among individuals over 65. 
The most devastating complication of AF is stroke, resulting from cardioembolization to 
the central nervous system. In all age groups of AF patients, the incidence of stroke is 
increased by four to five fold with a high mortality rate (7). Furthermore, stroke risk may 
increase up to seven fold in presence of additional risk factors such as hypertension, 
diabetes, and heart failure.  
 
The pathophysiology of AF is such that the abnormal electrical charges from the atria 
reduce the ability to pump blood into the ventricles resulting in stagnant blood flow 
particularly in the left atrial appendage. The stasis in this area in individuals with 
prolonged or insufficiently treated AF is a significant contributing factor to thrombus 
formation. Indeed, more than 90% of the thrombi associated with nonvalvular AF 
(absence of mitral valve disease) have been found in the left appendage (8). Emboli 
carried away from thrombus formation site to the brain cerebral vessels may result in an 
ischemic stroke or a transient ischemic attack (TIA).  
 
AF has been associated with markers of coagulation and platelet activation that reflects 
its hypercoagulable state. It has been shown that both vWF and TF are overexpressed in 
the atrial endothelium of AF patients (9). Based on available evidence, pathogenesis of 
thromboembolism in AF patients follows Virchow’s triad for thrombogenesis (9). 
Although a thrombus formed in the left atrial appendage is considered as an arterial 
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thrombus, the characteristics of an AF thrombus appear to be more similar to a venous 
clot. Therefore, anticoagulation therapy is recommended as the primary therapy for 
stroke risk reduction.  
 
CHADS2 Score 
The risk of stroke in AF patients is compounded with co-existing risk factors. The 
CHADS2 score is a clinical prediction tool for estimating the risk of stroke in patients 
with nonvalvular AF, where the annual stroke risk significantly increases in individuals 
with higher CHADS2 scores (10). This system also allows for determining the 
recommended treatment regimen, in terms of whether to initiate therapy with an 
antiplatelet or oral anticoagulant. Components of the CHADS2 score include congestive 
heart failure, hypertension, age ≥ 75, diabetes, and prior history of stroke or TIA (Table 
1.3.2).  
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Table 1.3.1 Risk factor and characteristic differences between arterial thrombosis 
and venous thrombosis. 
Arterial Thrombosis Venous Thrombosis 
Artery Vein 
Atherosclerosis Stasis 
Underlying cardiovascular disease Irregular thrombin generation 
Platelet rich Red blood cell rich 
Platelet aggregation dominates Coagulation cascade dominates 
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Table 1.3.2 CHADS2 scoring system for determining stroke risk in atrial fibrillation 
patients. 
Condition Points 
C Congestive heart failure 1 
H Hypertension 1 
A Age ≥ 75 1 
D Diabetes mellitus  1 
S2 Prior stroke or transient ischemic attack 2 
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1.3.3 Percutaneous coronary intervention 
Percutaneous coronary intervention (PCI) is often part of the standard of care for ACS 
patients, particularly those presented with STEMI or NSTEMI. The PCI procedure has 
evolved dramatically since its introduction with bare-metal stents (BMS) to the 
availability of drug-eluting stents (DES). The development of DES was to incorporate the 
release of pharmacological agents in the stent design to inhibit responses to injury, a 
primary contributor to restenosis after BMS implantation (11). However, although 
restenosis rates are evidently reduced with DES, stent thrombosis (ST) rate has not 
decreased. ST is the sudden occlusion of a stented coronary artery as a result of thrombus 
formation, a severe complication after implantation owing to its high mortality (12). A 
number of trials have observed occurrence of acute, subacute, and late ST following DES 
implantation, and the rate is suspected to be substantially greater in the real-world 
population (12). Moreover, ST as long as three years after stent implantation has been 
noted with DES, which was rarely seen with BMS.  
 
The pathogenesis of ST has not been completely delineated; however, factors increasing 
risk of ST include the procedure itself, patient and lesion characteristics, and premature 
cessfation of antiplatelet drugs (13). Stent implantation itself induces platelet adhesion 
and activation of the coagulation cascade, as it is the introduction of a foreign object in 
the vessel wall. DES were developed to prevent restenosis by reducing vascular smooth 
muscle cell proliferation and migration (13). However, they also impair 
reendothelialization, which prolong arterial healing and in fact, have been found to 
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induce TF expression and thereby thrombogenesis (14). Lastly, DES impair the 
endothelial function of coronary arteries, promoting risk of ischemia and coronary 
occlusion (13).   
 
1.3.4 Venous thrombosis 
In contrast to arterial thrombosis, venous thrombosis is typically not associated with 
underlying vascular pathology (Table 1.3.1). VTE comprises of DVT and PE; DVT 
occurs most often in the large veins of the lower extremities and when part of the 
thrombus dislodges, the embolism can travel to the lungs to block blood flow to the 
pulmonary artery resulting in PE. Venous stasis is an important risk factor for VTE by 
promoting thrombus formation with reduced ability to clear activated coagulation factors 
away from the site of injury (15). In fact, majority of venous thrombi is formed in regions 
of slow blood flow (15). Stasis may be caused by immobility, orthopaedic surgery, and 
increased venous pressure. Overall, prolonged impairment of venous function, sustained 
hypercoagulability, and imbalance in the endogenous anticoagulant and fibrinolytic 
systems all contribute to the risk of developing a clinically significant thrombus.  
 
As previously noted, venous thrombi mostly consist of red blood cells and fibrin and 
activation of the coagulation cascade is the primary contributor to venous thrombosis. 
Thus, anticoagulant therapy is the primary therapy for prevention and management of 
VTE.  
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1.4 Therapeutic interventions  
1.4.1 Oral anticoagulant therapy 
For many decades, the vitamin K antagonist warfarin has been the gold standard of 
therapy for prevention of ischemic stroke in AF patients. The mechanism of action of 
warfarin is inhibition of vitamin K dependent clotting factor (II, VII, IX, X) activation in 
the liver. In 1994, it was demonstrated in a group 3,692 patients that warfarin treatment 
reduced stroke risk by 68% compared to individuals without treatment, along with 
minimal bleeding risk (16). Indeed, pooled-analysis of six large randomized clinical trials 
(RCTs) comparing aspirin with warfarin demonstrated superiority of warfarin in 
reduction of ischemic stroke rate compared to aspirin (17). Furthermore, a meta-analysis 
of 29 trials incorporating 28,044 AF patients demonstrated that warfarin improved the 
incidence of stroke outcomes by 40% compared to antiplatelet therapy (18).   
 
Anticoagulation therapy is also crucial for prevention of recurrent DVT and PE. Oral 
anticoagulant therapy with warfarin has been the mainstay of long-term treatment and 
prophylaxis of VTE (19). However, warfarin has an indirect pharmacological mode of 
action whereby it inhibits the vitamin K epoxide reductase (VKOR) enzyme to prevent 
the formation of coagulation factors in the liver (20). Thus, the onset of warfarin’s 
anticoagulation activity is typically delayed up to 48 hours following initiation. In the 
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setting of VTE, immediate anticoagulantion is necessary for minimizing risk of 
recurrence. Accordingly, subcutaneous low-molecular-weight heparin (factor Xa 
inhibitor) is the anticoagulant of choice to be used concurrently with warfarin during the 
initial days of overlapping therapy.  
 
We note here that although warfarin has been the gold standard of therapy for the past 60 
years, its shortcomings (including the wide interindividual variation in responsiveness 
and the need to titrate dose to therapeutic response using continuous monitoring) have led 
to the development and market approval of several new oral anticoagulants. These new 
agents exert therapeutic efficacy by directly inhibiting the coagulation cascade in the 
systemic circulation. The new oral anticoagulants include direct thrombin inhibitors such 
as dabigatran, and factor Xa inhibitors such as rivaroxaban and apixaban. The clinical 
implications of the new agents to oral anticoagulation therapy will be discussed in the 
forthcoming chapters. 
  
1.4.2 Antiplatelet therapy 
Antiplatelet therapy has emerged as a major success in reducing the risk for MI 
associated with CAD. Currently, dual antiplatelet therapy with clopidogrel and aspirin is 
the mainstay of therapy for prevention of recurrent cardiovascular events in patients with 
ACS, and prevention of ST following PCI (21). The rationale for the dual therapy is to 
block two important pathways involved in platelet aggregation. Clopidogrel is a 
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thienopyridine drug, which inhibits ADP-mediated platelet activation by irreversibly 
binding to P2Y12 G-protein coupled receptors on platelets (22). Aspirin exerts its 
antiplatelet effect by inhibiting the activity of cyclooxygenase-1 (COX-1), preventing the 
production of thromboxane A2 from arachidonic acid (22). Dual antiplatelet therapy has 
been demonstrated to be effective in reducing arterial thrombosis and ischemic events in 
large RCTs such as CURE and PCI-CURE (23, 24).  
 
1.5 Conclusions 
Thromboembolic disorders are major causes of morbidity and mortality. Failure to 
provide optimal therapeutic intervention to reduce risks of stroke, ACS, and recurrent 
VTE will undoubtedly be a significant health burden. As outlined earlier, the therapeutic 
treatment of thromboembolic disorders heavily depends on the pathogenesis of the 
disease. In conditions of high blood flow (arterial thrombosis), the dominant role of 
platelets in the formation of a thrombus is the basis for use of antiplatelets in primary 
treatment. On the other hand, the coagulation cascade plays a more prominent role in low 
blood flow conditions (venous thrombosis) and anticoagulant therapy is more 
appropriate. However, review of hemostasis demonstrates that platelet activation and 
coagulation cascade play a synergistic role in thromboembolic events. Accordingly, 
combination therapy with anticoagulants and antiplatelets cannot be ruled out for better 
prevention of thromboembolic events compared to each therapy alone for high-risk 
patients. Finally, it is important to note that antithrombotic therapy represents a double-
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edged sword such that greater prevention of thrombosis is also associated with greater 
risk of bleeding. Thus, delivering optimal antithrombotic therapy to individual patients at 
risk for thrombosis will not only augment therapeutic prevention of thromboembolic 
events but also minimize drug-related hemorrhagic risk.    
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2 PHARMACOGENETIC ADVANCES IN 
CARDIOVASCULAR MEDICINE: RELEVANCE TO 
PERSONALIZED MEDICINE1 
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2.1 Introduction 
Clinical trials have clearly demonstrated the therapeutic benefit for many cardiovascular 
agents; however, some patients, even on the same dose, exhibit loss of efficacy or higher 
risk of toxicity. We know that while an average dose of a medication can benefit a large 
proportion of the patient population, the one-size-fits-all dosing regimen disregards the 
importance of identified variation in drug metabolism, transport, and response pathways 
known to exist in any given population. Not surprisingly, preventable adverse drug 
reactions (ADRs) often occur in subsets of susceptible patients. Interindividual 
differences in drug response are multifactorial and may be explained by an array of 
factors including environmental, genetic, comorbidities, and drug-drug interactions.  
 
Advances in the field of pharmacogenetics over the past decade have dramatically 
improved our understanding of the impact of genetic variability to observed variation in 
drug response and toxicity. Accordingly, we now have the capability to use an individual 
genetic makeup in combination with clinical variables to choose appropriate drug therapy 
and dosages in an a priori fashion. Therefore, the field of pharmacogenetics has 
significant implication for optimizing cardiovascular drug therapy, considering the large 
proportion of patients with cardiovascular disease requiring pharmacotherapy.  
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Associations of genetic variations with drug response largely fall within two categories 
(Figure 2.1): and polymorphisms that affect drug pharmacokinetics by introducing 
variability in systemic drug exposure; polymorphisms that affect pharmacodynamics by 
affecting the drug’s ability to act at the target site. Not surprisingly, for the most part, 
candidate gene approaches have been used to identify single nucleotide polymorphisms 
(SNPs) in genes suspected to influence variation in response. On the other hand, genome-
wide association studies (GWAS) for drug response represent an unbiased screen across 
the entire genome and may inform novel pathways of relevance to ADRs or therapeutic 
response.  
 
We now see a number of pharmacogenetic linkages for a number of medications, some of 
which have resulted in FDA label changes to incorporate guidance on consideration of 
genetic information during treatment. The present review highlights the genetic 
determinants of commonly used cardiovascular drugs (Table 2.1), and how the use of 
such information may enhance patient care in a clinical setting. 
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Figure 2.1 Pharmacogenetic determinants of interindividual variability in 
cardiovascular therapy. 
Genetic variability in drug transporter and metabolizing enzymes expressed at the level of 
enterocytes and hepatocytes affect pharmacokinetics and overall disposition. Genetic 
variability in the gene(s) encoding the drug’s pharmacological target affects 
pharmacodynamics. Identified genetic variants confer altered drug sensitivity, response 
and toxicity, allowing classification of patients as responders or nonresponders. 
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Table 2.1.1 Summary of current evidence in cardiovascular pharmacogenetics. 
Drug 
Drug 
Class 
Description Gene(s) Catego
ry 
Problem 
Clinical 
Implementa
tion 
Warfarin 
Anti-
coagula
nt 
Variation in 
dose 
requirement 
for achieving 
and 
maintaining 
INR in 
therapeutic 
range 
CYP2C9, 
VKORC1 
PK, PD 
CYP2C9*2, 
CYP2C9*3, 
VKORC1 -
1639G>A 
carriers 
have 
increased 
sensitivity 
to warfarin 
Dose 
reduction for 
loss-of-
function 
variant 
carriers 
Clopido
grel 
Anti-
platelet 
Variation in 
antiplatelet 
response 
leading to 
resistance in 
a subset of 
patients 
CYP2C19 PK 
CYP2C19*
2 and 
CYP2C19*
3 carriers 
have 
insufficient 
active 
metabolite 
formation 
leading to 
resistance 
Dose 
increase or 
consider 
newer 
antiplatelet 
agents for 
loss-of-
function 
variant 
carriers 
CYP, cytochrome P450; PD, pharmacodynamics; PK, pharmacokinetics; VKORC1, 
vitamin K epoxide reductase subunit 1. 
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2.2 Oral Anticoagulants 
2.2.1 Warfarin 
The vitamin K antagonist warfarin is a common oral anticoagulant prescribed in North 
America for stroke prevention in atrial fibrillation (AF) patients and thromboembolism 
prophylaxis in venous thromboembolism (VTE) (1). However, warfarin therapy is 
particularly challenging due to marked and often unpredictable interindividual dosing 
variation (up to 20-fold) to reach and maintain adequate anticoagulation. Not 
surprisingly, its clinical use is associated with ADRs, mainly in the form of bleeding 
events; in fact, warfarin was recently reported to account for one-third of hospitalizations 
in the elderly (2). For most indications, optimal warfarin therapy is achieved by 
maintaining the international normalized ratio (INR) within a narrow therapeutic range of 
2-3. An insufficient warfarin dose leads to a lack of antithrombotic effect while over-
anticoagulation is associated with elevated bleeding risk. Aside from demographic (age, 
gender, weight) and clinical variables (renal or hepatic disease, diet, drug-drug 
interactions), pharmacogenetics explains a large portion of the observed variability in 
warfarin dose requirement (3).  
 
2.2.1.1 CYP2C9  
Warfarin is administered as a racemic drug; S-warfarin is 3-5 times more potent than R-
warfarin. The clearance and thus pharmacokinetics of warfarin is largely dependent on 
the metabolic pathways of each enantiomer. While CYP1A2, CYP3A4, and CYP2C19 
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are enzymes that convert the R-warfarin to its inactive metabolite in varying extents, 
CYP2C9 is the primary enzyme responsible for metabolism of S-warfarin. As such, 
candidate gene studies have consistently shown that CYP2C9 polymorphisms 
significantly affect warfarin sensitivity (4). In particular, common CYP2C9*2 and *3 
variant alleles result in decreased enzymatic activity (30 and 90 % reduction, 
respectively) compared to the wild-type allele (5). The clinical implication for these 
SNPs is lower therapeutic dose requirement, increased time to stable anticoagulation and 
increased bleeding risk due to greater rate of over-anticoagulation (6). A large meta-
analysis of 39 studies (n = 7,907) demonstrated that maintenance dose for CYP2C9*2 and 
*3 homozygous patients were 36 and 78 % lower, respectively, as compared to wild-type 
patients (7).  
 
2.2.1.2 VKORC1  
S-warfarin inhibits the vitamin K epoxide reductase, encoded by VKORC1, the enzyme 
responsible for recycling oxidized vitamin K to the reduced form, an essential cofactor 
for γ-glutamyl-carboxylase carboxylation (GGCX) in clotting factor II, VII, IX and X 
activation (8). Common genetic variants in VKORC1 result in altered warfarin sensitivity 
while rare polymorphisms result in warfarin resistance (9). Of note, the common 
promoter SNP (VKORC1 -1639G>A, rs9923231) is thought to be the causative variation 
responsible for the greater warfarin sensitivity, resulting in lowered dose requirement 
(10). 
 
31 
 
 
2.2.1.3 Other SNPs  
In addition to CYP2C9 and VKORC1 polymorphisms, SNPs in other genes have been 
studied as potential contributors to warfarin response. These genes include GGCX, 
calumenin (CALU), apolipoprotein E (ApoE) as well as multidrug resistance protein 
(ABCB1) (11). However, the impact of these polymorphisms on warfarin response has 
generally been minimal or none at all.  An exception to this is the growing importance of 
the CYP4F2 1297C>T genotype, whereby several retrospective studies have 
demonstrated that variant T carriers (rs2108622) require 1 mg more than wild-type C 
carriers (12). Moreover, CYP4F2 is the metabolizing enzyme of vitamin K accounting for 
the pharmacological basis of the dose difference (13). However, CYP4F2 genotype only 
accounts for a small portion of the observed maintenance dose variability (0-4%) (14). 
These findings were confirmed by recent GWASs, where polymorphisms in CYP2C9 and 
VKORC1 were the only genetic markers identified to influence warfarin dosing, while the 
CYP4F2 genotype was only significant after adjusting for CYP2C9 and VKORC1 (15).  
 
2.2.1.4 Clinical Applicability of SNPs  
CYP2C9*2, CYP2C9*3 and VKORC1 -1639G>A variant carriers are at an increased risk 
of over anticoagulation (INR > 4) and bleeding as well as delayed time to therapeutic 
efficacy. Based on these findings, the FDA approved a new label for warfarin in 2007 
advising physicians to consider pharmacogenetic testing for patients requiring warfarin. 
Many dosing algorithms have been developed to predict warfarin dose requirement using 
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CYP2C9, VKORC1, and CYP4F2 SNPs and clinical parameters (16). The majority of 
these studies have focused on the effect of genetic variation on warfarin dose during 
maintenance phase of anticoagulation. However, warfarin initiation is arguably the most 
challenging therapeutic phase where risk of hemorrhage and recurrent VTE are greatest 
(17). Moreover, we and others demonstrated that CYP2C9 and VKORC1 modulate 
wafarin response even during early anticoagulation (18).  
 
2.2.1.5 Clinical Implementation 
There is a strong association between CYP2C9 and VKORC1 SNPs with warfarin 
response and dose. However, the widespread use of pharmacogenetics-based warfarin 
dosing remains has not yet been achieved, in part related to concerns regarding costs 
associated with pharmacogenetic testing and additional clinical evidence to support 
superiority of a pharmacogenetics-based approach. Recently, the COUMAGEN-II trial 
showed clear superiority of pharmacogenetics-based warfarin dosing over standard care 
with respective to time spent in therapeutic range and reduced occurrence of ADRs (19). 
Additionally, a recent large scale community-based study found that genotyping during 
warfarin therapy reduced the hospitalization rate for bleeding or thromboembolic event 
by 30 % compared to a historical control group (20). A number of RCTs 
(www.clinicaltrials.gov; COAG, GIFT, EU-PACT) involving larger sample sizes are 
currently underway to more fully confirm such findings focusing on safety and efficacy 
of pharmacogenetics-based dosing compared to standard dosing. Given the extent of 
supportive evidence to date for warfarin, pharmacogenetics-based warfarin dosing is 
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likely to be widely implemented, particularly given the rapid improvement in genotyping 
technologies that has resulted in greater accuracy, turn-around time, and lower cost.  
 
2.2.2 New oral anticoagulants: dabigatran, rivaroxaban, and 
apixaban 
Dabigatran, a direct thrombin inhibitor, and factor Xa inhibitors rivaroxaban and 
apixaban, are new oral anticoagulants recently approved for AF and VTE. Dabigatran 
etexilate is a pro-drug, requiring bioactivation to active dabigatran by esterases while 
rivaroxaban undergoes metabolism predominantly by CYP2J2 and CYP3A4 (21). 
Interestingly, all agents are substrates of P-glycoprotein (ABCB1) while rivaroxaban and 
apixaban are also substrates of breast cancer resistance protein (BCRP) (22). Very 
recently, a genome-wide subanalysis of the RE-LY trial demonstrated that a common 
variant in the carboxylesterase 1 (CES1) gene (rs2244613) was associated with 
dabigatran-related bleeding events. The polymorphism is thought to attenuate dabigatran 
formation resulting in lowered systemic exposure and reduced bleeding risk, indicating 
the potential for pharmacogenetics-based dosing. Further studies are needed to confirm 
these findings in addition to identification of additional genetic variations in candidate 
genes such as ABCB1 and BCRP to determine SNPs capable of modulating the efficacy 
and toxicity of these new agents. 
 
34 
 
 
2.3 Antiplatelets 
2.3.1 Aspirin 
Aspirin is commonly prescribed for prevention of cardiovascular events. Aspirin 
irreversibly binds and inactivates cyclooxygenase (COX) 1 and 2 in platelets, and thereby 
reduce platelet aggregation (23). The term of aspirin resistance has been coined to note 
the occurrence of cardiovascular events, presumably related to suboptimal antiplatelet 
inhibitory effect in patients prescribed with therapeutic doses of aspirin. However, 
classification of aspirin resistance has been highly controversial with prevalence of 5 – 60 
% depending on the population and ex vivo response measurement used; a patient defined 
as a non-responder in one test would be normal in another (24). Therefore, it has been 
challenging to interpret the relevance of genetic markers associated with aspirin response. 
 
2.3.1.1 PTGS1  
Since COX1 is the direct pharmacological target of aspirin, considerable amount of focus 
has been on the COX1 encoding gene, PTGS1. However, results of such studies have 
been variable. Although genetic polymorphisms in this gene have been linked to greater 
platelet aggregation in some studies, many others failed to replicate such an effect or find 
an association with cardiovascular events such as myocardial infarction (MI) (25).  
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2.3.1.2 Other SNPs 
Several other genes encoding platelet activation pathway proteins have been linked to 
aspirin antiplatelet response. The ITGB3 gene encodes GPIIIa protein and carriers of the 
risk allele (rs5918) appear to confer elevated risk of MI, arterial and venous thrombosis. 
However, other studies in this regard have been conflicting (25). A recent study found 
carriers of an intronic SNP in the PEAR1 gene (rs12041331) corresponded to higher 
aspirin response (26). Additionally, a SNP in the LPA gene (rs3798220) determined 
plasma levels of apolipoprotein A and associated with differential aspirin efficacy in a 
large placebo-controlled trial (27).  
 
2.3.1.3 Clinical Implementation 
The extent of clinically relevant genetic markers and their role to aspirin response remain 
to be defined. The lack of consistent associations indicates it may be premature to include 
genetic testing for aspirin therapy, at least based on currently published genetic markers. 
It addition, a key impediment has been the lack of a standardized antiplatelet response 
measurement assay for aspirin prescribed patients.  
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2.3.2 Clopidogrel 
Antiplatelet therapy with thienopyridine is an important therapeutic intervention for the 
prevention of ischemic events in patients with high-risk cardiovascular disease, 
particularly for those undergoing percutaneous coronary intervention (PCI) (28). 
Clopidogrel is the most widely prescribed thienopyridine known to exert its 
pharmacological effect by irreversibly binding to P2Y12 receptors on platelets, thereby 
diminishing platelet aggregation (29). Although benefits from clopidogrel has been 
widely documented in large clinical trials, marked interpatient variation in platelet 
responsiveness has meant that 21 % of patients (termed nonresponders) remain at risk for 
coronary artery and stent thrombosis (30).  
 
2.3.2.1 CYP2C19 
Clopidogrel is a prodrug and its clinical efficacy is a function of the amount of 
enzymatically derived active thiol metabolite formed (H4) (31). While most of the 
prodrug undergoes hydrolysis to an inactive metabolite, clopidogrel bioactivation is a 
two-step process catalyzed by several CYP isozymes (32). Both metabolic steps leading 
to H4 formation have been shown to be predominantly dependent on CYP2C19, and to a 
lesser extent CYP3A4 (32).  
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A number of studies have examined the influence of genetic variation in CYP enzymes 
on clopidogrel antiplatelet response. The most consistent finding is that CYP2C19*2 
(rs4244285) and CYP2C19*3 (rs4986893) loss-of-function SNPs results in lower platelet 
inhibition, high on-treatment platelet reactivity and consequently, an increased risk of 
major cardiovascular events, particularly stent thrombosis in PCI patients (33). A meta-
analysis including nine studies (n = 9,685) reported a gene-dose effect for variant 
carriers; one reduced function allele carrier had a hazard ratio of 1.57 (95 % confidence 
interval, 1.13-2.16) for a composite of cardiovascular endpoints while carriers of two 
reduced function alleles had an even greater risk (hazard ratio 1.76, 1.24-2.5) (33). 
Another common CYP2C19 polymorphism (*17, rs3758581) results in increased enzyme 
activity, greater efficacy, and better cardiovascular outcomes at the expense of increased 
bleeding risk (34). These findings prompted the FDA to update the clopidogrel label with 
a boxed warning for cautious use amongst CYP2C19 reduced function carriers. 
 
2.3.2.2 ABCB1 
Clopidogrel has been demonstrated to be a substrate of P-glycoprotein, which limits the 
extent of its bioavailability. Not surprisingly, the ABCB1 3435C>T SNP (rs1045642) has 
been shown to result in lower peak concentrations of clopidogrel and its active metabolite 
(35). However, the definitive role of this SNP on clopidogrel antiplatelet response 
remains controversial. While Mega et al. reported that the elevated cardiovascular risk of 
CYP2C19 variant allele carriers was accentuated in presence of homozygous 3435C>T 
genotype, other studies could not replicate this finding (36, 37).  
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2.3.2.3 P2Y12 
Clopidogrel exerts its pharmacodynamics effects by inhibition of P2Y12 receptor on 
platelets. Recently, Ziegler et al. reported a fourfold increase in cerebrovascular events in 
patients possessing the 34C>T (rs6809699) variant while another variant, 52G>T 
(rs6785930), confers clopidogrel resistance following PCI (38). However, other studies 
have failed to show the same trend for antiplatelet response and cardiovascular events 
(39).  
 
2.3.2.4 Other SNPs  
CYP2C19 undoubtedly predicts cardiovascular outcomes in patients treated with 
clopidogrel following PCI, yet it is thought to represent only a portion of the observed 
variation in antiplatelet response. A GWAS demonstrated that clopidogrel platelet 
aggregation was highly heritable (r2 = 0.73) in an Amish population (40). However, the 
CYP2C19*2 SNP only accounted for 12 % of the interindividual variation, indicating that 
other genetic markers affecting efficacy remain to be identified to explain the large 
heritable component of clopidogrel response. More recently, the Scripps Clinic conducted 
whole genome sequencing in 392 patients on clopidogrel and found two novel genes 
ATP2B2 and TIAM2 to predict poor platelet response (unpublished data).  
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2.3.2.5 Clinical Implementation  
Clopidogrel resistance and the lack of adequate therapeutic efficacy is a major concern, 
thus identification of resistant patients prior to treatment is of great value for favorable 
outcomes. Although there is ample evidence linking CYP2C19 with cardiovascular 
outcomes in PCI patients, RCTs assessing the benefit of genotyping for CYP2C19 over 
standard care has yet to be conducted. One recent RCT using point-of-care CYP2C19*2 
genotyping showed that such genetic information led to better prediction of antiplatelet 
response in a real world setting, indicating that personalized clopidogrel therapy may be 
effective in improving efficacy (41). Accordingly, a number of institutions (Vanderbilt 
University Medical Centre, Scripps Clinic) adopted routine CYP2C19 genotyping for 
patients undergoing PCI (42). Conversely, although several small prospective trials have 
restored diminished H4 exposure and poor antiplatelet response in CYP2C19 variant 
carriers by increasing clopidogrel loading and maintenance dose (43), recent larger 
studies failed to overcome the reduced antiplatelet response in individuals harboring 
CYP2C19*2 variant alleles (44). This indicates that clopidogrel potency at the P2Y212 
receptor is likely inadequate for CYP2C19 variant carriers. Accordingly, the Clinical 
Pharmacogenetics Implementation Consortium suggested that newer antiplatelet agents 
with greater affinity and potency (prasugrel and ticagrelor) should be considered for 
carriers of one or two loss-of-function variant alleles (45). Indeed, CYP2C19*2 carriers 
were more likely to switch to prasugrel due to high on-treatment platelet reactivity (46). 
Current ongoing studies include the GIANT trial which will assess the clinical efficacy of 
using high-dose clopidogrel for CYP2C19*2 carriers and the RAPID-STEMI trial that 
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will evaluate efficacy of either high-dose clopidogrel or switching to prasugrel for 
CYP2C19*2 and ABCB1 3435TT carriers. 
 
2.3.2.6 New Antiplatelets: Prasugrel and Ticagrelor 
Neither agents require extensive bioactivation by CYP2C19. Thus, CYP2C19 genetic 
variation has not been demonstrated to affect cardiovascular outcomes in subanalysis of 
the TRITON-TIMI (prasugrel) or the PLATO (ticagrelor) trial (47). However, we note 
that CYP3A4 and CYP2B6 are responsible for bioactivation of prasugrel to its active 
form, and the influence of polymorphisms in these enzymes to prasugrel platelet efficacy 
remains to be delineated. An important consideration of prasugrel use over clopidogrel is 
that, although it proved more efficacious than clopidogrel, this is at the price of increased 
bleeding risk. Similarly, ticagrelor use over clopidogrel is complicated by the finding that 
ticagrelor was as effect as clopidogrel across all international centres of PLATO trial 
except for North America. 
 
2.4 Conclusions 
Interindividual variation in drug exposure and efficacy lead to subsets of patients 
experiencing drug-related toxicities or inadequate therapeutic benefit. The one-dose-fits-
all paradigm for drug therapy is increasingly recognized as inappropriate for many drugs 
in clinical use. Alternative paradigm for pharmacotherapy pertains to individualized 
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therapies. In the past decade, substantial progress has been made linking commonly 
occurring genetic variants to cardiovascular treatment response. Despite this, 
pharmacogenetics-guided care is still in its infancy, as most centres have not 
implemented this approach to routine clinical practice. However, as the cost of 
genotyping continues to decline while the extent of clinical evidence supporting 
pharmacogenetics-based approach rises, there is little doubt that implementation of 
pharmacogenetics-guided personalized medicine will result in reduced incidence of 
ADRs, and greater likelihood of therapeutic benefit. Indeed, for drugs where 
pharmacogenetics-guided care has been shown to be noninferior, and potentially superior 
to standard care, such an approach should be implemented and further studied in a 
prospective fashion to show the overall merit of pharmacogenetics to enhancing patient 
care, reducing ADRs and health care costs in the real-world setting. We also recognize 
that, for many drugs, clinical decision support algorithms that integrate patient-specific 
pharmacogenetic data along with environmental and clinical variables will be essential to 
realizing the promise of personalized medicine.  
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3 SPECIFIC AIMS AND HYPOTHESES 
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3.1 Specific aim 1 
1. To develop a novel pharmacogenetics-based initiation protocol that incorporates 
loading and maintenance doses calculated based on individual patient genetics, 
clinical variables, and anticoagulation response.  
2. To evaluate the clinical utility of the novel initiation protocol in a prospective 
cohort of atrial fibrillation (AF) and venous thromboembolism (VTE) patients. 
 
Variable warfarin response poses a significant challenge to providing optimal 
anticoagulation therapy. Single nucleotide polymorphisms in genes that affect warfarin 
metabolism (cytochrome P450 2C9 gene, CYP2C9) and response (vitamin K epoxide 
reductase complex 1 gene, VKORC1) have an important influence on warfarin 
responsiveness, particularly during initiation. A number of algorithms have been 
proposed which incorporate genetics as well as clinical parameters to predict 
individualized maintenance dose with the intent of improving warfarin anticoagulation 
therapy (1-3). However, there is a paucity of information with respect to optimal 
pharmacogenetics-based warfarin initiation, arguably the most clinically challenging 
therapeutic phase where the risk of haemorrhage and recurrent thromboembolism is 
greatest (4-7). Accordingly, the use of a pharmacogenetics-based warfarin initiation 
algorithm may prove useful in maximizing therapeutic efficacy while minimizing 
bleeding risk during this critical period by diminishing interindividual variation in 
response.  
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We hypothesized that the use of a novel pharmacogenetics-based dosing algorithm 
for initiating patients requiring new anticoagulation therapy should effectively 
eliminate genotype-driven differences in anticoagulation response to provide a safe, 
rapid, and uniform anticoagulation response in AF and VTE patients. To test this 
hypothesis, we conducted a prospective cohort study in which patients requiring warfarin 
therapy for AF or VTE were initiated with a novel pharmacogenetics-initiation protocol 
(WRAPID, Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing) that 
incorporates loading and maintenance doses based on genetics, clinical variables, and 
response (n = 167, followed up for 90 days), to assess the influence of genetic variations 
on anticoagulation responses. As described in Chapter Four, application of the WRAPID 
algorithm resulted in negligible influence of genetic variation in VKORC1 or CYP2C9 on 
time to achievement of therapeutic response as measured by international normalized 
ratio (INR), risk of overanticoagulation, and time to stable anticoagulation. Overall, we 
demonstrate the clinical utility of genetics-guided warfarin initiation with the WRAPID 
protocol to provide safe and optimal anticoagulation therapy for patients with AF or 
VTE. 
 
3.2 Specific aim 2 
To elucidate the genetic and nongenetic determinants of interindividual variability 
in warfarin pharmacokinetics and pharmacodynamic responses.  
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Many of the factors influencing the required warfarin maintenance dose such as age, 
body surface area, drug interactions and importantly, CYP2C9 genotype relate to their 
effects on S-warfarin pharmacokinetic (PK) parameters, such as volume of distribution 
and clearance (1, 8-10). However, the influence of genetics and clinical parameters on S-
warfarin pharmacodynamics (PD) variability is less clear.  
 
We hypothesized that genetic variation in CYP2C9 and VKORC1, as well as clinical 
variables contribute to interindividual variation in warfarin PK and PD 
parameters. To test this hypothesis, we investigated the determinants of warfarin 
kinetics and responses during initiation of warfarin therapy in the cohort of 167 patients. 
During the first nine days of treatment with pharmacogenetics-guided dosing, S-warfarin 
plasma levels and INR were obtained to serve as inputs to a pharmacokinetic-
pharmacodynamic (PK-PD) model. Individual patient PK (S-warfarin clearance) and PD 
(Imax) parameter values were estimated. As described in Chapter Five, regression analysis 
demonstrated that CYP2C9 genotype, kidney function, and gender were independent 
determinants of S-warfarin clearance while the estimated Imax variability was dependent 
on VKORC1 and CYP4F2 genotypes, vitamin K status, indication for warfarin, and 
weight.  
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3.3 Specific aim 3 
To determine the efflux transporters expressed at the apical side of renal tubular 
cells capable of secreting rivaroxaban into the urine.   
 
Rivaroxaban is a new oral anticoagulant (factor Xa inhibitor), recently approved for the 
treatment and prevention of thromboembolic diseases. However, adverse events 
associated with its use, namely bleeding risk, continue to be an important concern, 
particularly in patients with renal impairment. Rivaroxaban disposition is governed by 
hepatic metabolism and renal excretion, whereby 30-40% of the administered 
rivaroxaban is excreted unchanged through the kidney via a combination of glomerular 
filtration and active tubular secretion. The renal excretion is greater than glomerular 
filtration rate, suggesting a significant contribution of active transport processes to 
rivaroxaban elimination (11). Indeed, tubular secretion is the predominant pathway as the 
ratio of active tubular secretion to glomerular filtration of unchanged rivaroxaban was 
estimated to be 4-to-1 in a population pharmacokinetics model (11). Furthermore, there 
has been a growing appreciation of drug transporters expressed in various tissues in 
determining the disposition and excretion of a wide range of clinically used drugs.  
 
We hypothesized that the efflux transporters P-glycoprotein (MDR1) and breast 
cancer resistance protein (BCRP) are capable of transporting rivaroxaban and 
contribute to the overall disposition of rivaroxaban. As described in Chapter Six, the 
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ability of MDR1 and BCRP efflux transporters to mediate rivaroxaban transport in vitro 
was assessed in polarized cell monolayers. Indeed, rivaroxaban is a shared substrate of 
MDR1 and BCRP. Following oral administration of rivaroxaban (2 mg/kg), plasma 
concentrations did not significantly differ between wild-type and Mdr1adef or Bcrp-/- mice 
(n = 6 per group). However, rivaroxaban clearance was significantly reduced in 
Mdr1a/Mdr1b-/-/Bcrp-/- mice. Interestingly, rivaroxaban brain to plasma ratio did not 
differ in mice lacking only Mdr1a or Bcrp, but was more than two times higher in the 
Mdr1a/Mdr1b-/-/Bcrp-/- mice. Our results demonstrate that MDR1 and BCRP function 
synergistically to modulate rivaroxaban disposition and appear to be particularly relevant 
to limiting its central nervous system entry. As clinically relevant polymorphisms exist in 
both MDR1 and BCRP, genetic variations in these efflux transporters may play an 
important role in determining rivaroxaban exposure and anticoagulation efficacy.  
 
 
3.4 Specific aim 4 
To systematically elucidate the mechanism and relative contribution of PON1 in 
comparison to CYP2C19 to clopidogrel bioactivation and antiplatelet response.  
 
The marked interindividual variation in clopidogrel antiplatelet responsiveness results in 
a subset of patients at sustained risk for atherothrombosis. It is thought that antiplatelet 
response to clopidogrel is highly heritable, but the precise genetic determinants of its 
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metabolism and response remain controversial. Polymorphisms in cytochrome P450 
2C19 (CYP2C19) have been correlated with clopidogrel antiplatelet response and clinical 
outcomes in a number of cohort studies and clinical trials, accounting for 12% of 
interindividual variation. However, a recent study challenged this notion by proposing 
CYP2C19 as wholly irrelevant, while identifying paraoxonase-1 (PON1) and its Q192R 
polymorphism as the major driver of clopidogrel bioactivation and efficacy. Given the 
breadth of data supporting the importance of CYP2C19 to clopidogrel bioactivation and 
clinical outcomes, additional studies are required to evaluate the validity and relevance of 
these findings.  
 
We hypothesized that both CYP2C19 and PON1 contribute to clopiodgrel 
metabolism and antiplatelet response at varying extents.  To test this hypothesis, we 
administered a single 75 mg dose of clopidogrel to a cohort of healthy subject (n = 21) 
and assessed the influence of CYP2C19 and PON1 polymorphisms and plasma 
paraoxonase activity on clopidogrel active metabolite (H4) plasma levels and antiplatelet 
response. As described in Chapter Seven, CYP2C19 but not PON1 genotype was 
predictive of H4 levels and antiplatelet response. Moreover, metabolic profiling of 
clopidogrel in vitro confirmed the role of CYP2C19 in bioactivating clopidogrel to H4. 
Conversely, PON1 cannot generate H4, but mediates the formation of another thiol 
metabolite, termed Endo. Our results demonstrate that PON1 does not contribute to 
clopidogrel active metabolite formation or antiplatelet action, while CYP2C19 activity 
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and genotype remains a predictor of clopidogrel pharmacokinetics and antiplatelet 
response. 
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4 PROSPECTIVE EVALUATION OF A 
PHARMACOGENETICS-GUIDED WARFARIN 
LOADING AND MAINTENANCE DOSE REGIMEN 
FOR INITIATION OF THERAPY2
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4.1 Introduction  
The vitamin K antagonist warfarin is an oral anticoagulant commonly prescribed in North 
America to treat venous thromboembolism (VTE) and decrease the risk of stroke in atrial 
fibrillation (AF) (1). Warfarin therapy is challenging because of marked and often 
unpredictable interindividual dosing variation to reach and maintain adequate 
anticoagulation. For most indications, optimal warfarin therapy is achieved by 
maintaining the international normalized ratio (INR) within a narrow therapeutic range of 
2.0 to 3.0. An insufficient warfarin dose leads to a lack of antithrombotic effect, whereas 
overanticoagulation is associated with elevated bleeding risk (2).   
 
Although warfarin has been in use for the past 60 years, genetic control of warfarin 
response has only recently been appreciated (3). In this regard, among the most studied 
genetic determinants are the single-nucleotide polymorphisms (SNPs) in genes that 
encode cytochrome P450 2C9 (CYP2C9) (4), and vitamin K epoxide reductase complex 
subunit 1 (VKORC1) (5, 6). CYP2C9 is the primary enzyme responsible for metabolism 
of the active S-enantiomer of warfarin, and its polymorphisms contribute significantly to 
variability in warfarin response (7). Possession of the common CYP2C9*2 (c.430C>T, 
rs1799853) and *3 (c.1075A>C, rs1057910) variant alleles results in lower dose 
requirement, increased time to stability and a higher risk of overanticoagulation (8). 
VKORC1 is the target of warfarin that recycles oxidized vitamin K to the reduced form, 
an essential cofactor for activation of clotting factors II, VII, IX, and X, through γ-
glutamyl carboxylation (9). Harboring common genetic variants of VKORC1, such as the 
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functional promoter SNP -1639G>A (rs9923231), results in enhanced warfarin 
sensitivity, whereas rare mutations have been linked to warfarin resistance (5, 6, 10). In 
addition to VKORC1 and CYP2C9 polymorphisms, several studies have reported 
recently that a functional SNP in CYP4F2 (c.1297G>A, rs2108622), the metabolizing 
enzyme for vitamin K (11), also determines warfarin dose requirement (12).  
 
Since the Food and Drug Administration revised the label for warfarin to note the 
importance of VKORC1 and CYP2C9 polymorphisms (13), several groups have 
proposed genotype-guided maintenance dose algorithms that incorporate both genetics 
and demographic parameters, such as age, weight, and body surface area (14, 15). 
However, there is a paucity of information with respect to dosing during warfarin 
initiation, arguably the most clinically challenging therapeutic phase, during which the 
risk of hemorrhage and recurrent thromboembolism is greatest (16, 17). Standardized 
loading dose nomograms developed to date have not considered genetics and other 
patient-specific characteristics and have not been applied to indications other than VTE, 
such as AF (18-20). We and others have recently shown that VKORC1 and CYP2C9 
genetic variations modulate early and stable response to warfarin during initiation when 
dosing by traditional means is used (21-24). Thus, in the present, a novel and practical 
VKORC1- and CYP2C9-based loading and maintenance dose algorithm (WRAPID, 
Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing protocol) was 
developed and evaluated in AF and VTE patients with the aim of providing a safe, rapid, 
and uniform anticoagulation response. 
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4.2 Experimental Section 
4.2.1 Study sample and eligibility 
This was a prospective cohort study of outpatients conducted at the London Health 
Sciences Center (LHSC) and The Ottawa Hospital (TOH). The study was approved by 
research ethics boards at both institutions. Patients requiring initiation of warfarin therapy 
were screened for eligibility. The requirement for warfarin therapy was determined on the 
basis of current American College of Chest Physicians guidelines (1). Patients who met 
the eligibility criteria were enrolled on provision of written informed consent in 
accordance with the Declaration of Helsinki. Table 4.1 summarizes patient 
characteristics.  
 
Study eligibility was determined by the following inclusion criteria: (1) at least 18 years 
of age, and (2) indication for new warfarin therapy for at least 3 months with a target INR 
range of 2.0 to 3.0. Exclusion criteria were diagnosis of cancer other than nonmelanoma 
skin cancer, alcohol or drug abuse, baseline INR > 1.4, known warfarin 
allergy/intolerance, terminal disease, prior use of warfarin therapy or vitamin K within 2 
weeks before study enrolment, and known or suspected pregnancy.  
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Table 4.2.1 Patient characteristics (n=167). 
Demographics 
 
 
Age, y 60 ± 17 
 
Sex, male/female, n 96/74 
 
Weight, kg 84 ± 19 
 
Height, cm 171 ± 10 
Ethnicity 
 
 
White 159 (95.2) 
 
Black 4 (2.4) 
 
Asian 3 (1.8) 
 
Other 1 (0.6) 
Prescribed medication 
 
 
Amiodarone 2 (1.2) 
 
Statins 45 (26.9) 
 
Antiplatelets 55 (32.9) 
 
Antibiotics 6 (3.6) 
 
Antifungals 1 (0.6) 
 
NSAIDs 12 (7.2) 
Indication for warfarin 
 
 
Atrial fibrillation  61 (36.6) 
 
Deep vein thrombosis  77 (46.1) 
 
Pulmonary embolism  21 (12.6) 
 
Other  8 (4.7) 
Prescribed warfarin dose  
 
 
Mean maintenance dose (mg/day)  5.54 
CYP2C9  
 
*1/*1 119 (71.3) 
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*1/*2 29 (17.4) 
 
*1/*3 14 (8.4) 
 
*2/*2 3 (1.7) 
 
*2/*3 2 (1.2) 
 
*3/*3 0 
VKORC1 -1639  
 G/G 66 (39.5) 
 G/A 75 (44.9) 
 A/A 26 (15.6) 
CYP4F2 c.1297  
 G/G 80 (48.6) 
 G/A 68 (40.7) 
 A/A 19 (11.3) 
Values are mean ± SD or n (%), unless otherwise indicated. 
NSAIDs indicates nonsteroidal anti-inflammatory drugs. 
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4.2.2 Clinical data collection and follow-up  
Demographic information was obtained at the time of enrolment. Therapy related 
information was collected by patient interview and review of medical records. A baseline 
venous blood sample was obtained for DNA extraction and assessment of INR. 
Subsequent INR measurements, dose adjustments, adverse events, and therapy-related 
interventions were recorded at both study sites. The study period was September 2008 to 
August 2010.  
 
4.2.3 Genotyping 
Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit 
according to the manufacturer’s protocol (Qiagen, Alameda, CA). Genotype analysis 
included CYP2C9*2, CYP2C9*3, VKORC1 -1639G>A and CYP4F2 c.1297G>A. At 
LHSC, genotypes were determined by allelic discrimination with TaqMan drug 
metabolism genotyping
 
assays using the 7500 RT-PCR System (assay IDs: 
C__25625805_10, C__27104892_10, C__1329189_10, C__16179493_40; Applied 
Biosystems, Foster City, CA). At TOH Research Institute, genotypes were determined 
with the Luminex 200 system (Luminex Corp). Briefly, forward and reverse primers for 
SNPs of interest were designed to amplify regions surrounding each SNP by standard 
multiplex PCR protocols. The PCR products were then hybridized with appropriate 
xMAP carboxylated microspheres at 52°C, followed by analysis with the Luminex 200. 
Genotyping was generally performed within 24 hours of receiving the baseline blood 
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sample and used prospectively to determine individualized initiation doses before 
warfarin commencement for all study subjects. 
 
4.2.4 Mathematical foundation for a novel pharmacogenetics-
based initiation protocol 
Using historical datasets compiled from Vanderbilt University (n = 297) (24) and TOH (n 
= 63) (25), we developed a pharmacogenetics-based initiation protocol aimed at 
providing a uniform anticoagulation response among all patients. The dosing regimen 
comprises of both a loading and maintenance dose algorithm. Development of the 
loading and maintenance dose algorithms required the integration of pharmacokinetic 
(PK) and pharmacodynamic (PD) factors to predict the time-course of warfarin plasma 
levels and response.  
 
In this mechanistic model, the plasma PK of warfarin was described with a simple 1-
compartment model for warfarin distribution of a set volume (V). The time course of 
estimated plasma S-warfarin concentration (Cplasma) arose from the interplay between 
drug absorption in the gut (ka) and drug elimination via CYP2C9 metabolism (ke). Values 
for kinetic parameters for S-warfarin were obtained from the literature (26-29). Warfarin 
metabolism capacity (ke) is mainly dependent on CYP2C9 genotype; thus, the values for 
ke were adjusted based on reported clearance reductions in heterozygous and 
homozygous variant allele carriers of either CYP2C9*2 or *3 (29). The pooling of 
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genotypes into 3 subgroups was performed because of the lack of confidence in the 
accuracy of limited available clearance
 
rates reported in literature for the CYP2C9*2/*2, 
*2/*3, and *3/*3 genotype groups as a result of low allelic frequencies (29).  
 
Warfarin PD was described by an indirect response model that incorporates the known 
delay and magnitude of anticoagulation effects after achieving the required plasma 
concentration (30). In this model, the degree of suppression of vitamin K-dependent 
clotting factor production is related to the effectiveness of warfarin concentrations to 
inhibit vitamin K epoxide reductase. Here, the rate of change in INR is modeled with 
zero-order input (K) and first-order output (ko) variables. Plasma warfarin levels dictate 
the inhibition of output response according to classic competitive enzyme inhibition 
kinetics described by the parameters Imax (enzyme content and intrinsic activity) and IC50 
(drug affinity) (31). Imax values corresponding to VKORC1 genotypes were determined 
on simulation of maintenance drug administration to stable therapeutic coagulation. 
Depiction and parameters of the PK-PD model are shown in supplemental material, 
Figure 4.5.  
 
The PK-PD model and corresponding parameter values presented here are preliminary 
and served only to guide the establishment of a practical WRAPID dosing protocol for 
various VKORC1 and CYP2C9 genotype combinations. A finalized version of the PK-
PD model with data-derived parameter values based on formal modeling of R/S-warfarin 
concentrations and INR measurements obtained in this patient cohort, along with 
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identification of key nongenetic and genetic determinants of warfarin kinetics and 
responses, will be published elsewhere.  
 
4.2.5 Loading doses 
Practical (5, 7.5, and 10 mg) daily loading doses were prescribed for 2 days and were 
dependent on VKORC1 and CYP2C9 genotypes (Table 4.2).  These doses were used to 
obtain sufficient warfarin plasma concentrations to reach and maintain optimal 
anticoagulation response (INR 2.0 – 3.0) with similar rapid initial time-course for all 
genotype groups (supplemental material, Figure 4.6).  
 
4.2.6 Maintenance doses 
To obtain the maintenance dose, key patient clinical parameters that are known to 
influence warfarin dose requirement along with genetics were combined in a generalized 
linear regression model (Table 4.3). Briefly, warfarin dose was the dependent variable, 
the VKORC1 and CYP2C9 genetics-based dose was a constant variable (Table 4.4), and 
coefficients of independent variables were varied according to the least-squares linear 
regression method.  
 
After the 2-day loading dose, patients were prescribed the calculated maintenance dose to 
begin on day 3. On 3 occasions within the first 9 days of therapy (initiation), INR 
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measurements were obtained (typically days 3, 5/6 and 7/8/9), because this frequency of 
INR measurements has been shown to be practical and efficacious for anticoagulation 
management (19). When the INR response at each measurement did not conform to the 
predicted trajectory based on the mathematical model, the daily maintenance dose was 
further adjusted according to a treatment day specific dose adjustment nomogram (Table 
4.5). Adjusted doses were rounded to either the nearest whole number or 0.5.  
 
To make dosing practical, we devised an automated dose calculator for the initiation 
phase (supplemental material, Figure 4.7). After initiation, dosing was adjusted by 
pharmacists at both centers on the basis of a standardized post initiation nomogram. Once 
patients had obtained 2 therapeutic INRs, dosing was assisted by Dawn AC 
anticoagulation software (4-S Information Systems Ltd). 
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Table 4.2.2 Pharmacogenetics-based loading dose grid according to VKORC1 and 
CYP2C9 genotype. 
VKORC1 
CYP2C9 
*1/*1 *1/*2 or *1/*3 *2/*2, *2/*3, *3/*3 
G/G 10 mg* 10 mg* 7.5 mg† 
G/A 10 mg* 7.5 mg† 5 mg† 
A/A 5 mg† 5 mg† 5 mg† 
Loading doses are in milligrams. 
* Loading dose was adjusted to 7.5 mg for patients with weight < 60 kg. 
† Loading dose was decreased by 2.5 mg for patients with weight < 45 kg. 
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Table 4.2.3 Final multiple linear regression for estimation of maintenance dose. 
Predictor Variable B Standard 
error 
P in final model 
Intercept -1.46 1.23 0.235 
Weight (kg) 0.06 0.01 <0.0001 
Genetics-based dose grid  
(Table 4.4) 
1 - <0.0001 
Age, y -0.05 0.01 <0.0001 
Sex, female -0.90 0.34 <0.01 
Amiodarone use, yes -1.97 1.1 0.07 
CYP4F2 c.1297G>A, per allele 0.33 0.25 0.199 
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Table 4.2.4 Genetics-dependent dose grid for maintenance dose regression. 
VKORC1 
CYP2C9 
*1/*1 *1/*2 or *1/*3 *2/*2, *2/*3, *3/*3 
G/G 7 mg 5 mg 3.5 mg 
G/A 5 mg 4 mg 2.5 mg 
A/A 3.5 mg 2.5 mg 1.5 mg 
Doses are in milligrams. 
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Table 4.2.5 Dose adjustment nomogram during initiation. 
 
INR Warfarin dose adjustment 
Day 3 <1.3 ↑ 10% 
 
1.3 – 1.5 No change 
 
1.6 – 1.8 ↓ 10% 
 
1.9 - 2.1 ↓ 20% 
 
2.2 – 2.5 ↓ 50% 
 
> 2.5 Hold dose for 1 day, then ↓ 50% 
Day 5/6 <1.3 ↑ 50% 
 
1.4– 1.7 ↑ 20% 
 
1.8 – 2.5 No change 
 
2.6 – 3.0 ↓ 20% 
 
3.1 – 3.9 ↓ 50% 
 
≥ 4.0 Hold dose for 1 day, then ↓ 50% 
Day 7/8/9 <1.5 ↑ 20% 
 
1.5– 1.9 ↑ 10% 
 
2.0 – 2.8 No change 
 
2.9 – 3.5 ↓ 10% 
 
3.6 – 4.0 Hold dose for 1 day, then ↓ 15% 
 
≥ 4.0 
Hold dose, test INR daily until in range (2.0-3.0),  then 
↓ 25% 
↑ indicates increase; and ↓, decrease. 
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4.2.7 Refinement of loading and maintenance dose algorithm 
It was our objective to refine the loading and maintenance dose algorithm after 
monitoring an initial cohort of patients (n = 87) for application in a final cohort. After the 
initial cohort, we observed a disproportionate number of out-of-range INR responses in 
those patients with a high loading dose-to-weight ratio. Thus, we modified the loading 
dose algorithm to consider weight after the first cohort. For patients who weighed 60 kg 
who had been given a 10 mg load according to the original loading algorithm, we 
decreased the dose to 7.5 mg. For patients who weighed 45 kg, all loading doses were 
decreased by 2.5 mg (7.5 - 5 mg, and 5 mg - 2.5 mg).  
 
Planned optimization of the maintenance dose regression was performed by slight 
modification of the contribution of clinical parameters to dose, whereas the impact of 
VKORC1 and CYP2C9 remained unchanged. In univariate analysis, we observed a 
significant relationship between CYP4F2 c.1297G>A genotype and dose, in which A/A 
carriers required a 1 mg higher warfarin dose than the wild-type group (P < 0.05). Thus, 
we included CYP4F2 genotype in the final regression model to determine maintenance 
doses of the final cohort.  
 
4.2.8 Sample size  
The WRAPID study was powered to assess the effect of VKORC1 -1639G>A genotype 
on anticoagulation response, after pharmacogenetics-guided initiation. A study size of 
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150 patients was estimated to have 80% power to detect a response hazard of 2 at a 2-
sided significance level of 0.05, which allowed for a dropout rate of 10%. A hazard ratio 
(HR) of 2 was chosen on the basis of previously published VKORC1-carrier status 
hazard risk for primary outcomes.(24) Power analysis was performed with SAS Version 
9.2 (SAS Institute). 
 
4.2.9 Primary and secondary outcomes 
The primary outcomes of the present study were time to first therapeutic INR and time to 
first overanticoagulation (INR ≥ 4). We choose these primary outcomes because they are 
critical markers of anticoagulation pace and quality of control. Therapeutic INR was 
defined as 2.0 – 3.0 for all patients. 
 
Secondary outcomes were time to first stable anticoagulation, time spent in therapeutic 
range, and time spent above therapeutic range during the first 30 days (prestabilization 
phase) and after 30 days (stabilization phase). Stable anticoagulation was defined as 2 
consecutive in-range INRs, at least 7 days apart, with no dose adjustments. For estimation 
of time spent in or out of range, we adopted the Rosendaal linear interpolation method to 
calculate the percentage of time each patient spent within and out of the therapeutic range 
(32). The difference between one INR value and the subsequent INR value was divided 
by the number of days elapsed between the 2 measurements to produce the average daily 
increment or decrement of INR.  
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Additional secondary outcomes included percentage of patients within range during 
initiation, percentage of patients with an INR ≥ 5, percentage of time spent above INR ≥ 
4, percentage of time spent in therapeutic range, and extended therapeutic range (1.8 - 
3.2), as well as average maintenance dose.  
 
The outcomes were selected to assess the influence of VKORC1 genotype on 
anticoagulation response. Although the present study was not powered to evaluate the 
individual effects of CYP2C9*2 and *3 genotypes on response, analysis was conducted 
to compare wild-type and any CYP2C9 variant-carrier status.  
 
4.2.10 Statistical analysis 
Patients were divided into 3 groups for VKORC1 and 2 groups for CYP2C9: VKORC1 
wild-type, heterozygous, and homozygous carriers of -1639G>A; CYP2C9 wild-type 
(*1/*1) and a CYP2C9 variant group that included 1 or 2 variant allele carriers (*1/*2, 
*1/*3; *2/*2, *3/*3 or *2/*3). Hardy-Weinberg equilibrium was assessed for each 
genotype with the chi-square goodness-of-fit test.   
 
The influence of VKORC1 and CYP2C9 genotype on the primary outcomes was 
evaluated with survival analysis techniques. Kaplan-Meier plots were used to depict the 
proportion of subjects without events over time. Comparison between survival curves 
was conducted by the log-rank test. Unadjusted HR and its 95% confidence interval (CI) 
between genotype groups were computed. The Cox proportional hazard model was 
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adopted to adjust for potential confounding effects of age, sex, weight, warfarin dose, 
amiodarone use, indication, patient cohort, and VKORC1, CYP2C9 and CYP4F2 
genotype to obtain adjusted HRs and their 95% CIs. For comparison of differences in 
outcomes between patients with various VKORC1 statuses, G/G genotype was 
considered as the reference group, because it is the most warfarin-resistant group. 
Statistical analysis of Schoenfeld residuals and visual inspection of log-minus-log plots 
revealed no significant variation from the proportional hazards assumption. 
 
Percentages of time spent in therapeutic range and time spent above the therapeutic range 
were compared among VKORC1 and CYP2C9 genotype groups with the use of Kruskal-
Wallis test followed by Tukey-Kramer posttest or Mann-Whitney test, as appropriate.  
 
All enrolled patients (initial and second cohort) were included for outcome analysis to 
obtain at least 80% power to detect the association of VKORC1 genotype and response. 
This was acceptable because there were no statistical differences between the 2 cohorts 
with respect to primary outcomes of time to first therapeutic INR and time to first INR ≥ 
4. In addition, potential variations between cohorts because of dosing-regimen 
modifications were accounted for as a confounding variable in the Cox regression 
analysis of primary survival data and should not interfere with assessment of genetic 
variation effects on rate of INR anticoagulation responses. Because no significant 
differences were observed between the initial and second cohorts for secondary 
outcomes, both patient groups were combined for secondary analysis.     
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To assess and compare the predictability of our dosing model, we determined the 
association between maintenance dose and model-derived dose. The proportion of 
variance explained was calculated as the R2 statistic. In addition, we determined the mean 
absolute error of each model for the same purpose. 
 
A 2-tailed P-value < 0.05 was considered significant for all analyses. Statistical analysis 
was performed with the use of GraphPad Prism Version 5.0 or SPSS Version 17.0.  
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4.3 Results 
4.3.1 Population characteristics 
Of the 196 patients enrolled, 29 were excluded from analysis for the following reasons: 3 
because of entry error, 4 because they self-administered the wrong dose, 1 for failure to 
comply with INR measurements, 14 dropouts, 6 because of incomplete follow-up and 1 
because of death (cause not attributed to study participation). Of those included for 
outcome analysis, 61 and 96 patients were enrolled at the LHSC and TOH, respectively.  
 
The allelic frequencies for VKORC1 -1639G>A and CYP4F2 c.1297G>A were 38.0% 
and 31.7%, respectively. The CYP2C9*2 and *3 allelic frequencies were 11.1% and 
4.8%, respectively. There were no deviations from the Hardy-Weinberg equilibrium.  
 
4.3.2 Time to first therapeutic INR (2.0-3.0) and 
overanticoagulation (INR ≥ 4) 
The primary outcomes were compared in terms of VKORC1 and CYP2C9 genotypes. 
VKORC1 genotype had no significant effect on time required to reach the first INR 
within the therapeutic range (P = 0.52) or time required to obtain an INR ≥ 4, according 
to log-rank test (P = 0.64; Figure 4.1A, 4.1C). Similarly, there was no significant 
difference between CYP2C9 wild-type and variant genotype for either of these outcomes 
(P = 0.28 for first INR, P = 0.96 for first INR ≥ 4; Figure 4.1B, 4.1D). Concordant with 
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these findings, HR estimates for the VKORC1 and CYP2C9 genotype groups were not 
significantly different from unity before or after adjustment for covariates by Cox 
regression analysis (Table 4.6). Because outcomes during the first 30 days would be most 
sensitive to the initiation protocol, we compared the time to first INR ≥ 4 during the first 
month of therapy among genotype groups.  
 
VKORC1 and CYP2C9 polymorphisms were without influence on this outcome (data not 
shown). Importantly, these outcomes were not associated with genotype when we 
considered the first and second cohorts of patients independently (data not shown). 
 
4.3.3 Time to stable anticoagulation  
 
The time to first stable anticoagulation was significantly different between VKORC1 (P < 
0.05) genotype groups, whereas there were no differences between CYP2C9 groups (P = 
0.37; Figure 4.2). However, when adjusted for confounding covariates, neither VKORC1 
nor CYP2C9 showed a significant influence on time to stability (Table 4.6).  
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Figure 4.1 The effect of pharmacogenetics-guided dosing on time to primary events. 
Kaplan-Meier plots represent the lack of association for attainment of first international 
normalized ratio (INR) within therapeutic range (2.0-3.0) and first above-range INR (INR 
≥ 4) among VKORC1 (A, C) and CYP2C9 (B, D) genotype groups after initiation with 
WRAPID nomogram. The statistic in each panel represents the log-rank P value for 
testing the equality of survival functions. WT indicates wild type. 
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Figure 4.1 The effect of pharmacogenetics-guided dosing on time to primary events. 
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Table 4.3.1 Unadjusted and adjusted HRs for anticoagulation outcomes in patients 
with VKORC1 G/A or A/A and CYP2C9 variant genotype. 
Genotype and outcome Unadjusted Adjusted 
 
HR (95% CI) P HR (95% CI) P 
VKORC1 G/A genotype*     
Time to first therapeutic INR 
0.79  
(0.50-1.25) 
0.32 
0.62  
(0.27-1.39) 
0.24 
Time to first above-range 
INR 
0.71  
(0.32-1.59) 
0.40 
0.58  
(0.11-3.19) 
0.53 
Time to stable 
anticoagulation 
1.03  
(0.65-1.63) 
0.91 
1.11  
(0.64-1.90) 
0.72 
VKORC1 A/A genotype* 
Time to first therapeutic INR 
0.87  
(0.55-1.37) 
0.54 
0.76  
(0.34-1.57) 
0.43 
Time to first above-range 
INR 
0.70  
(0.32-1.56) 
0.39 
0.56  
(0.14-3.15) 
0.60 
Time to stable 
anticoagulation 
0.69  
(0.43-1.10) 
0.12 
0.8  
(0.47-1.37) 
0.41 
CYP2C9 variant genotype† 
Time to first therapeutic INR 
0.85  
(0.61-1.19) 
0.34 
1.04  
(0.69-1.57) 
0.86 
Time to first above-range 
INR 
1.02  
(0.53-1.94) 
0.96 
0.91  
(0.43-1.92) 
0.81 
Time to stable 
anticoagulation 
1.17  
(0.83-1.65) 
0.38 
0.88  
(0.60-1.29) 
0.51 
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CI, confidence interval; CYP2C9, cytochrome P450 2C9; HR, hazard ratio; INR, 
international normalized ratio; VKORC1, vitamin K epoxide reductase subunit 1.  
All Cox regression models were adjusted for age, gender, weight, warfarin dose, 
indication for therapy, cohort, VKORC1, CYP2C9, and CYP4F2 genotype. 
* Survival function was compared with VKORC1 wild-type G/G genotype group. 
† Survival function was compared with CYP2C9 wild-type *1/*1 genotype group. 
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Figure 4.2 The effect of pharmacogenetics-guided dosing on time to stability. 
Kaplan-Meier plots representing the time to stable anticoagulation among VKORC1 (A) 
and CYP2C9 (B) genotype groups. The statistic in each panel represents the log-rank P 
value for testing the equality of survival functions. WT indicates wild type. 
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4.3.4 Time spent within therapeutic range (INR 2.0-3.0) and above 
therapeutic range (INR > 3) 
To separate the initiation and stabilization phases of therapy, we considered 
prestabilization as day 1 to 30 and the stabilization phase as day 31 to the end of the study 
period. We chose 30 days because the median time to stability was 29 days. There was no 
significant influence of VKORC1 or CYP2C9 genotype on time spent in therapeutic 
range or above range during prestabilization or stabilization phase (supplemental 
material, Table 4.8). The present study was not powered to detect secondary outcomes. 
 
4.3.5 INR response time course during first 3 weeks of therapy 
With the PK-PD model, the response profiles for various genotype groups were predicted 
to be similar during the attainment of therapeutic INR. Our algorithm was developed to 
enable patients to reach the first therapeutic response in a steady and safe manner, with a 
goal of reaching optimal anticoagulation by the end of initiation. Figure 4.3A illustrates 
the average INR time course of patients in the present study up to treatment week 3. The 
time-course observed was similar to the model predicted response profile, particularly 
during the critical first week. Concordant with our primary outcomes, average INR 
during initiation rose to the target range in a similar fashion among VKORC1 and 
CYP2C9 genotype groups, and importantly, anticoagulation stability, as represented by 
maintenance of INR within range after initiation was comparable (Figure 4.3B, 4.3C).   
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Figure 4.3 The effect of genotype-guided dosing on response time course during the 
first 3 weeks of warfarin therapy. 
(A) The average response observed in patients dosed by the WRAPID nomogram, 
represented as mean with 95% CI of the SE, is similar to the PK-PD model-predicted 
anticoagulation response time course. The observed INR time courses among VKORC1 
(A) and CYP2C9 (B) genotype groups, presented as LOWESS (locally weighted 
scatterplot smoothing regression) smoothed plots, rises and is maintained within 
therapeutic range in a parallel and similar manner. 
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4.3.6 Secondary outcomes 
Secondary efficacy and safety outcomes of anticoagulation are summarized in Table 4.7. 
By day 6 of therapy, 40.1% of patients enrolled in the present study had an INR within 
the therapeutic range, whereas 57.5% had an INR within the therapeutic range by day 9. 
The proportion of patients reaching extended INR range of 1.8-3.2 by days 6 and 9 was 
60.5% and 78.4%, respectively. Although approximately 20% of patients reached an INR 
≥ 4 during the entire study duration, the percentage of time spent with INR ≥ 4 was only 
1.2%. Moreover, only 3.6% of patients experienced excessive overanticoagulation with 
an INR ≥ 5 during the entire study period. The average maintenance dose was 5.54 mg/d 
and followed the known gene-dose relationship (supplemental material, Table 4.9). 
 
4.3.7 Dosing algorithm assessment  
The association between observed maintenance dose, algorithm predicted dose, and day 
7/8/9 dose was determined. The proportion of variance explained by the final 
maintenance regression was 42% (Figure 4.4A), whereas the variance explained 
following INR-guided dose adjustments was 70% (Figure 4.4B). In addition, there was 
less bias between day 7/8/9 dose and maintenance dose than that of the algorithm 
predicted. The mean absolute error (SE) of the final model was 10.4 (0.1) mg/wk, 
whereas for the INR-adjusted dose, it was 8.5 (0.9) mg/wk, comparable to that of other 
pharmacogenetics-based nomograms (33). 
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Figure 4.4 Association of predicted maintenance dose to observed maintenance dose. 
Scatter plots show the association of algorithm-predicted maintenance dose (A) and day 
7/8/9 dose after response-based adjustments (B) with the observed maintenance dose. The 
solid lines represent the linear regression, and the dashed lines represent its 95% CI. 
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Table 4.3.2 Secondary outcomes following dosing with pharmacogenetics-based 
algorithm. 
Initiation phase (Day 1-9), n (%)  
 
 
INR 2-3 within 3 days 13 (7.8) 
 
INR 2-3 within 6 days 67 (40.1) 
 
INR 2-3 within 9 days 96 (57.5) 
 
INR extended 1.8-3.2 within 3 days 23 (13.8) 
 
INR extended 1.8-3.2 within 6 days 101 (60.5) 
 
INR extended 1.8-3.2 within 9 days 131 (78.4) 
 
INR ≥ 5, No. (%) 0 (0) 
90-day follow up period*  
 
 
Time spent in range, % (SD) 64.8 (19.8) 
 
Time spent in extended therapeutic INR (1.8-3.2), % (SD) 77.3 (14.4) 
 Time spent in INR ≥ 4, % (SD) 1.2 (2.9) 
 
Number of INR measurements in 90 days, mean±SD  12.3±2.7 
 
INR ≥ 5, n (%) 6 (3.6) 
Post 30 day follow up period  
 
 
Time spent in range, % (SD)  68.1 (25.0) 
INR, international normalized ratio; SD, standard deviation.  
* Ninety-day follow-up period excludes initiation phase (day 1- 9). The outcomes change 
slightly when initiation is included.  
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4.4 Discussion 
The clinical benefit of warfarin for decreasing stroke risk among AF patients and treating 
VTE is well established; however, the unpredictable anticoagulation response for a 
significant proportion of patients poses a substantial clinical challenge to optimal 
warfarin therapy. Several studies have examined various initiation strategies for treatment 
of VTE and AF (1, 34-36). Although several of these studies have incorporated loading 
dose nomograms during initiation, most have been in the setting of VTE (19, 20), and 
few studies incorporating loading dose strategies for other indications have been reported 
(34, 37). Pharmacogenomic studies conducted in the last decade have established the 
contribution of both VKORC1 and CYP2C9 genetic variations to maintenance dose 
requirements; however, VKORC1 is a more important modulator of early warfarin 
response than CYP2C9 (24). Not surprisingly, both genes have recently been reported to 
predict therapeutic doses during the initial weeks of therapy (38, 39). With these 
considerations, we developed and evaluated a practical and universal pharmacogenetics-
based loading dose algorithm for both AF and VTE patients.  
 
In contrast to the findings previously observed with nonpharmacogenetics-based 
dosing,(24) we show that use of the WRAPID algorithm eliminated VKORC1 and 
CYP2C9 genotype-related differences in attainment of first therapeutic INR in both AF 
and VTE patients. This finding did not change after adjustment for confounding 
variables. Interestingly, subanalysis of patients in the initial cohort, in which CYP4F2 
was not included as a predictor of dose, demonstrated that the c.1297G>A SNP did not 
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significantly influence attainment of therapeutic INR. This was in contrast to a recent 
study by Zhang et al. that examined the role of CYP4F2 as a genetic determinant during 
initiation in patients dosed according to standard methods (40). The present findings 
suggest that dosing according to VKORC1 and CYP2C9 genotype is sufficient. This is 
consistent with the fact that CYP4F2 genotype accounts for only a small portion of the 
observed maintenance dose variability (0-4%) (12, 41). However, a caveat here is that the 
present study was not powered to detect an association between response and CYP4F2 
genotype. Thus, the definitive role of CYP4F2 genotype in individualized warfarin 
therapy requires further assessment in a powered study of sufficient sample size.  
 
With respect to risk for excessive anticoagulation (INR ≥ 4), several groups have reported 
that variant carriers of VKORC1 and CYP2C9 are subject to significantly increased risk 
of overanticoagulation (22). After initiation with a pharmacogenetics-based dosing 
algorithm, neither the VKORC1 nor the CYP2C9 variant groups had an elevated risk of 
supratherapeutic INR during the first month of therapy or throughout the entire study 
period. The present findings contrast with those of a study conducted by Voora et al. in 
which patients were dosed prospectively only according to CYP2C9 genotype (42). In 
that study, carriers of a variant CYP2C9 allele still exhibited an increased risk for 
excessive anticoagulation. This may be explained by dosing algorithm and adjustment 
differences during initiation compared with the present study. 
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An important measure of variability in anticoagulation quality is the time to stability. 
Higashi et al. reported that variant carriers of CYP2C9 required significantly longer to 
attain stability in the absence of pharmacogenetics-based dosing (8). The present study 
demonstrates that differences in time to stability between VKORC1 and CYP2C9 
genotype groups can be effectively reduced with the use of pharmacogenetics-guided 
dosing. Moreover, Wadelius et al. and Limdi et al. recently reported that the INR 
response profile differed between genotype groups during initiation using a standard-
dosing regimen, in which variant carriers had greater warfarin sensitivity (22, 23). In 
contrast, the increase in INR to therapeutic range in the present study was similar among 
genotype groups. 
 
It cannot be entirely ruled out that the lack of association observed in the present study 
may have been caused by insufficient sample size; however, calculations showed that we 
had ample power (> 80%) to detect the association of a causal VKORC1 -1639G>A SNP, 
with an allele frequency of 35%, with anticoagulation response, for an HR of 2. Because 
we observed no evidence of an association between VKORC1 genotype and 
anticoagulation responses, it would be reasonable to conclude that the WRAPID 
algorithm eliminated the VKORC1-driven response variation. Although we did not 
observe a significant association between CYP2C9*2 or *3 genotype and response, this 
may be because of lack of power. When one considers the small proportion of 
heterozygous and homozygous carriers of CY2C9*2 and *3 allele, the sample size 
required to detect such individual associations would be very large (~ 1000). Thus, we 
92 
 
 
 
assessed the association of pooled CYP2C9 variant status (at least 1 of *2 or *3 allele), a 
frequency of 30% in the present study population, with anticoagulation response. In this 
case, calculation showed that sufficient power was achieved (> 80%) to detect the 
association of CYP2C9 variant status with anticoagulation responses for an HR of 2. 
Such pooling of CYP2C9*2 and *3 variants has been used previously by other studies for 
similar reasons.(8, 43) In particular, these studies demonstrated that among patients 
whose therapy was initiated with standard dosing protocols, CYP2C9 variant carriers 
spent more time above therapeutic INR, had an elevated risk of overanticoagulation, and 
a lower dose requirement overall.  
 
To the best of our knowledge, the WRAPID nomogram is the first warfarin initiation 
algorithm that incorporates both VKORC1 and CYP2C9 genotype-determined loading 
doses, which differs from the typical doubling of the maintenance dose. Thus far, there 
have been 2 prospective randomized clinical trials (RCTs) in which pharmacogenetics-
based warfarin initiation with loading doses was compared with standard warfarin 
loading dose initiation, whereas other studies have not incorporated loading doses. In the 
first trial, control patients were loaded with 5 mg, whereas study patients were loaded 
according to CYP2C9 genotype (44). In the second trial, control patients were initiated 
with 10 mg, whereas study patients were initiated with double the maintenance dose 
determined with VKORC1 and CYP2C9 genotype (45). Evidently, there is a lack of 
consensus with respect to warfarin initiation and especially concerning loading dose 
selection from genetic information. The aforementioned trials, albeit small, indicate that 
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pharmacogenetics-guided dosing improves warfarin response in terms of more time spent 
within the therapeutic range, decreased bleeding events, and faster attainment of 
therapeutic INR, supporting the use of loading doses for initiation. In addition, some 
studies recommend that loading dose should be age adjusted because of concern about 
warfarin sensitivity (34). However, we did not observe a disproportional number of 
elderly patients with excessive anticoagulation with our loading dose regimen, in which 
some elderly patients were indeed loaded with 10 mg as per genotype. Thus, the present 
data do not support age-modified loading doses. We did, however, observe an effect of 
decreased weight on response sensitivity during initiation. 
 
Limitations of the present study include the inability to determine the influence of a 
pharmacogenetics-guided dosing algorithm on rare bleeding complications because of 
insufficient sample size; however, we can comment on the general safety of our dosing 
regimen. The number of INRs over 5 has been used previously as a measure of the safety 
of a dosing protocol (19). In the present study, only 3.6% of patients experienced such 
excessive anticoagulation, which is lower than that observed with other initiation 
protocols (5.6 – 8.6%) (19, 36). Several RCTs involving larger sample sizes are currently 
under way to evaluate the safety and efficacy of pharmacogenetics-based dosing 
compared with standard-dosing (www.clinicaltrials.gov; NCT01006733, NCT00839657, 
and NCT01119300). Interestingly, a proposal has been made for a multicenter trial in 
Europe that will test pharmacogenetics-guided initiation with the use of a genotype-based 
loading doses to examine the clinical utility of such dosing methods. The present study 
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supports the use of genotype-guided loading dose during warfarin initiation. Another 
limitation is that because the present study lacked a control group (nongenetics-based 
warfarin initiation), the results may be attributed in part to management of warfarin 
therapy by anticoagulation clinics. However, the present study was not designed as an 
RCT; rather, it had the goal of demonstrating the minimization of genotype-dependent 
differences in early anticoagulation response, because this has not been demonstrated 
conclusively in the warfarin-pharmacogenetics field. Furthermore, several studies 
published to date have described the contribution of genetic variations to initial warfarin 
response variability in patients whose treatment was initiated with respective 
anticoagulation clinic regimens, likely with similar INR-response monitoring schedules 
as WRAPID (22, 23, 43). Thus, we believe that pharmacogenetics-based initiation, 
particularly with the use of loading doses, should result in a safe and similar rise to 
optimal anticoagulation responses among VKORC1 and CYP2C9 genotype groups. 
Supportive of the role of genotype-guided initiation for warfarin therapy, a recent study 
suggested that genotyping for patients in whom therapy was being initiated significantly 
reduced the hospitalization rate for bleeding or thromboembolic events compared with a 
control group.(46) Furthermore, the results of 5 small RCTs (range from 38-200 patients) 
completed thus far largely suggest that pharmacogenetics-guided dosing improves 
warfarin response, in terms of more time spent within the therapeutic range and decreased 
bleeding events compared with standard dosing (44, 45, 47, 48), with the exception of 1 
study in orthopaedic patients (49). In that RCT, patients were followed up for only 2-4 
weeks, and daily INR monitoring in addition to a similar dose adjustment protocol 
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between the 2 arms may have rendered the effect of genotype-guided dosing 
nonsignificant. Indeed, larger RCTs that incorporate models such as WRAPID are 
required to compare adverse event rates between standard and pharmacogenetics-guided 
dosing of warfarin-based anticoagulation.   
 
To the best of our knowledge, this is the first prospective study to demonstrate the utility 
of a genotype-guided warfarin initiation algorithm for the minimization of widely 
recognized VKORC1 and CYP2C9 genotype-associated differences in anticoagulation 
response for both AF and VTE patients. The pharmacogenetics-based algorithm proposed 
here is feasible and effective for outpatient management of individuals requiring 
warfarin-based anticoagulation.  
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4.6 Supplemental Material 
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Table 4.6.1 Comparison of percent time spent within therapeutic range (2.0-3.0) and 
over range (>3) among VKORC1 and CYP2C9 genotype groups. 
 
VKORC1 CYP2C9 
 
G/G G/A A/A P value 
Wild-
type 
Variant P value 
Time 
within 
range (day 
1-30), % 
53.20 46.60 52.40 0.12 49.83 50.24 0.90 
Time 
within 
range (day 
30-90), % 
75.04 64.77 68.22 0.19 66.46 70.86 0.30 
Time 
above 
range (day 
1-30), % 
15.80 10.18 16.62 0.11 13.14 14.74 0.45 
Time 
above 
range (day 
30-90), % 
6.35 5.37 6.97 0.95 5.74 7.18 0.37 
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Table 4.6.2 Mean prescribed daily maintenance dose (mg) in relation to VKORC1 
and CYP2C9 genotype. 
 
CYP2C9 
VKORC1 *1/*1 *1/*2 *1/*3 *2/*2 *2/*3 
G/G 7.10 6.71 4.12 6.5 NA* 
G/A 5.59 4.60 3.91 2.50 NA* 
A/A 4.10 2.35 2.13 NA 1.93 
* Not available 
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Figure 4.5 A schematic representation of the pharmacokinetic-pharmacodynamic 
(PK-PD) model employed to determine loading doses and dose-adjustment 
nomogram.  
 PK of warfarin is described by a one-compartment model with first-order absorption (A) 
while PD is described by an indirect response model (B), that accounts for delay in 
anticoagulation response. (C) Parameter values used for simulation of drug concentration 
and response time course during model development. 
Gut CplasmaV
ka
ke
Anticoagulation
Response
K ko
Imax
IC50
Cplasma
Pharmacokinetic
Model
Pharmacodynamic
Model
Dose
Model Parameter Values 
Parameter Value Unit Genotype 
ka 28.32 days-1   
ke 0.475 days-1 *1*1 
  0.322 days-1 *1/*2 or *1/*3) 
  0.19 days-1 *2/*2, *2/*3, *3 /*3 
V 10 L   
ko 1     
K 1     
Imax 2   G/G 
  2.375   G/A 
  3.5   A/A 
IC50 1500 ng/mL   
A B 
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Figure 4.6 Concentration response curves necessary for formulating loading doses.   
Loading doses were determined by simulating adequate S-warfarin plasma concentrations 
(A-C) to increase international INR response (D) to therapeutic range (2.0 – 3.0) at a 
similar trajectory for various VKORC1 and CYP2C9 genotype combinations. 
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Figure 4.7 An automated dose calculator that incorporates the WRAPID 
pharmacogenetics-based dosing algorithm and adjustment nomogram for warfarin 
initiation.
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 Reprinted with permission from Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-
Langner A, Wells PS, Kim RB, Tirona RG. 2011. Clinical and genetic determinants of 
warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PloS One, 
6(11): e27808. Copyright 2011 Gong et al.  
 
5 CLINICAL AND GENETIC DETERMINANT OF 
WARFARIN PHARMACOKINETICS AND 
PHARMACODYNAMICS DURING TREATMENT 
INITIATION3
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5.1 Introduction  
 
The vitamin K antagonist, warfarin, is an oral anticoagulant commonly prescribed to 
prevent and treat venous thromboembolism (VTE) and decrease the risk of stroke in atrial 
fibrillation (AF) (1). Warfarin therapy is complicated by the wide interindividual 
variation in response and dose requirements for adequate anticoagulation. Optimal 
warfarin therapy is achieved by maintaining the anticoagulation response, international 
normalized ratio (INR), within a narrow therapeutic range of 2.0 to 3.0 for most 
indications. Due to the unpredictable pharmacokinetic (PK) and pharmacodynamic (PD) 
responses to warfarin, initiation of therapy is the most clinically challenging phase as the 
optimal dose is often determined iteratively, guided by INR (2).    
 
Warfarin is administered as a racemic drug; however, the S-warfarin enantiomer is 3-5 
times more potent than R-warfarin.(3) CYP2C9 is the primary enzyme responsible for 
metabolism of S-warfarin (4), and studies have consistently shown that CYP2C9 
polymorphisms (*2, c.430C>T, rs1799853; *3, c.1075A>C, rs1057910) significantly 
contribute to the variable warfarin response (5). Non-genetic factors of warfarin PK 
variability and dose requirements are also important.  For example, age and co-
administration with drugs that inhibit or induce CYP2C9 can alter S-warfarin elimination 
(6-10). Moreover, S-warfarin volume of distribution is dependent on weight (11, 12). 
Taken together, it has been estimated that PK factors determine 26-40% of warfarin 
maintenance dose variability (10, 13, 14).  
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Warfarin exerts its anticoagulation effects by inhibiting vitamin K epoxide reductase 
(VKOR encoded by the VKORC1 gene), the enzyme responsible for recycling oxidized 
vitamin K epoxide to its hydroquinone form, an essential cofactor for activation of 
clotting factors II, VII, IX and X (15). It is appreciated that single nucleotide 
polymorphisms (SNPs) in VKORC1 result in altered warfarin sensitivity while rare 
mutations have been linked to warfarin resistance (8, 16). Of note, the common promoter 
SNP (VKORC1 -1639G>A, rs9923231) is likely the causative variation responsible for 
greater warfarin sensitivity (17, 18). In addition to CYP2C9 and VKORC1 
polymorphisms, several studies have reported that a functional SNP in CYP4F2 
(c.1297G>A, rs2108622), the metabolizing enzyme for vitamin K (19), also determines 
dose requirement (20, 21). Furthermore, diet has long been considered an important 
environmental determinant of warfarin response. Indeed, reduced anticoagulation 
response was observed in warfarin-stabilized patients with intake of vitamin K-rich foods 
(22, 23), and vitamin K status was associated with warfarin sensitivity at the onset of 
treatment (24).   
 
With the intent of improving warfarin anticoagulation therapy, a number of algorithms 
have been proposed which incorporate genetics as well as clinical parameters to predict 
individualized maintenance dose (8, 25, 26). Many of the factors influencing required 
maintenance dose such as age, body surface area, drug interactions and importantly, 
CYP2C9 genotype relate to their effects on S-warfarin PK parameters, such as volume of 
distribution and clearance (7-9, 27). The influence of genetics and clinical parameters on 
S-warfarin PD variability is less clear. Although the influence of VKORC1 genetic 
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variations and vitamin K intake on dose and anticoagulation response is evident, the 
quantitative and dynamic influence of these variables on PD parameters, such as drug 
affinity and maximal inhibition, has not been well established (28). Moreover, there is a 
paucity of information regarding the influence of other genetic and clinical variables on 
S-warfarin PD variation.   
 
In this study, we aimed to separate warfarin pharmacokinetic factors from intrinsic 
pharmacodynamic factors to elucidate crucial covariates of each, and their contribution to 
the overall anticoagulation response variation. To this end, PK-PD modeling was applied 
to a cohort of patients commencing warfarin therapy using a novel initiation protocol 
(29).   
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5.2 Experimental Design 
5.2.1 Study subjects and design 
Patients with AF (n = 61), VTE (n = 98) or other conditions (n = 8) were prospectively 
enrolled to evaluate the safety and efficacy of a pharmacogenetics-based warfarin 
initiation protocol.  Patient characteristics and clinical outcomes were described 
previously in detail (29). The inclusion criteria for study enrolment were minimum of 18 
years of age and indication for new warfarin therapy for at least 3 months with a target 
INR range of 2.0 to 3.0. Patients were excluded on the basis of diagnosis of cancer other 
than non-melanoma skin cancer, alcohol or drug abuse, baseline INR>1.4, known 
warfarin allergy/intolerance, terminal disease, prior use of warfarin or vitamin K use 
within 2 weeks prior to study enrolment, and pregnancy.  The majority of patients were 
Caucasian (95%) with mean age of 60 years (range, 19-88) and mean weight of 84 Kg 
(43-155). The allelic frequencies for VKORC1 -1639G>A and CYP4F2 c.1297G>A were 
38.0% and 31.7%, respectively. The CYP2C9*2 and *3 allelic frequencies were 11.1% 
and 4.8%, respectively. There was no homozygous CYP2C9*3 carrier in this population. 
Amiodarone, statin, antiplatelet, antibiotic, antifungal and NSAID medication use were 
present in 2%, 45%, 55%, 6%, 1% and 12% of the cohort, respectively. 
 
The Warfarin Regimen using A Pharmacogenetics-guided Initiation Dosing (WRAPID) 
protocol has been described elsewhere (29). Briefly, a 2-day loading dose (according to 
VKORC1 and CYP2C9 genotype) was administered, followed by a day 3 INR 
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measurement that was used in combination with the maintenance algorithm to determine 
the subsequent dose. Two subsequent INR measurements were obtained within the first 9 
days of therapy where the maintenance dose was further adjusted accordingly to the dose 
adjustment nomogram. Simultaneous with INR monitoring, additional blood samples 
were collected for drug level analysis.  
 
This study was conducted at the London Health Sciences Centre and The Ottawa 
Hospital upon approval by Research Ethics Boards at the University of Western Ontario 
and Ottawa Hospital. Patients requiring initiation of warfarin therapy were prospectively 
screened for study eligibility and informed written consent was acquired. 
 
5.2.2 Genotyping 
Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit 
(Qiagen, Valencia, CA). At London Health Sciences Center, genotypes were determined 
by allelic discrimination using TaqMan Drug Metabolism Genotyping
 
assays with the 
7500 RT-PCR System (Applied Biosystems, Carlsbad, CA). At Ottawa Health Research 
Institute, genotypes were determined using the Luminex 200 system (Luminex, Austin, 
TX).  
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5.2.3 Warfarin drug level analysis 
Racemic warfarin and internal standard (IS) R/S-para-chloro-warfarin were purchased 
from Sigma-Aldrich. Plasma was extracted from patient blood samples within 1 hour of 
collection and stored at -80°C until use. Total S-warfarin plasma concentration was 
determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Briefly, 300 µL of acetonitrile and 25 µL of IS was added to 100 µL of plasma and 
centrifuged at 14,000 rpm for 20 min. The resulting supernatant was added to 5 mM 
ammonium acetate pH 4 (1:3 v/v). Warfarin and IS enantiomers were separated with the 
Astec CHIROBIOTIC™ V Chiral Column (5 cm × 4.6 mm, 5 µM particle size) using 
gradient elution with 5 mM ammonium acetate (pH 4) and acetonitrile (5 to 70%) in a 10 
min run time. The MS was set in negative mode for detection of warfarin and IS with 
transitions 307.2  160.0 m/z and 340.8  160.0 m/z, respectively. Calibration curves 
were prepared by spiking blank plasma with known concentrations of R/S-warfarin. The 
lowest limit of quantification was 1 ng/mL for both enantiomers. The interday coefficient 
of variation and bias of S-warfarin quality controls was 10.5% and 9.3%.  
 
5.2.4 Proteins induced by vitamin K absence factor II (PIVKA-II) 
assay 
PIVKA-II concentrations were analyzed with use of an enzyme-linked immunosorbent 
assay kit as per manufacturer’s protocols (Diagnostica-Stago, Parsippany, NJ). 
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5.2.5 Kidney function 
We measured patient plasma creatinine concentrations by LC-MS/MS. Briefly, creatinine 
and the IS, creatinine-D3, was purchased from Sigma-Aldrich and Toronto Research 
Chemicals, respectively. Creatinine and IS were separated with the reverse-phase 
Hypersil Gold column (50 × 5 mm, 5 µM particle size) using isocratic elution with 25% 
1% formic acid in water v/v and 75% acetonitrile with 1% formic acid v/v in a 7 min run 
time. The MS was set in positive mode for detection of creatinine and IS with transitions 
114.1  44.3 m/z and 117.1  47.3 m/z, respectively. The lowest limit of quantification 
was 50 ng/mL. The interday coefficient of variation and bias of creatinine quality 
controls was 8.7% and 6%.  eGFR was estimated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation (30). Renal function was categorized 
according the National Kidney Foundation’s classification of chronic kidney disease.  
 
5.2.6 PK-PD modeling 
S-warfarin PK was described using a linear one-compartment model with a set volume of 
distribution (V; 0.14 L/kg) on a per patient basis (12). The time-course of plasma S-
warfarin concentration (Cp) arose from the interplay between first-order drug absorption 
(ka) and drug elimination (ke) processes. Parameter values for ka were fixed (28.56 day-1) 
based on the literature (31). Bioavailability was assumed to be complete (32). Individual 
ke values were obtained by least squares fitting (Scientist, Micromath, St. Louis, MO) of 
the concentration data during the first 9 days with prescribed doses as input.  Clearance 
(CL) was calculated according as the product of V and ke. 
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S-warfarin PD was described by an established indirect response model which 
incorporates the known delay in anticoagulation effects (33). In this model, the rate of 
change in INR was modeled using zero-order input (K) and first-order output (kout) 
variables. Plasma S-warfarin levels (Cp) modulate the output response according to 
classical inhibition kinetics, described by parameters maximum inhibitory factor (Imax, i.e. 
inversely related to enzyme content) and drug affinity (IC50) (34). Since VKORC1 -
1639G>A promoter SNP has been correlated with altered mRNA expression levels, Imax 
values were expected to vary with VKORC1 genotype. Rmax and kout values in the indirect 
response model were both fixed at 1. The IC50 for S-warfarin was fixed at 1500 ng/mL, as 
reported previously (35). The following equation describes the PD model. 
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The response analysis was conducted following estimation of individual S-warfarin 
plasma concentrations. These estimated drug concentrations were used in combination 
with measured INRs to estimate the individual PD parameter, Imax, by least squares 
fitting.  
 
We note that clearance and Imax parameter estimates should be considered independent of 
the dosing regimen and anticoagulation responses observed in the WRAPID study 
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because estimations of individual warfarin clearance and individual drug concentration-
response profile are unaffected by the doses received. 
 
5.2.7 Vitamin K epoxide reductase protein expression in human 
liver 
The collection and processing of liver samples was described elsewhere (36).  In order to 
obtain a positive control for VKOR protein analysis, the enzyme was over-expressed in 
cells using previously described protocol (37). For this purpose, human VKORC1 cDNA 
was amplified from a human liver cDNA library using primers 5’-
TGGAGATAATGGGCAGCACCTGGGGG-3’ (forward) and 5’-
GTTGAGGGCTCAGTGCCTCTTAGCCTTG-3’ (reverse). Samples were separated by 
SDS-PAGE on 4-10% gels (Invitrogen, Carlsbad, CA) and subsequently transferred onto 
nitrocellulose membranes. Blots were probed with a custom anti-VKOR antibody (kindly 
provided by Dr. Kathleen Berkner, Learner Research Institute, Cleveland Clinic (38)) and 
subsequently probed with anti-rabbit horseradish peroxidise-labeled secondary antibodies 
(Bio-Rad, Hercules, CA). The bands were detected using the BM Chemiluminescence 
Western Blotting Substrate (Roche, Indianapolis, IN) and KODAK ImageStation 4000 
MM (Carestream, Rochester, NY). Protein expression levels were normalized to a wild-
type VKORC1 sample (HLM100), repeated on all blots. 
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5.2.8 Determinants of warfarin kinetics and response 
Regression analysis was performed to determine factors affecting S-warfarin clearance 
and Imax . Since the distribution of both of these parameters in our patient population was 
skewed, square-root transformation was adopted to normalize the data. The variables age, 
gender, body weight, amiodarone use, other known interacting medications, indication 
for warfarin therapy, kidney function, vitamin K status as measured by PIVKA-II, 
VKORC1 genotype, CYP2C9*2 and *3 genotype were considered as covariates for both 
S-warfarin clearance and Imax. The covariates were added to the model according to the 
stepwise forward regression. A P-value < 0.05 was considered as significant and the 
variable was subsequently entered into the equation; variables included with P-values > 
0.1 in subsequent models were removed. The models with significant covariates were 
then internally validated through bootstrapping. Bootstrapping was achieved by random 
sampling with replacements to obtain 1000 samples, allowing estimation of the standard 
error and the 95% confidence interval (CI) of parameter estimates. Potential collinearity 
between variables was assessed using condition indices and variance proportions.  
 
The clearance and Imax regression equations were then integrated with the PK-PD model 
in order to predict and compare anticoagulation response profiles following initiation 
with various nomograms for typical warfarin patients. 
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5.2.9 Statistical analysis 
The Kruskal-Wallis one-way analysis of variance followed by Tukey’s test for pairwise 
comparisons was employed for the following analysis: S-warfarin concentration 
differences with respect to VKORC1 genotype, influence of VKORC1 genotype on 
attainment of therapeutic INR and dose, effect of VKORC1 genotype on liver protein 
expression, relationship between S-warfarin clearance and CYP2C9 genotype, effect of 
kidney function on S-warfarin clearance, relationship between VKORC1 genotype and 
Imax. Mann-Whitney U’s test was employed to examine gender effect on S-warfarin 
clearance and warfarin indication effect on Imax. A two-tailed P value of less than 0.05 
was considered significant for all analyses. Statistical analysis was performed with the 
use of GraphPad Prism v.5.0 (GraphPad, La Jolla, CA) or SPSS v. 17.0 (SPSS, Chicago, 
IL).  
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5.3 Results 
5.3.1 PK-PD model performance 
We fitted the individual patient S-warfarin plasma levels during the first 9 days of therapy 
to a one-compartment PK model (Figure 5.1A) to furnish estimates of S-warfarin 
clearance. The S-warfarin clearance estimated here was similar to that previously 
observed (39). Moreover, good fits to individual patient levels with the PK model were 
obtained (Figure 5.1C).  Overall, the PK model was sufficiently accurate in describing the 
data as linear regression analysis for predicted and actual S-warfarin concentrations 
yielded a coefficient of determination (r2) of 0.91, with a slope of 0.92 (Figure 5.1D). The 
mean absolute error (MAE) between estimated and actual was 0.04 µg/mL, and 88% of 
these estimated values were within 25% of actual concentrations. 
 
An indirect response model was used to estimate maximal inhibitory factor (Imax), the PD 
parameter related to the amount of hepatic VKOR enzyme. Here, the S-warfarin plasma 
concentration-INR response relationship is governed by the parameters IC50 (related to 
warfarin affinity to VKOR) and Imax, where at constant IC50, increasing Imax enhances 
drug sensitivity (Figure 5.1B). Individual predicted S-warfarin concentrations estimated 
from the PK model in conjunction with observed INR values served as inputs for the PD 
model.  Fits to individual patient INRs over the initiation period were good (Figure 5.1E). 
Linear regression analysis for predicted and actual INR values of the entire data set 
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yielded an r2 of 0.89, with a slope of 0.91 (Figure 5.1F). The MAE was 0.17, and 90% of 
these estimated values were within 25% of actual INR.  
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Figure 5.1 PK-PD model performance. (A) Model simulated S-warfarin plasma 
concentration-time profiles after single dose with CYP2C9 variant alleles. (B) Model 
simulated steady-state therapeutic INR (2.5) vs. S-warfarin plasma concentration with 
varying Imax corresponding to VKORC1 -1639G>A genotype. (C) Model fit of measured 
S-warfarin concentrations in a single patient. (D) Scatter plot of actual vs. predicted S-
warfarin plasma concentration throughout the initiation phase (coefficient of 
determination, r2 = 0.91, n = 459). The diagonal line represents the unity line. (E) Model 
fit of measured anticoagulation INR response values in the same patient as in (C).  (F) 
Scatter plot of actual vs. predicted INR during the initiation phase (r2 = 0.89, n = 459). 
The diagonal line represents the unity line. Imax, maximal inhibitory factor; INR, 
international normalized ratio.  
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Figure 5.1 PK-PD model performance. 
 
0.0 1.0 2.0 3.0 4.0 5.0 6.0
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Actual INR
M
od
el
 
Pr
ed
ict
ed
 
IN
R
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Actual [S-warfarin] (µg/mL)
Pr
ed
ict
ed
 
[S
-
w
ar
fa
rin
] (
µ
g/
m
L)
A B 
E F 
0.75 
0.60 
0.45 
0.30 
0.15 
0 
1 2 3 4 5 6 7 
Treatment Day 
Pl
as
m
a
 
[S
-
w
ar
fa
rin
] (µ
g/
m
L) 
4 
3 
2 
1 
0 
1 2 3 4 5 6 7 
Treatment Day 
IN
R
 
C D 
0 5 10 15 20 25
0.0
0.1
0.2
0.3
0.4
0.5
Wild Type
One Variant
Two Variant
Time (hours)
Pl
as
m
a 
[S
-
w
ar
fa
rin
] µ
g/
m
L
10 10
0
10
00
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
A/A (Imax=3.8)
G/A (Imax=2.9)
G/G (Imax=2.2)
Steady-State [S-warfarin] (ng/mL)
St
ea
dy
-
St
at
e 
IN
R
VKORC1 
CYP2C9 
123 
 
 
5.3.2 Determinants of S-warfarin clearance 
Mean S-warfarin clearance was 7.5 L/day (SD 3.4) with a range of 0.8 to 20.8, indicating 
a more than 20-fold interindividual variability in S-warfarin PK (Figure 5.2A). S-warfarin 
clearance was significantly associated with CYP2C9 genotype with mean clearance 
values of 8.1, 7.0, 4.3, 4.5, and 2 L/day, for CYP2C9 *1/*1, *1/*2, *1/*3, *2/*2, and 
*2/*3 genotypes, respectively (Figure 5.2B). Interestingly, lower S-warfarin clearance 
was observed in patients with decreased renal function as estimated by glomerular 
filtration rate (eGFR) (Figure 5.2C, P<0.0001). The cohort average eGFR was 91 
mL/min/1.73 m2 (SD 23) with a range of 22 to 140. Moreover, eGFR was significantly 
decreased with increase in age (P<0.0001, data not shown). Gender also had an influence 
on S-warfarin clearance, where on average, females had significantly lower clearance 
compared to males (Figure 5.2D, P<0.001).  With stepwise regression, clearance was 
found to be dependent on CYP2C9*3 allele, kidney function, gender, and CYP2C9*2 
allele, in order of covariate entry into the regression equation.  VKORC1 genotype was 
without influence on S-warfarin clearance.  The r2 of the final model for clearance 
estimation was 36.5%.  Parameter estimates of the final clearance model and bootstrap 
validation results are given in Table 5.1. 
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Figure 5.2 Determinants of S-warfarin clearance. (A) Frequency distribution of estimated 
S-warfarin clearance, shown as percent of total patients for each bin. (B) Relationship 
between CYP2C9 genotype and S-warfarin clearance. Lines represent mean clearance. 
(C) S-warfarin clearance is significantly correlated with kidney function, as defined by 
eGFR. (D) Observed S-warfarin clearance segregated by gender. Lines represent mean 
clearance. eGFR, estimated glomerular filtration rate. * P < 0.05, ** P < 0.005, ***P < 
0.0005 
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Figure 5.2 Determinants of S-warfarin clearance. 
  
1 3 5 7 9 11 13 15 17 19 21
0
5
10
15
20
25
30
S-warfarin clearance (L/day)
Fr
eq
u
e
n
cy
 
(%
)
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3
0
5
10
15 *
***
**
**
CYP2C9 Genotype
S-
w
ar
fa
rin
 
Cl
ea
ra
n
ce
 
(L/
da
y)
A B 
C 
0
5
10
15
20
25
Female Male
*
S-
w
ar
fa
rin
 
Cl
ea
ra
nc
e 
(L/
da
y)
D 
≥ 90 60-89 30-59
0
2
4
6
8
10
***
*** *
eGFR (mL/min/1.73 m2)
S-
w
ar
fa
rin
 
Cl
ea
ra
n
ce
 
(L/
da
y)
126 
 
 
Table 5.3.1 Multiple linear regression analysis of independent predictors of S-
warfarin clearance (L/day). 
Entry 
into 
model 
Predictor 
Variable 
B 
Standard 
error 
95% CI 
R2 after 
entry 
(%) 
P in 
final 
model 
- Intercept 3.105 0.072 
2.966,  
3.248 
- <0.0001 
1 
CYP2C9*3, 
per allele 
-0.812 0.151 
-1.093,  
-0.510 
14.3 <0.0001 
2 eGFRa -0.278 0.080 
-0.417,  
-0.145 
24.9 <0.0001 
3 Gender (F) -0.357 0.081 
-0.511,  
-0.186 
32.3 <0.0001 
4 
CYP2C9*2, 
per allele 
-0.274 0.080 
-0.427,  
-0.113 
36.5 <0.0001 
CI, confidence interval; CYP2C9, cytochrome P450 2C9; eGFR, estimated glomerular 
filtration rate in mL/min/1.73m2; F, female. 
a
 Coded as follows: ≥ 90 mL/min/1.73 m2, 0; 60-89, 1; 30-59, 2; 15-29, 3; ≤ 15, 4. 
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5.3.3 Therapeutic S-warfarin plasma concentration correlates with 
VKORC1 genotype 
S-warfarin plasma concentrations on day 7/8/9 were statistically different between 
VKORC1 -1639G>A genotype groups (P<0.0001) despite similar INR (Figure 5.3A). 
Patients carrying at least one -1639G>A allele required lower plasma concentrations than 
wild-type patients for similar therapeutic efficacy, and this was gene-dose dependent 
(Figure 5.3A, 5.3B). The mean plasma S-warfarin concentrations for VKORC1 A/A, G/A, 
and G/G genotype groups were 0.291 ng/mL (SD 0.157), 0.347 ng/mL (0.170), and 0.503 
ng/mL (0.217), corresponding to mean warfarin daily doses of 4.4 mg (2.7), 5.0 mg (2.5) 
and 7.6 mg (3.0), respectively. 
 
5.3.4 Determinants of S-warfarin PD 
The mean Imax value for subjects was 2.7 (SD 1.0), with a range of 0.3 to 6.9, 
demonstrating a more than 20-fold interindividual variability in S-warfarin PD (Figure 
5.3C).  A significant relationship between VKORC1 -1639G>A genotype and Imax (Figure 
5.3D, P<0.0001) was observed. The mean Imax values for VKORC1 A/A, G/A, and G/G 
genotypes were 3.7 (SD 1.2), 2.8 (1.0) and 2.2 (0.7), respectively.  
 
Stepwise regression analysis indicated that Imax was dependent on VKORC1 genotype, 
indication for warfarin, pre-treatment plasma proteins induced by vitamin K absence 
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(PIVKA-II) concentration, CYP4F2 1297C>T genotype, and weight, in order of covariate 
entry into the regression equation. The r2 of the final model for Imax estimation was 41%. 
Parameter estimates of the final Imax model and the bootstrap validation results are given 
in Table 5.2.  The mean baseline PIVKA-II concentration was 7.1 ng/mL (SD 4.8), with a 
range of 1.8 to 30.6, indicating that majority of our patients did not exhibit vitamin K 
deficiency. Imax was greater in patients with AF than VTE, denoting that VTE patients 
were more resistant to warfarin’s therapeutic effect. Moreover, there was an additive 
effect of VKORC1 genotype and indication, where VTE patients had lower Imax than AF 
patients irrespective of VKORC1 genotype (Figure 5.3E). VTE patients who were 
VKORC1 G/G carriers had the lowest average Imax (2.1) while AF and A/A carriers had 
the highest Imax (4.4). These findings imply that differences in INR response would be 
evident between patients with AF and VTE when warfarin is initiated by a common 
dosing protocol. Indeed, we found a more rapid response in patients with AF in 
comparison to VTE over the first week of therapy (Figure 5.3F), despite that the 
WRAPID protocol eliminated the previously known genetic and clinical contributors to 
early response variability (29).  
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Figure 5.3 Determinants of maximal inhibitory factor, Imax.  (A) Box-and-whisker plots of 
S-warfarin plasma concentration and INR on days 7/8/9 segregated by VKORC1 -
1639G>A genotype. Box-and-whisker plots representing VKORC1 gene-dose effect 
during initiation. The top and bottom of the boxes represents 25th and 75th percentile, 
respectively; median is represented by the middle line, whiskers are the 95% CI, and 
outliers are identified as closed circles. (B) Warfarin daily dose on days 7/8/9 with 
respect to VKORC1 genotype. (C) Frequency distribution of estimated Imax, shown as 
percent of total patients for each bin. (D) Association between VKORC1 genotype and 
Imax. Results are represented as mean with standard deviation. (E) Additive effect of 
indication for warfarin therapy and VKORC1 genotype on Imax. (F) INR time course for 
patients with AF and VTE over the initial 10 days of therapy with common genetics-
guided dosing protocol. Results are represented as mean with 95% CI of the standard 
error. AF, atrial fibrillation; INR, international normalized ratio; VTE, venous 
thromboembolism. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001        
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Figure 5.3 Determinants of maximal inhibitory factor, Imax. 
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Table 5.3.2 Multiple linear regression analysis of independent predictors of Imax. 
Entry 
into 
model 
Predictor 
Variable 
B 
Standar
d error 
95% CI 
R2 after 
entry 
(%) 
P in 
final 
model 
- Intercept 1.383 0.101 
1.156,  
1.570 
- <0.0001 
1 
VKORC1, 
per allele 
0.211 0.030 
0.148,  
0.267 
26.3 <0.0001 
2 
Indication 
(VTE) 
-0.281 0.049 
-0.380,  
-0.190 
34.9 <0.0001 
3 
PIVKA-II 
(ng/mL) 
0.017 0.007 
0.005,  
0.033 
37.9 <0.05 
4 
CYP4F2, per 
allele 
-0.072 0.031 
-0.133, 
 -0.009 
39.6 <0.05 
5 Weight (Kg) 0.002 0.001 
0.000,  
0.004 
41.0 <0.05 
CI, confidence interval; CYP4F2, cytochrome P450 4F2; Imax, maximal inhibitory factor; 
PIVKA-II, proteins induced by vitamin K absence; VKORC1, vitamin K epoxide 
reductase complex subunit 1; VTE, venous thromboembolism. 
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5.3.5 Correlation of VKORC1 genotype to hepatic VKOR protein 
levels 
With Western blot analysis, hepatic microsomal VKOR had electrophoretic mobility 
consistent with an 18 kDa protein while the two immunoreactive bands observed in over-
expressed VKOR control samples likely represent differentially glycosylated forms of the 
protein (Figure 5.4A, 5.4B, 5.4C). VKOR protein level was significantly correlated to 
VKORC1 genotype (Figure 5.4D, P<0.05), where the VKORC1 G allele was associated 
with higher liver enzyme level than the A allele.  
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Figure 5.4 The influence of VKORC1 -1639G>A promoter genotype on hepatic 
VKOR protein expression levels. 
(A, B, C) VKOR expression determined in 17 healthy human livers by Western blot 
analysis. The band intensity was normalized to HLM100. A positive control sample was 
included on each blot. (D) Semiquantitative measurement of hepatic expression in 
relation to VKORC1 genotype. * P < 0.01 
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5.3.6 Simulated anticoagulation response with different warfarin 
initiation protocols 
To demonstrate the utility of the PK-PD model, we simulated and compared INR 
response profiles of individuals with different combinations of covariates using different 
published dose initiation schemes (25, 29, 40-42). Specifically, we compared response-
time curves of typical patients following initiation with our WRAPID protocol (29), the 
Kovacs nomogram (non-pharmacogenetics, validated in VTE) with the day 8 dose 
refinement algorithm (42), and finally, initiation with the pharmacogenetics-based as well 
as clinical-only maintenance dose algorithms available at www.warfarindosing.org 
incorporating the recently published day 4 dose refinement algorithm (25, 40). Doses 
were adjusted according to simulated INR values on days 3, 5, and 8 for WRAPID and 
Kovacs and on day 4 for warfarindosing.org as per nomogram. Clearance and Imax values 
were calculated based on regression equations (Tables 5.1 and 5.2) for various VKORC1 
and CYP2C9 genotype combinations in typical AF and VTE patients. Homozygous 
CYP2C9*3 patients were not considered in the simulations as we did not encounter such 
individuals in our population. We used CYP4F2 wild-type C/C genotype (increased 
sensitivity) for all calculations of Imax. Figure 5.5 illustrates the predicted effect of 
VKORC1 or CYP2C9 variant allele burden on responses of AF and VTE patients initiated 
with WRAPID nomogram (Figure 5.5A, 5.5B), Kovacs nomogram (Figure 5.5C, 5.5D), 
warfarindosing.org genetics (Figure 5.5E, 5.5F), and clinical nomogram (Figure 5.5G, 
5.5H), respectively. The simulated response curves indicate that increased possession of 
variant alleles is associated with slightly greater time above therapeutic INR with fixed 
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10 mg loading doses and iterative response-based Kovacs nomogram than initiation 
strategies which incorporate genetic and patient factors. In contrast, pharmacogenetics-
guided initiation schemes eliminated the genotype-dependent response differences. 
Furthermore, pharmacogenetics-guided dosing nomograms resulted in comparable rise to 
optimal anticoagulation response among different genotypes within groups of AF and 
VTE patients. Evidently, loading dose was not used in simulations of patients initiated 
with warfarindosing.org and thus, the time to reach optimal anticoagulation was 
approximately 3 days slower as compared to the WRAPID nomogram. Simulations with 
the warfarindosing.org clinical algorithm indicate that there would be significant 
differences in initial INR responses as the burden of genetic variants increases.  
 
136 
 
 
Figure 5.5 Model predicted response curves following warfarin initiation using various 
initiation protocols. Simulations were performed using non-genetics and genetics-based 
nomograms for typical AF and VTE patients harbouring variable number of variant 
alleles. The genotype of zero-variant patients is VKORC1G/G-CYP2C9*1/*1. Patients 
carrying 1 variant allele have one of the following genotype combinations: VKORC1G/A-
CYP2C9*1/*1, VKORC1G/G-CYP2C9*1/*2, or VKORC1G/G-CYP2C9*1/*3. Patients 
carrying 2 variant alleles have one of the following genotype combinations: 
VKORC1A/A-CYP2C9*1/*1, VKORC1G/A-CYP2C9*1/*2, VKORC1G/A-
CYP2C9*1/*3, or VKORC1G/G-CYP2C9*2/*2. Patients carrying 3 variant alleles have 
one of the following genotype combinations: VKORC1A/A-CYP2C9*1/*2, 
VKORC1A/A-CYP2C9*1/*3, VKORC1G/A-CYP2C9*2/*2, or VKORC1G/A-
CYP2C9*2/*3. Patients carrying 4 variant alleles have one of the following genotype 
combinations: VKORC1A/A-CYP2C9*2/*2, or VKORC1A/A-CYP2C9*2/*3. AF, atrial 
fibrillation; VTE, venous thromboembolism.    
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Figure 5.5 Model predicted response curves following warfarin initiation using 
various initiation protocols. 
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5.4 Discussion 
Warfarin initiation is a challenging therapeutic phase, associated with the highest 
occurrence of major bleeding events and thromboembolism (43-46). Thus, effective 
initiation protocols that pre-emptively account and adjust for interindividual variability 
have significant potential to improve warfarin anticoagulation therapy.  
 
A major contributor to dose requirement and response is S-warfarin clearance. The 
analysis demonstrates that kidney function, gender, CYP2C9*2 and *3 genotype are 
major determinants of S-warfarin clearance. The finding that S-warfarin clearance is 
reduced in renal impairment supports recent studies that found relationships between both 
warfarin dose requirement and propensity for over-anticoagulation with kidney function 
(47, 48). Although age has been correlated with decreased warfarin clearance, we failed 
to observe this relationship after multivariate regression that included both age and eGFR 
(7-9, 27). It is plausible that age, as a contributor to clearance, somewhat reflects age-
related decline in renal function. Indeed, we note that including eGFR as an additional 
factor into the regression analysis resulted in 36.5% of clearance variation explained, 
while only 27.6% of this variation was accounted for when eGFR was absent and age 
included in the analysis. Interestingly, gender was a significant independent contributor 
to S-warfarin clearance in this study, with females having 22% lower S-warfarin 
clearance than males. While females require lower doses than males for similar 
anticoagulation quality and efficacy (49), there remain conflicting reports on the role of 
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gender on S-warfarin pharmacokinetics (7, 8, 27). Drug interactions, particularly with 
amiodarone and antifungals, are significant contributors to variable warfarin response 
(50-52). Because of the limited number of patients in this cohort taking these 
medications, we did not find associations between concomitant drugs and warfarin 
clearance.  Larger studies in patients are required to better characterize the quantitative 
influence of co-administered drugs on warfarin clearance. 
 
While determinants of S-warfarin PK have been studied, less is known regarding 
determinants of the S-warfarin plasma concentration-response relationship. We identified 
VKORC1, weight, indication for warfarin, PIVKA-II and CYP4F2 genotype as significant 
predictors of S-warfarin Imax, the PD parameter that governs the magnitude of observed 
anticoagulation INR response. In addition, we demonstrate that promoter -1639G>A SNP 
results in lower hepatic VKOR protein expression. In concordance with that previously 
observed for warfarin-stabilized patients (53), there was a significant relationship 
between VKORC1 genotype and S-warfarin plasma concentrations at the end of the 
initiation phase where therapeutic INR was achieved. Taken together, the VKORC1 -
1639G>A promoter SNP confers lower hepatic expression, thus lower plasma S-warfarin 
concentrations and dose required for optimal anticoagulation.  
 
The finding that Imax differences exist between AF and VTE patients, following 
adjustment of confounding variables such as age and weight, suggests that indication for 
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treatment maybe a prominent contributor to response variability during initiation. This 
may be attributed to different coaguability states among patients during therapy initiation, 
in addition to inherent disease differences between the two subsets of patients. Further 
studies are required to investigate the physiological basis mediating the PD differences 
between AF and VTE patients. It is also of interest to know whether this dynamic 
difference would diminish or be maintained throughout the course of anticoagulation 
therapy. Indeed, indication for anticoagulation was an independent determinant of 
maintenance dose in the present cohort and one dose algorithm (warfarindosing.org) 
incorporates VTE as a factor requiring higher warfarin maintenance dose (25). In the 
present study population, we find a 2.3 mg/day difference in mean maintenance dose 
between AF and VTE patients.  This value is greater than the 0.7 mg/day difference 
predicted by the WRAPID maintenance dose algorithm when accounting for the average 
age (21 yrs) and weight (6.5 kg) differences between the AF and VTE groups. While a 
component of this maintenance dose difference is likely related to the lack of 
consideration of renal function differences among the disease groups with the WRAPID 
algorithm, the current PK-PD analysis suggests that indication for anticoagulation 
remains a contributor to warfarin dose.  
 
In agreement with previous studies linking CYP4F2 genotype and vitamin K intake to 
warfarin dose requirement (18, 23, 24), our data demonstrate that pre-treatment plasma 
PIVKA-II levels and CYP4F2 1297G>A genotype affects S-warfarin PD sensitivity 
during initiation. PIVKA-II, a des-carboxylated form of prothrombin, is a direct 
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biomarker for liver vitamin K status and dietary intake (54). We did not find a 
relationship between PIVKA-II level and CYP4F2 genotype during statistical analysis or 
collinearity during stepwise regression of Imax for this cohort of patients.  Taken together, 
our findings highlight the importance of the balance between the VKOR agonist (vitamin 
K) and antagonistic (warfarin) concentrations in achievement and maintenance of optimal 
anticoagulation, particularly during initiation.  
 
An important outcome of this study was the formulation of an overall PK-PD model that 
incorporates the determinants of warfarin kinetics and response. We demonstrate the 
utility of the model to predict S-warfarin concentrations and INR response curves in 
simulated individuals initiated with different protocols. The simulations predict 
substantial differences in initial anticoagulation responses depending on the initiation 
scheme, indication for warfarin treatment and burden of genetic variation in CYP2C9 and 
VKORC1.  Within all of the initiation protocols examined, AF patients would be 
predicted to have greater initial response than VTE.  The indication difference 
exaggerates the effect of genetic polymorphisms on response especially for initiation 
protocols that do not consider CYP2C9 and VKORC1 genotypes. Interestingly, the 
simulations indicate that the Kovacs nomogram results in a safe and rapid initiation in 
VTE patients, consistent with the observed good safety profile in real-world patients (41, 
55). On the other hand, the Kovacs nomogram is predicted to be less optimal for in AF as 
it may pose an over-anticoagulation risk in these patients. Simulations in patients initiated 
with pharmacogenetics-based dosing algorithms suggest they would be safe and effective 
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for both patient populations and that the response curves of individuals possessing variant 
alleles were similar. In comparing initiation with WRAPID and warfarindosing.org, time 
to therapeutic range was delayed without the use of loading dose. In the case for VTE, 
delayed attainment of therapeutic INR may have economic consequences as bridging 
therapy with low molecular weight heparins would need to be extended when loading 
doses are not administered. The simulations also forecast the time-course of initial INR 
responses in the large multi-centered randomized clinical trial comparing outcomes 
between pharmacogenetic and clinical-based warfarin dosing (Clarification of Optimal 
Anticoagulation Through Genetics, COAG trial) as defined by warfarindosing.org 
algorithms. The model predicts significant differences in INR response between the two 
dosing methods during initiation, particularly for patients harbouring variant alleles.  
 
While maintenance dose prediction algorithms typically utilize a number of clinical and 
genetic parameters, these models are not designed to delineate how each parameter 
affects warfarin PK, PD or both. The formal PK-PD analysis described herein 
demonstrates that the interindividual variation in both components of the overall warfarin 
response can be separated and quantitatively ascribed to respective combinations of non-
genetic and genetic factors. Moreover, our integrated PK-PD model allows for robust 
prediction of INR response profiles particularly during initiation phase of therapy 
following any initiation-dose scheme, in addition to assessment of covariate effect on 
responses by altering PK or PD estimates. It should be noted that based on the current 
model form and input parameters, the PK determinants only account for 36.5% of the 
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variability observed in S-warfarin clearance, while PD determinants accounted for 41% 
of the Imax variation. For this reason, it is expected that the current model would not 
provide precise response estimations on an individual patient basis due to the large 
variation still unaccounted for.  
 
In conclusion, the data presented here provides additional insight into the combination of 
patient characteristics contributing to warfarin PK and PD variability, in turn allowing 
better prediction of anticoagulation response outcomes without the need for intensive 
sampling of drug concentrations. Until there is a better understanding of additional 
determinants of PK and PD variation, and better quantitative characterization of drug-
drug interactions, the current model may be useful for predicting outcomes in populations 
of patients within the context of comparing the effectiveness of various dosing algorithms 
in early attainment and maintenance of therapeutic INR responses and in guiding future 
study designs.  
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(ABCG2) TRANSPORTERS SIGNIFICANTLY ALTER 
RIVAROXABAN DISPOSITION AND CNS ENTRY4 
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6.1 Introduction 
Thromboembolic events resulting from blood clotting disorders are a significant source 
of mortality and morbidity and thus often require life-long anticoagulation therapy (1). 
Although warfarin has been the mainstay of therapy, important limitations in its use have 
prompted development of newer agents (2). Rivaroxaban is a reversible factor Xa 
inhibitor recently approved for stroke prevention in atrial fibrillation (AF) patients and 
treatment of venous thromboembolism (VTE) (3).  
 
Rivaroxaban oral bioavailability was reported to be over 80% and achieves maximal 
anticoagulation 2-4 hr after administration (4). Excretion of rivaroxaban occurs through 
two main pathways; cytochrome P450 (CYP) 2J2 and CYP3A4-dependent metabolism 
are responsible for two-thirds of its elimination while one-third is renally excreted 
unchanged (4). However, renal elimination may be greater than currently assumed as 
rivaroxaban exposure is 50% higher in patients with renal impairment (4). Furthermore, 
bleeding complications were higher in patients with poor renal function (2, 5). Renal 
excretion appears to be greater than glomerular filtration rate, suggesting a significant 
contribution of active secretory processes to rivaroxaban elimination (2).  
 
There has been growing appreciation of drug transporters expressed in various tissues in 
determining the disposition and excretion of a wide range of xenobiotics (6). P-
glycoprotein (P-gp), or multi-drug resistance protein 1 (MDR1, ABCB1) and breast 
cancer resistance protein (BCRP, ABCG2) belong to the ATP-binding cassette family of 
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efflux transporters. Both are expressed in organs important for drug elimination such as 
the intestine, liver, and kidney. Moreover, their expression in organs such as the brain and 
placenta prevent the entry of substrate drugs (7, 8). 
 
Rivaroxaban was recently reported to be a substrate of P-gp (9), and correspondingly, 
concomitant administration of potent P-gp inhibitors in human beings increases plasma 
levels by over two times 
(http://www.ema.europa.eu.proxy1.lib.uwo.ca/docs/en_GB/document_library/EPAR_Pro
duct_Information/human/000944/WC500057108.pdf). However, rivaroxaban 
pharmacokinetics (PK) was not altered in P-gp knockout mice, likely due to involvement 
of other efflux transporters (9). It is known that P-gp and BCRP exhibit overlapping 
substrate specificity and tissue expression (10). For common drug substrates, the 
transporters tend to exhibit a synergistic effect at the blood brain barrier (BBB) (11). 
Thus, we suggested that BCRP may be the key compensatory transporter for rivaroxaban. 
Accordingly, we investigated the transcellular transport of rivaroxaban in polarized cell 
monolayers followed by assessment of the in vivo relevance of P-gp and BCRP to 
rivaroxaban disposition using knockout mouse models.  
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6.2 Methods 
6.2.1 Rivaroxaban permeability in polarized LLCPK, LMDR1 and 
Caco-2 monolayers  
LLCPK, LMDR1 (LLCPK cells over-expressing MDR1) and Caco-2 cells were grown in 
DMEM (Lonza, Walkersville, MD, USA) supplemented with 10% FBS (Invitrogen, 
Carlsbad, CA), 2 mM L-glutamine, 50 U/mL penicillin (Invitrogen), 50 µg/mL 
streptomycin (Invitrogen), and 1% non-essential amino acids (Invitrogen) and incubated 
at 37°C in 5% CO2. LMDR1 cells were cultured with 640 nM vincristine (Sigma-
Aldrich, St. Louis, MO, USA) to maintain MDR1 expression. LLCPK and LMDR1 cells 
were seeded at a density of 2 x 105 cells per 12 mm well while Caco-2 cells were seeded 
at 3 x 105 cells/mL onto 0.4 µm porous membrane inserts (BD, Franklin Lakes, NJ, 
USA). LLCPK and LMDR1 cells were allowed to polarize over a 7-day incubation 
period while Caco-2 cells were allowed to polarize for 12 days, with media change every 
2 days. Prior to commencement of the transport experiment, cells were washed and 
incubated with Opti-MEM (Invitrogen) for 1 hr. To initiate transport, media from either 
the basal or apical compartment were replaced with 700 µL Opti-MEM with or without 5 
µM rivaroxaban (Toronto Research Chemicals, Toronto, ON, Canada), as appropriate. 
Cells were incubated at 37°C in 5% CO2 and transcellular flux was measured in the 
apical-basal or basal-apical direction over 4 hr by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). In LLCPK and LMDR1 monolayers, rivaroxaban transport 
was also conducted in the presence of the selective P-gp inhibitor LY335979 (12) (1 µM; 
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Eli Lilly Pharmaceuticals, Indianapolis, IN, USA). In Caco-2 monolayers, rivaroxaban 
transport was also conducted in the presence of LY335979, the selective BCRP inhibitor, 
fumitremorgan C (13, 14) (1 µM; Sigma-Aldrich) or both. Digoxin ([3H]-radiolabeled, 1 
µM) was used as the positive control. Apparent permeability (Papp) was calculated from 
the following equation: Papp = dQ/dt*1/(A*C0), where dQ/dt is the rate of transport over 4 
hr, C0 is the resultant rivaroxaban concentration, and A is the surface area of the 
membrane insert.  
 
6.2.2 In vivo disposition of rivaroxaban disposition in transporter 
knockout mice models 
Male 6-12 week old Mdr1a-deficient mice (Mdr1adef), a subpopulation of CF-1 mouse 
strain lacking expression of P-glp in the intestine and brain, and age matched male wild-
type CF-1 mice were obtained from Charles River Laboratories (Wilmington, MA, USA). 
Bcrp knockout (Bcrp-/-), Mdr1a/Mdr1b/Bcrp triple knockout (Mdr1a/Mdr1b-/-/Bcrp-/-) 
mice, and age-matched (6-12 weeks old) wild-type FVB mice were obtained from 
Taconic Farms (Hudson, NY, USA). Mice were administered 2 mg/kg of rivaroxaban via 
oral gavage. Doses were prepared by dissolving rivaroxaban in DMSO (2%) and (1:1 v/v) 
PEG-400/sterile water. Serial blood samples (60 – 100 µL) were obtained over 4 hr from 
the saphenous vein and centrifuged to obtain plasma. At 4 hr, mice were killed using 
isoflurane, blood was collected via cardiac puncture and liver, kidney, and brain tissues 
were harvested and flash-frozen. Tissues were weighed and homogenized in 5 mM 
ammonium acetate, pH 4.  
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6.2.3 Rivaroxaban drug level analysis by LC-MS/MS 
Samples from in vitro permeability studies, plasma and tissue homogenates were spiked 
with 15 µL of internal standard (D3-rivaroxaban, 500 ng/mL; Toronto Research 
Chemicals). Subsequently, acetonitrile was added to samples (3:1 v/v) and centrifuged at 
9000 x g for 20 min to precipitate protein. The resulting supernatant was added to two 
volumes of 5 mM ammonium acetate pH 4 and injected into the liquid chromatograph. 
Analytes were separated with the reverse-phase Hypersil Gold column (50 × 5 mm, 5 µM 
particle size) using gradient elution with 5 mM ammonium acetate pH 4 and acetonitrile 
(20 to 80%) in a 6 min run time. The MS was set in positive mode for detection of 
rivaroxaban and IS with transitions 437  144 m/z and 440  144 m/z, respectively. 
The lowest limit of quantification was 1 ng/mL. The interday coefficient of variation and 
bias of rivaroxaban quality controls were 10.5% and 9.3%, respectively. 
 
6.2.4 Statistical analysis 
The Mann-Whitney non-parametric t-test was used to analyse the statistical difference 
between two groups (Graphpad Prism v5.0, La Jolla, CA, USA). Rivaroxaban clearance 
was determined by non-compartmental analysis of plasma concentration curves in mice.  
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6.3 Results  
6.3.1 Permeability of rivaroxaban in LLCPK and LMDR1 cells  
The ability of P-gp to transport rivaroxaban was assessed using the parental LLCPK and 
LMDR1 cells. Rivaroxaban flux was markedly greater in the basal-apical direction, 
where the permeability difference was 5.46 (Figure 6.1A). Modest basal-apical transport 
was observed in LLCPK cells (1.68), suggesting transport by an endogenously expressed 
transporter. In the presence of a specific P-gp inhibitor, LY335979, the basal-apical flux 
in LMDR1 monolayers was attenuated, whereas apical-basal flux was enhanced, 
abrogating the net efflux (Figure 6.1B). In contrast, little change was observed in the net 
efflux of rivaroxaban in LLCPK cells in the presence of LY335979. As expected, net flux 
of digoxin, a well-recognized P-gp substrate, was in the basal-apical direction in LMDR1 
cells, which was abrogated with LY335979.  
 
6.3.2 Permeability of rivaroxaban across intestinal Caco-2 cells 
Vectorial transport of rivaroxaban was also assessed in the intestinal Caco-2 model, 
known to express both MDR1 and BCRP. There was significantly greater permeability of 
rivaroxaban in the basal-apical direction, leading to an efflux ratio of 2.82 (Figure 6.1C). 
In the presence of either LY335979 or the specific BCRP inhibitor, fumitremorgan C, 
rivaroxaban net flux was attenuated, reducing the efflux ratio to 1.61 and 1.88, 
respectively (Figure 6.1D, 6.1E). Moreover, co-administration of both LY335979 and 
fumitremorgan C with rivaroxaban lead to near complete loss of directional transport 
difference (1.29) (Figure 6.1F). The permeability data are summarized in Table 6.1. 
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Figure 6.1 In vitro transport of 5 µM rivaroxaban across monolayers. Rivaroxaban 
transport was assessed in LMDR1 (A) and Caco-2 cells (C). The flux in LMDR1 cells 
was also evaluated with co-administration of 1 µM of the specific MDR1 inhibitor, 
LY335979 (B). The flux in Caco-2 cells was also evaluated with co-administration of 1 
µM of the specific BCRP inhibitor, fumetrimorgan C (D), 1 µM LY335979 (E) or both 
(F). Symbols and bars represent the mean and standard error. All transport experiments 
were conducted in triplicates. ** P  < 0.01, *** P  < 0.001 
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Figure 6.1 In vitro transport of 5 µM rivaroxaban across monolayers. 
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Table 6.3.1 Apparent permeability of rivaroxaban across cell monolayers. 
P
app A-B (SEM) Papp B-A (SEM) 
Efflux Ratio  
(P
appB-A/PappA-B) 
10
-6
 cm/s 
LLCPK 
Rivaroxaban  5.55 (0.49) 9.35 (0.20) 1.68 
Rivaroxaban + LY 6.72 (1.16) 8.88 (1.15) 1.32 
LMDR1 
Rivaroxaban  2.28 (0.67) 12.44 (2.48) 5.46 
Rivaroxaban + LY 12.10 (4.61) 10.40 (1.84) 0.86 
[3H]Digoxin 2.59 (0.30) 7.01 (0.50) 2.70 
[3H]Digoxin + LY 4.26 (0.29) 4.86 (0.28) 1.14 
Caco-2 
Rivaroxaban  3.85 (0.44) 10.85 (0.15) 2.82 
Rivaroxaban + LY 5.82 (0.56) 9.37 (0.22) 1.61 
Rivaroxaban + FTC 5.29 (0.28) 9.93 (0.27) 1.88 
Rivaroxaban + LY + FTC 7.26 (0.90) 9.38 (0.76) 1.29 
[3H]Digoxin 2.44 (0.12) 6.16 (0.28) 2.52 
[3H]Digoxin + LY 3.57 (0.31) 4.13 (0.45) 1.16 
BCRP, breast cancer resistance protein; FTC, fumitremorgan C; LY, LY335979; MDR1, 
multi-drug resistance protein 1; P
app, apparent permeability; S.E.M., standard error of the 
mean. 
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6.3.3 Rivaroxaban in vivo disposition in wildtype and knockout 
mice 
To determine the relevance of MDR1 and BCRP in vivo, plasma (Table 6.2) and tissue 
(Table 6.3) concentrations were assessed after rivaroxaban oral administration (2 mg/kg) 
to wild-type, Mdr1adef, Bcrp-/-, and Mdr1a/Mdr1b-/-/Bcrp-/- mice (n = 6 per group). Plasma 
concentrations did not significantly differ between wild-type and Mdr1adef or Bcrp-/- mice 
(Figure 6.2A, 6.2B). However, the Mdr1a/Mdr1b-/-/Bcrp-/- mice appeared to exhibit 
higher rivaroxaban plasma levels (Figure 6.2C). At 4 hr, rivaroxaban liver-to-plasma ratio 
was significantly lower in the absence of Mdr1a, while no difference was observed in 
Bcrp-/- or Mdr1a/Mdr1b-/-/Bcrp-/- mice compared with wild-type (Figure 6.3A-C). 
Rivaroxaban kidney-to-plasma ratio did not differ across the various knockout mice 
assessed (Figure 6.3D-F). However, kidney rivaroxaban accumulation was significantly 
higher in Mdr1a/Mdr1b-/-/Bcrp-/- mice, likely due to the higher plasma concentration 
observed in these mice (data not shown). Importantly, rivaroxaban total apparent 
clearance was only significantly reduced in the absence of both Mdr1 and Bcrp compared 
with wild-type (Figure 6.2D). Interestingly, rivaroxaban brain-to-plasma ratio was not 
increased in Mdr1adef or Bcrp-/- mice, but was significantly elevated in Mdr1a/Mdr1b-/-
/Bcrp-/- mice by over two times (Figure 6.3G-I).  
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Table 6.3.2 Mean plasma tissue concentrations of rivaroxaban (ng/mL) after oral 
administration of 2 mg/kg rivaroxaban (n = 6) in knockout and wild-type mice. 
  Time (hr) 
0.5 1 2 4 
Mdr1adef   
Wildtype 29.3 (14.7) 20.5 (8.5) 12.1 (3.20 9.7 (2.6) 
Mdr1adef 32.4 (24.5) 16.8 (7.6) 13.0 (6.2) 7.5 (3.5) 
Bcrp-/-     
Wildtype 182 (28) 94 (15) 31 (8) 11 (4) 
Bcrp-/- 133 (38) 85 (30) 26 (6) 18 (10) 
Mdr1a/Mdr1b-/-/Bcrp-/-     
Wildtype 45.8 (23.7) 27.1 (3.4) 12.3 (3.2) 5.0 (2.2) 
Mdr1a/Mdr1b-/-/Bcrp-/- 31.6 (12.8) 27.0 (9.4) 19.8 (8.0) 8.5 (2.8) 
Bcrp, breast cancer resistance protein; Mdr1a, multi-drug resistance protein isoform 1a; 
Mdr1a, multi-drug resistance protein isoform 1b. 
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Table 6.3.3 Mean tissue concentrations of rivaroxaban (ng/mL) 4 hr after oral 
administration of 2 mg/kg rivaroxaban (n = 6) in knockout and wild-type mice. 
  Organ 
Liver Kidney Brain 
Mdr1adef   
Wildtype 12.5 (3.5) 2.9 (2.1) 0.14 (0.05) 
Mdr1adef 6.6 (3.0) 4.0 (3.9) 0.18 (0.05) 
Bcrp-/-    
Wildtype 19.7 (8.2) 3.1 (2.2) 0.7 (0.3) 
Bcrp-/- 38.6 (18.0) 4.8 (2.3) 0.7 (0.3) 
Mdr1a/Mdr1b-/-/Bcrp-/-    
Wildtype 4.6 (1.7) 2.5 (0.8) 0.05 (0.01) 
Mdr1a/Mdr1b-/-/Bcrp-/- 7.7 (1.8) 4.0 (1.0) 0.22 (0.07) 
Bcrp, breast cancer resistance protein; Mdr1a, multi-drug resistance protein isoform 1a; 
Mdr1a, multi-drug resistance protein isoform 1b. 
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Figure 6.2 Rivaroxaban pharmacokinetics in mice. 
Rivaroxaban was administered by oral gavage to wildt-ype, Mdr1a deficient (Mdr1adef), 
Bcrp-/-, and Mdr1a/Mdr1b-/-/Bcrp-/- mice (n = 6 for each group). The ratio of rivaroxaban 
concentration and apparent systemic clearance in knockout and wild-type mice over 4 hr 
was determined. Data are represented as mean with standard error of the mean. * P  <  
0.05 
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Figure 6.3 Rivaroxaban liver, kidney and brain distribution in mice. 
Liver to plasma ratios in Mdr1adef (A), Bcrp-/- (B), Mdr1a/Mdr1b-/-/Bcrp-/-(C) are 
compared to wild-type. Kidney to plasma ratios in Mdr1adef (D), Bcrp-/- (E), 
Mdr1a/Mdr1b-/-/Bcrp-/-(F) are compared to wild-type. Brain to plasma ratios in Mdr1adef 
(G), Bcrp-/- (H), Mdr1a/Mdr1b-/-/Bcrp-/-(I) are compared to wild-type. Data are 
represented as mean with standard deviation. * P <  0.05 
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6.4 Discussion 
In this report, we demonstrate that rivaroxaban is a shared substrate of both P-gp and 
BCRP. In vivo relevance and interplay of both transporters are demonstrated through the 
observation of a lack of any impact to rivaroxaban clearance in the individual transporter 
knockout mice, but significantly reduced in the Mdr1a/Mdr1b-/-/Bcrp-/- mice. Similar to 
certain tyrosine kinase inhibitors (11), rivaroxaban accumulation in the brain was 
considerably higher when both transporters were absent than either one alone, suggesting 
the collective effect of P-gp and Bcrp in determining rivaroxaban brain exposure in brain. 
 
Although drug interaction studies have traditionally been focused on metabolizing 
enzyme-mediated interactions, emerging evidence in recent years indicates the important 
role of drug transporters in modulating pharmacokinetics and hence, efficacy and toxicity 
(6, 15). Therefore, identification of drug transporters involved in rivaroxaban disposition 
in addition to metabolizing enzymes is crucial for optimal efficacy while reducing side 
effects. Accordingly, our findings are of particular importance in predicting rivaroxaban 
exposure and certain drug drug interactions (DDIs) involving P-gp and BCRP. While 
anticoagulation therapy effectively reduces ischaemic strokes, the elevated risk of 
haemorrhage complications paradoxically causes intracranial bleeding, including the life-
threatening haemorrhagic stroke in some patients (16). Moreover, the risk of rivaroxaban-
associated adverse events was compounded by poor renal function, driven by increased 
systemic levels of the drug (5). Thus, exposure to rivaroxaban is expected to modulate the 
extent of bleeding risk in patients. Our findings would suggest that patients at the highest 
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bleeding risk likely have not only poor renal function but also reduced P-gp and BCRP 
function, where the net effect would be increased gastrointestinal rivaroxaban absorption 
leading to increased bioavailability, made worse through reduced rivaroxaban renal 
secretion.   
 
 
The lack of dramatic change in rivaroxaban disposition in vivo in mice lacking P-gp 
function is in concordance with a previous report (9). Moreover, there may be rodent and 
human differences in substrate specificity of P-gp, leading to differential P-gp-mediated 
transport efficiency (17). Consequently, caution should be used for translating results 
found in animal models to human beings, particularly for weak substrates of P-gp. 
Nonetheless, mice deficient in P-gp has been used as a powerful tool for assessing the 
role of P-gp in vivo, likely attributed to the overlapping expression pattern and function 
between rodents and human P-gp (18). Despite this, the role of P-gp in modulating 
rivaroxaban efficacy and risk of bleeding complications in human beings should not be 
overlooked. In fact, concurrent use of rivaroxaban and P-gp inhibitors is contraindicated 
due to prolonged anticoagulation and increased bleeding risk as a result of elevated 
plasma levels, as observed with ketoconazole and ritonavir. Given that the bioavailability 
of rivaroxaban is high, it is likely that the observed clinical interaction is owing to 
inhibition of metabolism and excretion of rivaroxaban rather than affecting its absorption. 
We know that P-gp and CYP3A4 share a large number of common inhibitors (19), and 
thus the over two times increase in rivaroxaban exposure in human beings with co-
administration of ketoconazole and ritonavir is likely a result of dual inhibition of P-gp 
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and CYP3A4. In addition, it is possible that the inability to translate from deficient mouse 
model to the observed P-gp interaction in human beings is due to the less prominent role 
of renal excretion to overall rivaroxaban disposition in rodents (20). Thus, although our 
data indicated that the overall clearance was only modestly reduced even in the 
Mdr1a/Mdr1b-/-/Bcrp-/- knockout mice, the relevance of P-gp and BCRP-mediated 
rivaroxaban excretion in humans should not be disregarded and requires further 
assessment.  
 
Drug interactions with BCRP are less likely as a large fraction of BCRP substrates and 
inhibitors are chemotherapeutic agents (21). However, there are clinically relevant 
polymorphisms that exist in MDR1 and BCRP, particularly the common reduced function 
polymorphisms in BCRP (c.34 G>A, c.421 C>T) recognized for affecting the PK of its 
substrates (22, 23). Thus, genetic variations in efflux transporters may play an important 
role in determining rivaroxaban exposure, efficacy, and toxicity. Collectively, we 
postulate that homozygous carriers of BCRP variants concomitantly taking P-
gp/CYP3A4 inhibitors likely possess the greatest risk for haemorrhage. This is especially 
a concern for AF patients, the predominant disease of the elderly with declining renal 
function, whereby comorbidities and concomitant use of P-gp/CYP3A4 inhibiting 
medications may be difficult to avoid. Our findings would suggest that the highest at risk 
subset of such patients would be those who carry loss of function polymorphisms in 
BCRP.  
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Additionally, higher rivaroxaban entry in central nervous system (CNS) in Mdr1a/Mdr1b-
/-/Bcrp-/- mice suggests that patients with attenuated P-gp and BCRP transport function 
could potentially be at greater risk of intracranial haemorrhage. Modulation of P-gp 
function with use of inhibitors has indeed been shown to allow greater CNS access for P-
gp substrates, such as HIV protease inhibitors and loperamide (12, 24). The mechanisms 
underlying haemorrhagic strokes have not been clearly delineated; however, oral 
anticoagulant-associated haemorrhage has been suspected to be due to increased 
haematoma expansion, particularly in patients with over-anticoagulation as a result of 
elevated systemic exposure of the drug (25). Moreover, rivaroxaban was developed with 
the intent of eliminating routine response monitoring. Hence, evaluation of 
anticoagulation efficacy and bleeding risk in patients will likely be problematic in real-
world patients without the use of a standardized test. Furthermore, the lack of a validated 
antidote for reversing rivaroxaban overdose will likely potentiate the danger of bleeding 
events (26). Thus, similar to other new anticoagulant agents (27), there is a need for post-
marketing surveillance of adverse events, including analysis of bleeding events within the 
context of drug transporter pharmacogenetics, to more fully delineate rivaroxaban safety 
and efficacy. Future clinical studies are required to elucidate the combined effect of P-gp 
and BCRP in modulating rivaroxaban exposure in plasma, bleeding complications, and 
anticoagulation efficacy. 
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7 CLARIFYING THE IMPORTANCE OF CYP2C19 AND 
PON1 IN THE MECHANISM OF CLOPIDOGREL 
BIOACTIVATION AND IN VIVO ANTIPLATELET 
RESPONSE5
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7.1 Introduction 
Antiplatelet therapy is an important therapeutic intervention for prevention of ischaemic 
events in patients with high-risk cardiovascular disease, particularly for those who 
undergo percutaneous coronary intervention (PCI) (1). Currently, the standard of care for 
managing such patients is dual antiplatelet therapy with a P2Y12 receptor antagonist and 
the cyclooxygenase I inhibitor aspirin. Clopidogrel is the most widely prescribed 
thienopyridine that exerts its pharmacological effect by irreversibly binding to P2Y12 
receptors on platelets, thereby diminishing adenosine diphosphate (ADP)-mediated 
platelet aggregation (2). Although benefits from clopidogrel have been widely 
documented in large clinical trials, marked interpatient variation in platelet 
responsiveness has meant that 21% of the patients remain at risk for coronary artery and 
stent thrombosis (3).  
 
Clopidogrel is a prodrug and its clinical efficacy appears to be a function of the amount 
of enzymatically derived active thiol metabolite formed (4, 5). Previous in vitro studies 
have delineated that this bioactivation is a two-step process, catalysed by several 
cytochrome P450 (CYP) isozymes (6-8). Clopidogrel is first metabolized to the 
intermediate metabolite, 2-oxo-clopidogrel, followed by metabolism to a number of thiol 
metabolite stereoisomers, only one of which (H4) is active in vivo (2, 5, 9). Notably, both 
metabolic steps leading to H4 formation have been shown to be predominantly dependent 
on CYP2C19 and to a lesser extent CYP3A4 (6). Importantly, in large clinical trials, 
CYP2C19*2 or *3 loss-of-function single nucleotide polymorphisms (SNPs) have been 
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associated with lower platelet inhibition and consequently, an increased risk of major 
cardiovascular events (10-12).  
 
In contrast, Bouman et al. recently demonstrated that a non-CYP enzyme, paraoxonase-1 
(PON1) was the key determinant of clopidogrel active metabolite formation (13). 
Importantly, they showed that plasma PON1 activity as well as the Q192R SNP (rs662) 
in PON1, but not CYP2C19 SNPs was predictive of antiplatelet response and risk for 
stent thrombosis in clopidogrel-treated patients. These findings fundamentally challenged 
our prior understanding of clopidogrel metabolism and efficacy.  In the report, we set out 
to define a mechanistic link between clopidogrel metabolism and antiplatelet action to 
clarify the clinical relevance of PON1 and CYP2C19 to clopidogrel response. 
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7.2 Methods 
7.2.1 Clinical study design  
The study was approved by the Research Ethics Board at the University of Western 
Ontario. All subjects (age 18-65) were non-smokers, not taking concomitant medications, 
without previous exposure to clopidogrel, and deemed healthy per medical exam. Healthy 
volunteers who met the eligibility criteria were enrolled upon provision of written 
informed consent (n = 21; supplemental material, Table 7.3).  
 
Overnight fasted subjects received a single oral dose of clopidogrel (75 mg). In addition, 
100 µg of midazolam was administered orally as an in vivo probe for CYP3A4 activity. 
For pharmacokinetic analysis, blood samples were collected over an 8 h period. 
Clopidogrel thiol metabolites were stabilized for analysis using EDTA tubes containing 
50 µL of 125 mM 2-bromo-3-methoxyacetophenone (MPB) (Sigma-Aldrich, Oakville, 
Canada).  
 
To determine antiplatelet response, blood was collected using a 1.8 ml sodium citrate 
(3.2%) tube at baseline and 4 hours post-clopidogrel dose and subjected to the 
VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA), as per the manufacturer’s 
protocol.  
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Genotype analysis and plasma paraoxonase activity were determined as described in 
supplemental materials.  
7.2.2 Clopidogrel bioactivation  
The in vitro metabolic profiling of clopidogrel metabolism was conducted in microsomes 
(supplemental material).  
 
7.2.3 Liquid Chromatography Tandem Mass Spectrometry (LC-
MS/MS) analysis  
Quantitation of midazolam and clopidogrel metabolites (in vivo and in vitro) was 
performed as described in supplemental materials. 
 
7.2.4 Data analysis 
All data analyses are as described in supplemental material.  
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7.3 Results 
7.3.1 Influence of CYP2C19, PON1, and CYP3A4 on clopidogrel 
kinetics and response 
Following a 75 mg dose, carriers of at least one reduced function CYP2C19 allele 
[CYP2C19*2 or *3 allele, reduced metabolizers (RMs); 38% of the study population] had 
significantly decreased total plasma exposure (area under the plasma concentration curve, 
AUC) of the H4 active metabolite when compared with the non-carrier extensive 
metabolizers (EMs) (Figure 7.1A; supplemental material, Figure 7.6). Similarly, the 
maximum plasma concentration (Cmax) was higher in EMs than RMs (Table 7.1). Prior to 
administration of clopidogrel, the mean platelet responsiveness [platelet reactive units 
(PRU)] induced by 20 µmol/L ADP and 22 nM prostaglandin E1 (PGE1) was similar 
between EMs and RMs (VerifyNow P2Y12 assay; Table 7.2). Four hours following 
clopidogrel administration, the absolute percentage change in PRU was significantly 
lower in RMs when compared with EMs (Figure 7.1B). In fact, we observed a strong 
correlation between H4 plasma exposure and platelet inhibition, demonstrating that 
individuals with highest exposure to H4 active metabolite have the greatest antiplatelet 
response (Figure 7.1C). Interestingly, we did not observe any correlation between gain-
of-function PON1 Q192R polymorphism and clopidogrel pharmacokinetics or response, 
despite the fact that PON1 plasma activity, assessed ex vivo using paraoxon as the 
prototypical substrate, in the same healthy volunteers correlated well with the PON1 
Q192R genotype (Figure 7.1D, 7.1E; supplemental material, Figure 7.6). In addition, no 
significant correlation was found between paraoxonase plasma activity and antiplatelet 
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response (Figure 7.1F). Of note, exclusion of non-Caucasian participants in these 
analyses does not modify the above findings (data not shown).  
 
Midazolam plasma AUC was not related to H4 AUC or antiplatelet response (P = 0.91, 
0.65) (Figure 7.2).  
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Figure 7.1 The role of CYP2C19 and PON1 genetic polymorphisms in clopidogrel 
pharmacokinetic and pharmacodynamic responses. 
 (A and B) Box-and-whisker plots of total active metabolite H4 plasma exposure (AUC) 
and antiplatelet response according to CYP2C19 genotype. (C) Scatter plot of H4 AUC 
and antiplatelet response (r2 = 0.78). (D and E) Box-and-whisker plots of H4 AUC, 
paraoxonase plasma activity, and antiplatelet response according to the PON1 genotype. 
(F) Scatter plot of plasma paraoxonase activity and antiplatelet response. Boxes indicate 
25th and 75th percentile, whiskers denote the 95% confidence interval, and ‘+’ represents 
the mean. *P < 0.05; **P < 0.01. 
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Table 7.3.1 H4 active metabolite pharmacokinetic parameters following 
administration of a single 75 mg oral dose of clopidogrel. 
Cmax, (ng/mL) 33.9 (21.0) P-Value 
CYP2C19 
  
 
EM 40.2 (23.3) 
 
 
RM 25.5 (13.7) 0.05 
PON1 
  
 
Q192Q 30.34 (19.80) 
 
 
Q192R 41.84 (30.67) 
 
 
R192R 27.70 (6.08) 0.55 
tmax, (h) 0.73 (0.18) 
 
CYP2C19 
  
 
EM 0.77 (0.16) 
 
 
RM 0.67 (0.17) 0.18 
PON1 
  
 
Q192Q 0.78 (0.16) 
 
 
Q192R 0.68 (0.19) 
 
 
R192R 0.65 (0.13) 0.33 
t1/2 (h) 0.67 (0.19) 
 
CYP2C19 
  
 
EM 0.67 (0.20) 
 
 
RM 0.68 (0.19) 0.91 
PON1 
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Q192Q 0.63 (0.25) 
 
 
Q192R 0.69 (0.20) 
 
 
R192R 0.67 (0.16) 0.77 
AUC0-8 hr (ng h/mL) 37.40 (21.97) 
 
CYP2C19 
  
 
EM 44.79 (25.09) 
 
 
RM 27.54 (12.27) 0.03 
PON1 
  
 
Q192Q 35.31 (21.57) 
 
 
Q192R 43.27 (28.33) 
 
 
R192R 27.47 (6.64) 0.66 
Cmax, maximum plasma concentration; EM, extensive metabolizers (CYP2C19 *1/*1 or 
*1/*17); RM, reduced metabolizers (*1/*2, *2/*2 or *1/*3); tmax, time to Cmax; t1/2, half-
life; AUC0

8 hr , area under the plasma concentration curve. Data are represented as mean 
with standard deviation.  
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Table 7.3.2 Platelet response pre- and 4 h post-clopidogrel administration. 
Pre-dose PRU P-value 
CYP2C19   
 
EM 348 (32)  
 
RM 315 (43) 0.30 
PON1  
  
 
Q192Q 343 (41)  
 Q192R 306 (34)  
 R192R 361 (29) 0.07 
Antiplatelet response (absolute % change PRU)  
CYP2C19   
 EM 24.5 (19.0)  
 RM 11.31 (14.82) 0.02 
PON1    
 Q192Q 15.4 (13.4)  
 Q192R 24.8 (28.2)  
 R192R 14.51 (4.5) 0.55 
EM, extensive metabolizers; RM, reduced metabolizers; PRU, platelet reactive units. 
Data are represented as mean with standard deviation.  
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Figure 7.2 The role of CYP3A4 activity in clopidogrel pharmacokinetics and 
pharmacodynamics. 
(A and B) Scatter plot of total midazolam plasma exposure and H4 active metabolite 
exposure, or antiplatelet response, respectively.  
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7.3.2 Identification of other clopidogrel thiol metabolites in plasma 
Using an ultra-high-performance liquid chromatography-tandem mass spectrometry 
(UHPLC-MS/MS) method, we were able to detect and quantify other clopidogrel thiol 
metabolites isobaric to H4 in the plasma of study subjects (Figure 7.3A) (9). One 
metabolite, known to be inactive is termed H3, is stereochemically similar to H4 except 
being diastereomeric at the carbon 4 position. Another observed thiol metabolite is 
termed Endo, which differs from H3/H4 in that the carbon double bond is in the 
endocyclic position. In addition to chromatographic separation of H3, H4 and Endo 
(Figure 7.3C, 7.3E), the MS fragmentation signatures of the H3/H4 and Endo thiol 
metabolite were distinct (Figure 7.3D, 7.3F), ensuring analytical specificity of the 
isomers being analysed.  
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Figure 7.3 Representative chromatograms of derivatized H4 and Endo metabolite. (A) 
Chromatogram of a human plasma sample derivatized with 2-bromo-3-
methoxyacetophenone. (B) Chromatogram of a sample derived from PON1-mediated 
hydrolysis of 2-oxo-clopidogrel. (C and D) Chromatogram of Endo standard and its 
MS/MS fragmentation signature. (E and F) Chromatogram of H4 standard and its 
MS/MS fragmentation signature.  
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Figure 7.3 Representative chromatograms of derivatized H4 and Endo metabolite. 
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7.3.3 Biotransformation of clopidogrel to 2-oxo-clopidogrel  
In the first step of the bioactivation process, the intrinsic clearances (CLint) calculated 
from estimated Km and Vmax values show that CYP2C19 is more efficient in forming the 
intermediate metabolite than CYP3A4 in vitro (Figure 7.4A; supplemental material, 
Table 7.4).  
 
7.3.4 Biotransformation of 2-oxo-clopidogrel to H3 and H4 thiol 
metabolites  
In the second step of the bioactivation process, the CLint for H4 formation from 2-oxo-
clopidogrel by CYP2C19 was greater than that with CYP3A4 (Figure 7.4B; see 
Supplemental material, Table 7.4). Notably, the formation of H4 from 2-oxo-clopidogrel 
was dependent on the presence of 5 mM reduced glutathione (GSH) (data not shown). 
Based on lower H4 formation compared with 2-oxo-clopidogrel formation, it appears that 
the second reaction is the rate-limiting step of the overall clopidogrel bioactivation. We 
observed that the inactive metabolite, H3, was also formed from 2-oxo-clopidogrel by 
CYP2C19 at a relatively similar efficiency as H4 (supplemental material, Table 7.4).  
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7.3.5 Biotransformation of 2-oxo-clopidogrel to Endo thiol 
metabolite 
We incubated a range of 2-oxo-clopidogrel concentrations with baculovirus microsomes 
heterologously expressing CYP2C19 and HeLa cell-derived microsomes constitutively 
expressing PON1 while lacking any drug-metabolizing CYP enzymes. In the baculovirus 
microsomes, Endo metabolite formation was greater with CYP2C19 than in control 
baculovirus microsomes (Figure 7.4C; supplemental material, Table 7.5). In addition, 
HeLa cell microsomes constitutively expressing PON1 were capable of forming Endo 
metabolite but not H4 (Figure 7.3B, 7.4D; supplemental material, Table 7.5). We further 
confirmed the ability of PON1 to hydrolyse 2-oxo-clopidogrel using an adenovirus 
overexpressing system in HeLa cells, where Endo formation was 3.5-fold higher than 
vector control (LacZ) and no H4 was detected (Figure 7.4E). Moreover, Endo formation 
by PON1 was attenuated by the specific PON1 inhibitor 2-hydroxyquinoline (Figure 
7.4E). We note that PON1-mediated Endo formation was not dependent on GSH (data 
not shown). Overall, our data suggests that PON1 can hydrolyse 2-oxo-clopidogrel to 
form Endo metabolite while unable to mediate H4 formation and that CYP2C19 also 
catalyses Endo formation. Analysis of total Endo plasma exposure in healthy volunteers 
demonstrated that its levels were more than 20-fold lower than H4 (data not shown), and 
unlike H4 (Figure 7.1C), Endo AUC did not correlate with antiplatelet response (Figure 
7.4F).  
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Figure 7.4 Clopidogrel bioactivation in vitro. (A) Formation of 2-oxo-clopidogrel by 
CYP2C19 and CYP3A4. (B) Formation of H4 active metabolite by CYP2C19 and 
CYP3A4. (C) Formation of the Endo metabolite by CYP2C19 and CYP-lacking 
baculovirus insect-cell microsomes. (D) 2-oxo-clopidogrel metabolism to Endo 
metabolite by HeLa cell-line derived microsomes. (e) PON1-mediated hydrolysis of 2-
oxo-clopidogrel to the Endo metabolite in the absence or presence of PON1 inhibitor, 2-
hydroxyquinoline. Symbols and bars represent means and standard errors. (F) Scatter plot 
of Endo metabolite plasma exposure and antiplatelet response. *P < 0.001. 
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Figure 7.4 Clopidogrel bioactivation in vitro. 
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7.4 Discussion 
The impact of CYP2C19 genetic variations on clopidogrel antiplatelet response has been 
documented in a number of studies (11, 14). In fact, a recent meta-analysis reported that 
carriers of CYP2C19*2 allele had a higher risk for major adverse cardiovascular events, 
increased mortality and stent thrombosis compared with non-carriers, independent of 
baseline cardiovascular risk (14). We note that in contrast to these studies, one trial 
(CURE) reported similar clopidogrel efficacy irrespective of the CYP2C19 genotype 
(15). A potential explanation for the disparate findings is the difference in rate of PCI 
with stenting, where only 14.5% of the population underwent stenting in the CURE trial 
while majority of patients underwent stenting in other CYP2C19-supportive trials. 
Indeed, it has been consistently shown that the greatest clinical benefit with clopidogrel 
use is the reduction in stent thrombosis rate (16).  Moreover, several prospective trials 
have restored diminished H4 exposure and poor antiplatelet response in CYP2C19 variant 
carriers by increasing clopidogrel dose, including one recently published multi-centre 
double-blinded randomized clinical trial (17-19). However, our understanding of 
clopidogrel response in the context of pharmacogenomics was further complicated when 
Bouman et al. challenged the aforementioned findings by identifying the PON1 Q192R 
polymorphism as the only genetic marker associated with stent thrombosis, accounting 
for 72.5% of the response variation.  
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In the present study, we aimed to determine the influence of CYP2C19 and PON1 on 
clopidogrel metabolism and antiplatelet response. In contrast to Bouman et al., our results 
support the notion that decreased CYP2C19 function reduces the formation of 
clopidogrel active thiol metabolite, while PON1 showed no effect on active metabolite 
exposure. It should be noted that there are several challenges to accurate quantification of 
the active metabolite, H4. First, H4 is one of several diastereomeric thiol metabolites of 
clopidogrel observed during in vitro metabolomic analysis that requires analytical 
techniques capable of distinguishing the related species (5, 9). Secondly, due to the 
reactive nature of the free thiol metabolites, derivatization using alkylating agents, such 
as MPB, has been required to trap the metabolite for quantitation (9). In the current study, 
we followed a recently published stereoselective UHPLC-MS/MS method to determine 
plasma concentrations of clopidogrel thiol metabolites (H4, H3, and Endo) in our cohort 
(9). In the study by Bouman et al., stereo-specific separation of H3, H4, and Endo was 
not demonstrated, thus resulting in inaccurate clopidogrel pharmacokinetic analysis (13). 
Furthermore, they used an alternative method of stabilizing the active metabolite for 
quantitation and thus, these technical discrepancies may in part explain the discordant 
findings with regards to contribution of CYP2C19 and PON1 to clopidogrel 
pharmacokinetics.  
 
Similar to a number of recent studies that refuted a clinically relevant role of PON1 
genotypes to clopidogrel response, we show that CYP2C19 but not PON1 genotype is 
related to ADP-induced antiplatelet response (20-22). This agrees well with a recently 
published genome-wide association study in a healthy Amish population showing that the 
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CYP2C19*2 allele had a significant association with clopidogrel platelet aggregation, 
while the PON1 genotype did not (23). The strong correlation between H4 exposure and 
antiplatelet response (r2=0.78) presented here suggests that known genetic variation in 
CYP2C19 as well as interpatient variation in expression and activity of this enzyme likely 
account for clopidogrel resistance observed in nonresponders.  
 
The role of CYP3A4 in clopidogrel pharmacokinetics and pharmacodynamics remains 
unclear. While some studies postulate that CYP3A4 genotype and inhibition modulates 
clopidogrel pharmacokinetics and action (24), many others do not (25). Midazolam has 
been well documented as an in vivo probe drug for CYP3A4 activity (26). Thus, 
administration of a microdose of midazolam was used here to measure CYP3A4 
phenotype in subjects. To the extent of our knowledge, we demonstrate for the first time 
that CYP3A4 activity, as measured by midazolam exposure, is not an important driver of 
clopidogrel pharmacokinetics or antiplatelet response. 
 
Recently, a correspondence from Dansette et al. questioned the validity of the original 
findings of Bouman and colleagues (27). Specifically, they report that the Endo 
metabolite, but not other thiol metabolites is formed in human liver microsomes 
incubated with 2-oxo-clopidogrel in the absence of CYP-requiring NADPH. This Endo 
formation was attenuated in the presence of the PON1 substrate paraoxon but unaffected 
by the presence of a CYP inhibitor. Moreover, Dansette and colleagues found that the 
Endo metabolite was generated in serum (devoid of CYP enzymes) upon ex vivo 
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incubation with 2-oxo-clopidogrel. Those results indicate a role for PON1 in the 
formation of the Endo metabolite but not in the bioactivation to H4.  The results from the 
current study not only confirm the findings of Dansette et al., but solidify PON1 as the 
key player in Endo but not H4 generation through systematic and definitive metabolic 
experiments that include a PON1 overexpression system and recombinant CYP enzymes.  
 
We believe that lack of analytical specificity, followed by misidentification of the 
synthesized analytical standard used to quantify clopidogrel active metabolite levels may 
have been the critical missteps which led to the conclusion by Bouman et al. that PON1 
generates the active metabolites 16. First, the conditions for the separation of H4 from 
other structurally similar, but inactive metabolites requires high-resolution 
chromatographic techniques such as UHPLC coupled with MS/MS. The liquid 
chromatographic method used by Bouman et al. was likely insufficient for discriminating 
between active H4 from the inactive H3 and Endo metabolites.  It is also not certain 
whether the analytical method used could quantify non-Endo thiol metabolites such as 
H4. Secondly, Bouman et al. obtained their thiol metabolite reference standard from 
purification of PON1-mediated 2-oxo-clopidogrel hydrolysis 16. They suggest that this 
product was active based on platelet reactivity experiments. However, those experiments 
were performed at purified thiol metabolite concentrations of 2 mg/L, which is 100 times 
greater than the reported plasma thiol metabolite concentration. Since we clearly show 
that PON1 can only generate Endo and not H4, it is clear that the thiol metabolite they 
had used as analytical standard to represent the active metabolite was in fact the inactive 
Endo metabolite. Bouman and colleagues admit that their analytical methods did not 
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distinguish between different thiol metabolites derived from PON1, human liver 
microsomes, or human serum in vitro (27).  They argue that the ratio of produced active 
thiol metabolites to total thiol metabolites was constant between enzyme preparations 
based on platelet reactivity studies of purified thiols, suggesting that PON1 creates a 
similar degree of active metabolites as human liver microsomes.  Again, it is important to 
note that those platelet incubations were performed at purified thiol metabolite 
concentrations of 0.5 - 5 mg/L, values that are 25 - 250 times greater than their reported 
concentration of thiol metabolites patient plasma, bringing to question the relevance of 
such experiments as an argument for not requiring greater analytical specificity. Without 
identification and quantitation of these unknown PON1-derived active metabolites in 
relation to the amount of H4 active metabolite known to be found at significant levels in 
patient/subject plasma, it would seem that Bouman and colleagues have not clarified a 
role for PON1 in clopidogrel bioactivation. 
  
Here, the in vitro data are consistent with previous studies that demonstrated the 
importance of CYP isozymes in clopidogrel bioactivation (6, 7, 27). In addition, the 
mechanism by which the 2-oxo-clopidogrel ring opens to expose the free thiol in H4 
metabolite has been shown to be dependent on the presence of a reducing agent such as 
GSH (7, 8). Consistent with such data, we see a lack of H4 formation by CYP enzymes in 
the absence of GSH.  Overall, we propose that both steps of clopidogrel bioactivation are 
mainly driven by CYP2C19, ultimately generating active H4, while PON1-mediated 
hydrolysis of 2-oxo-clopidogrel generates the Endo metabolite (Figure 7.5). Notably, we 
show that the estimated enzyme affinity (Km) of 2-oxo-clopidogrel to CYP2C19 is much 
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higher than that of PON1, concordant with the low 2-oxo-clopidogrel affinity for PON1 
demonstrated by Bouman et al. Accordingly, in hepatocytes, where clopidogrel 
bioactivation occurs, CYP2C19-mediated oxidation of 2-oxo-clopiodgrel would be the 
preferred pathway at therapeutic concentrations of the drug. Importantly, to the extent of 
our knowledge, this is the first study to quantify Endo and H4 concentrations 
simultaneously in humans. We demonstrate that Endo levels are nearly 20-fold lower 
compared with H4; thus, Endo is unlikely to contribute substantially to clopidogrel 
antiplatelet response, in addition to the lack of association between Endo levels and 
antiplatelet response. Moreover, these results are further substantiated by our findings of 
no association between PON1 plasma activity and genotype with H4 levels or antiplatelet 
activity.  
 
There are several noteworthy limitations to our study. First, the current clinical study was 
conducted in a relatively small cohort of study subjects. Therefore, we combined carriers 
of one or two alleles of CYP2C19*2 or CYP2C19*3 into one group and cannot comment 
on the differential influence of these alleles or its gene-dose effect on clopidogrel 
pharmacokinetics and pharmacodynamics. Such pooling of CYP2C19 variant carriers has 
been done previously for similar reasons (28). It should be noted that in terms of sample 
size, an 80% power was achieved to detect a 40% difference in antiplatelet response 
between CYP2C19 EM and RM genotype groups with a two-sided significance level of 
0.05, and a standard deviation of 20%. With respect to PON1 analysis, the high 
interindividual variability observed within PON1 genotype groups lead to reduction in 
power below 80%. However, the lack of PON1 Q192R genetic influence on clopidogrel 
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response is in agreement with recently published studies of large sample sizes. Secondly, 
this study used the point-of-care VerifyNow P2Y12 assay to measure clopidogrel 
antiplatelet response. While VerifyNow utilizes ADP and PGE1 to induce and measure 
global platelet aggregation, it is not as direct a measure of platelet P2Y12 signalling 
activity as the vasodilator-stimulated phosphoprotein (VASP) assay or even direct 
receptor occupancy assays using 33P-2MeS-ADP (29). Indeed, clopidogrel H4 metabolite 
plasma exposure tracks with the VASP phosphorylation platelet reactivity index (17). 
Whether the H4 metabolite level is associated with VerifyNow PRU response has not 
been well described until now. Although some studies show high correlation between 
VASP and VerifyNow measured antiplatelet response(19, 30, 31), others did not (32). 
Nevertheless, clopidogrel response as measured by VerifyNow has consistently been 
shown to predict therapy resistance and clinical outcomes in a number of large trials and 
thus represents a feasible alternative technique for monitoring clopidogrel response (30, 
33). Indeed, the more pressing issue to address is delineating relevant cut-off thresholds 
for distinguishing between responders and non-responders, which will then allow 
clinicians to increase clopidogrel dose as appropriate. A standardized optimal cut-off 
value for each P2Y12 activity assay remains to be evaluated and defined. Lastly, since this 
is a proof-of-principle study in healthy subjects given a single 75 mg dose of clopidogrel, 
designed to delineate the role of PON1 relative to that of CYP2C19, we cannot directly 
extrapolate our findings to clopidogrel responsiveness in patients but it should be noted 
that the influence of CYP2C19 and PON1 on clopidogrel platelet aggregation has been 
assessed large patient cohorts in multiple studies (20-22). However, a key advantage of 
our study population and design is the ability to more clearly delineate the effect of 
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pharmacogenetic markers on clopidogrel pharmacokinetics and response and elimination 
of the potentially confounding effects of concomitant medications and existing disease 
states. In addition, quantification of the active H4 thiol metabolite here allowed for a 
more precise assessment of the role of genetics on clopidogrel pharmacokinetics.   
 
In conclusion, we show that PON1, unlike CYP2C19, is incapable of generating the 
clopidogrel active metabolite H4 in vitro. In human subjects, the CYP2C19 loss-of-
function genotype is a major driver of H4 exposure, corresponding to lowered ADP-
induced antiplatelet response. Furthermore, we demonstrated that PON1 generates the 
Endo metabolite; however, no correlation existed between plasma paraoxonase activity 
and Endo levels to antiplatelet response. Accordingly, although it remains likely that 
there are other genetic and non-genetic determinants of clopidogrel efficacy, our study 
suggests that CYP2C19 but not PON1 or CYP3A4 is a mechanistic determinant of 
interpatient antiplatelet response variability to clopidogrel therapy.  
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Figure 7.5 Schematic summary of clopidogrel bioactivation.
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7.6 Supplemental material 
7.6.1 Genotyping  
Genomic DNA was isolated with Gentra Puregene or DNA Blood Midi extraction kit as 
per manufacturer’s protocol (Qiagen, Alameda, CA). Genotype analysis included 
CYP2C19*2(rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 (rs12248560), and 
PON1 Q192R (rs662). Genotypes were determined by allelic discrimination using 
TaqMan Drug Metabolism Genotyping
 
assays with the 7500 RT-PCR System (assay IDs: 
C_25986767_70, C_27861809_10, C_469857_10, C_2548962_20; Applied Biosystems, 
Foster City, CA). Genotype analysis was conducted in parallel with known, sequence-
verified wild-type, heterozygous, and variant controls for each SNP.    
 
7.6.2 Kinetics of clopidogrel metabolism  
Microsomes from baculovirus cells overexpressing human cytochrome P450 2C19 and 
3A4 as well as NADPH CYP Oxidoreductase (BD Biosciences, Mississauga, Ontario) 
were used to examine the formation of 2-oxo-clopidogrel. Clopidogrel (0 – 45 µM) was 
incubated with microsomes at 37°C for 5 min, followed by addition of NADPH-
regenerating system to start the reaction, yielding a final volume of 100 µL in potassium 
phosphate buffer (100 mM pH 7.4). After incubation at 37°C for 10 min, the reaction was 
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terminated by adding 2-fold volume of acetonitrile with 125 mM MPB and 500 ng/mL 
D4-clopidogrel carboxylic acid as the internal standard (IS).  
 
7.6.3 Kinetics of 2-oxo-clopidogrel metabolism  
CYP2C19, CYP3A4 and control baculovirus microsomes were used to characterize the 
metabolism of 2-oxo-clopidogrel. 2-oxo-clopidogrel (0 – 50 µM) was incubated with 
microsomes at 37°C for 5 min, followed by addition of NADPH-regenerating system and 
5 mM reduced glutathione (GSH) to start the reaction, yielding a final volume of 100 µL 
in potassium phosphate buffer (100 mM pH 7.4). After incubation at 37°C for 30 min, the 
reaction was terminated by adding 2-fold volume of acetonitrile with 125 mM MPB and 
500 ng/mL IS.  
 
7.6.4 PON1-mediated hydrolysis of 2-oxo-clopidogrel  
LacZ control and PON1 overexpressing HeLa microsomes (Supplemental Methods) were 
pre-incubated with 100 mM Tris buffer (pH 7.4), 1 mM calcium chloride, and 5 mM 
GSH at 37°C for 5 min, followed by addition of 2-oxo-clopidogrel to start the reaction 
(total volume of 50 µL) in presence or absence of specific PON1 inhibitor, 2-
hydroxyquinoline (400 µM). After incubation at 37°C for 15 min, the reaction was 
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terminated by adding 2-fold volume of acetonitrile with 125 mM MPB and 500 ng/mL 
IS.  
 
7.6.5 UHPLC-MS/MS analysis  
Clopidogrel active metabolite H4-MPB derivative, Endo-MPB derivative, and internal 
standard (IS) D4-clopidogrel carboxylic acid were purchased from Toronto Research 
Chemicals (Toronto, Canada). H4 and Endo concentrations were determined using ultra 
high pressure liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS, 
Agilent 1290 UPLC coupled with ThermoScientific TSQ Quantum). Briefly, 200 µL of 
acetonitrile and 10 µL of IS (0.5 µg/mL) were added to 100 µL of MPB-treated plasma 
and centrifuged at 14,000 rpm for 20 min. The resulting supernatant was added to water 
(1:2 v/v) prior to injection into the chromatograph. Analytes were separated by reverse-
phase chromatography (Hypersil Gold Column 100 × 2 mm, 1.9 µM; or Shimpack XR-
ODS II 75 mm x 2.0 mm, 2.2 µM) using gradient elution of 0.1% formic acid in water 
v/v and 0.1% formic acid in acetonitrile (35 to 70%) with a flow rate of 0.3 mL/min in an 
8 min run time. The MS was equipped with heated electrospray ionization in positive 
mode for detection of H4, Endo, and IS with transitions 504  354 m/z, 504  155 m/z 
and 312  212 m/z, with collision energies of 44 eV, 22 eV and 20 eV, respectively. The 
lowest limit of quantification was 1 ng/mL for all analytes.  The interday coefficient of 
variation of H4 and Endo quality controls were 10.3% and 7%, respectively. 
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7.6.6 Midazolam LC-MS/MS analysis 
Midazolam and the IS, alprazolam, were purchased from Diagnostix (ThermoFisher, 
Mississauga, Canada). Midazolam plasma concentrations were determined using LC-
MS/MS (Agilent 1200 coupled with ThermoScientific TSQ Vantage). Midazolam was 
extracted using solid-phase extraction (SPE), using a Waters Extraction Plate manifold 
coupled with Oasis Hydrophilic-Lipophilic-Balanced µElution 96-well plates. Briefly, 
column packings were conditioned with 200 µL of acetonitrile and equilibrated with 200 
µL of water, followed by 200 µL of 0.1% formic acid in water. Subsequently, each 
column was loaded with 500 µL of 0.1% formic acid in water and alprazolam (10 ng/mL) 
mixed with 500 µL of plasma. The sample was washed with 200 µL of 10 mM 
ammonium acetate and eluted with 100 µL of 0.1% formic acid in acetonitrile. The 
resulting elutant was added to 0.1% formic acid in water (1:2 v/v). Upon injection into 
the liquid chromatograph, analytes were separated with the reverse-phase Hypersil Gold 
Column (50 × 5 mm, 5 µM particle size) using gradient elution of 0.1% formic acid in 
water and 0.1% formic acid in acetonitrile (20 to 80%) in a 6.5 min run time. The MS 
was set in positive ionization mode for detection of midazolam and alprazolam of 
respective transitions 309  281 m/z and 326  291 m/z, with collision energy of 30 eV. 
The lowest limit of quantification was 0.025 ng/mL. The interday coefficient of variation 
of midazolam quality controls was 12.1%. 
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7.6.7 Determination of paraoxonase activity  
Plasma paraoxonase activity was measured by UV spectrophotometry in a 96-well plate 
format using paraoxon as the substrate, as previously described.(34) Briefly, the reaction 
mixture composed of 9 mM Tris hydrochloride pH 8, 1 mM calcium chloride, 1 M 
sodium chloride, 1.5 mM paraoxon, and 40-fold diluted plasma. The rate of para-
nitrophenol generation was monitored at 405 nm over 10 mins at 25°C, in 30 sec 
intervals. An extinction coefficient of 17000 M-1 cm-1 was used to calculate units of 
paraoxonase activity, expressed as nmol/mL/min para-nitrophenol produced.  
 
7.6.8 PON1 overexpression in an adenovirus system 
Microsomes from HeLa cells overexpressing human PON1 was used to study PON1-
mediated 2-oxo-clopidogrel hydrolysis. Briefly, the full open reading frame of human 
PON1 cDNA was amplified by PCR from a pooled human liver cDNA library using the 
oligonucleotide primers 5’- ctatccccgaccatggcgaagctgattg-3’ and 5’- 
catgggtgcaaatcggtctgttagagctc-3’, and subsequently cloned into expression vectors pEF 
and pENT (Invitrogen, Carlsbad, CA). Adenoviral expression vector containing PON1 
was generated in pAD/CMV/V5-DEST using the ViraPower adenoviral expression 
system (Invitrogen, Carlsbad, CA). Adenovirus containing LacZ was used as a negative 
control. Following a 48-hour adenovirus transduction, HeLa cells were lysed with 
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hypotonic buffer (5 mM Tris HCl) and subsequently sonicated. Microsomes were 
prepared using differential centrifugation methods. 
7.6.9 Western blot analysis 
Microsome samples were separated by SDS-PAGE on 4-10% gels (Invitrogen, Carlsbad, 
CA) and subsequently transferred onto nitrocellulose membranes. Blots were probed with 
a mouse anti-PON1 antibody (Abcam, Cambridge, MA) and subsequently probed with 
anti-mouse horseradish peroxidise-labeled secondary antibodies (Bio-Rad, Hercules, 
CA). The bands were detected using BM Chemiluminescence Western Blotting Substrate 
(Roche, Indianapolis, IN). 
 
7.6.10 Data analysis 
In the clinical study, the PK parameters maximum observed plasma concentration (Cmax), 
time to reach Cmax (tmax), area under the plasma concentration vs time curve from time 0 
to 8 hr (AUC0-8hr), and half-life (t1/2) were calculated using noncompartmental analysis 
techniques with GraphPad Prism v5.0 (GraphPad, La Jolla, CA) and PKSolver v2.0. 
Briefly, AUC0-8hr was calculated using the linear trapezoidal rule while t1/2 was defined as 
Ln2/ke, where ke represents the slope of the elimination phase of the log plasma 
concentration profile.  
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For evaluation of genetic variation on clopidogrel disposition and response, subjects were 
divided into 2 groups for CYP2C19 and 3 groups for PON1: CYP2C19 extensive 
metabolizers, EMs (*1/*1 or *1/*17) and CYP2C19 reduced metabolizers, RMs (*1/*2, 
*1/*3 or *2/*2); PON1 wild-type, heterozygous, and homozygous carriers of Q192R. The 
independent effect of CYP2C19*2 and *3 variation could be not be evaluated due to 
insufficient subjects with heterozygous and homozygous variant status of each. However, 
a dominant model for PON1, comparing PON1 wild-type Q192Q carriers to those 
subjects with either Q192R or R192R genotype, was assessed to further evaluate the 
influence of PON1 on clopidogrel response. Hardy-Weinberg equilibrium was assessed 
for each genotype using the chi-square goodness-of-fit test. No genotype deviated from 
Hardy-Weinberg equilibrium.  
 
For all in vitro experiments, the Michaelis-Menten enzyme kinetic parameters Km and 
Vmax were calculated using GraphPad Prism v5.0. The calculated Km and Vmax values 
were expressed as mean ± standard error (SEM). The intrinsic clearance (CLint) was 
calculated as Vmax/Km.  
 
The Mann-Whitney test and Kruskal-Wallis test one-way analysis of variance followed 
by Tukey’s test for pairwise comparisons was employed to test the differences between 
two or three groups of data, respectively. Linear regression analysis was used to examine 
the association between two variables. A two-tailed P value of less than 0.05 was 
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considered significant for all analysis. Statistical analysis was performed with the use of 
GraphPad Prism v.5.0. 
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Table 7.6.1 Healthy volunteer baseline demographics (n = 21). 
Age, mean (SD) years 35 (13) 
Men, n (%) 11 (52) 
Ethnicity, n (%) 
 
 
Caucasian 17 (81) 
 
Black 1 (5) 
 
Asian 2 (10) 
 
Other 1 (5) 
Weight, mean (SD) Kg 70 (15) 
Height, mean (SD) cm 169 (10) 
CYP2C19, n (%) 
 
 
*1/*1 11 (52) 
 
*1/*2 6 (28) 
 
*1/*3 1 (5) 
 
*2/*2 1 (5) 
 
*1/*17 2 (10) 
PON1 Q192R, n (%) 
 
 
QQ 8 (38) 
 
QR 8 (38) 
 
RR 5 (24) 
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Table 7.6.2 Kinetic parameters of clopidogrel metabolism determined in vitro. 
 
Vmax (SEM) Km (SEM) Vmax/Km 
Clopidogrel to 2-oxo-clopidogrel 
 
 
CYP2C19 2.869 (0.094) 3.008 (0.414) 0.954 
 
CYP3A4 0.263 (0.039) 18.870 (6.366) 0.014 
2-oxo-clopidogrel to H4 active 
metabolite     
 
CYP2C19 0.016 (0.0005) 2.696 (0.353) 0.006 
2-oxo-clopidogrel to H3 metabolite    
 CYP2C19 0.012 (0.0004) 1.729 (0.373) 0.007 
Vmax represents maximum rate achieved by enzymatic system; Km represents substrate 
concentration required to reach half the value of Vmax; Vmax/Km represents the intrinsic 
clearance (CLint). Units are as follows: pmol/pmol P450/min for Vmax; µM for Km; 
µL/pmol P450/min for intrinsic clearance. Data represented as mean (standard error, 
SEM). 
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Table 7.6.3 Kinetic parameters of 2-oxo-clopidogrel metabolism to Endo metabolite 
determined in vitro. 
 
Vmax (SEM) Km (SEM) Vmax/Km 
2-oxo-clopidogrel to Endo metabolite 
   
 
CYP2C19 0.3544 (0.024) 8.036 (1.631) 0.044 
 
Control (insect cell) microsomes 0.108 (0.009) 15.38 (3.434) 0.007 
 
HeLa cell microsomes 250.5 (30.9) 732.9 (109.7) 0.342 
Vmax represents maximum rate achieved by enzymatic system; Km represents substrate 
concentration required to reach half the value of Vmax; Vmax/Km represents the intrinsic 
clearance. Units are as follows: pmol/mg protein/min for Vmax; µM for Km; mL/mg 
protein/min for intrinsic clearance (CLint). Data represented as mean (standard error, 
SEM). 
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Figure 7.6 Plasma concentration curves of H4 active metabolite measured over 8 
hours following 75 mg oral administration of clopidogrel in healthy volunteer study 
subjects. 
(A, B) Curves grouped by CYP2C19 and PON1 Q192R genotype respectively. Symbols 
represent mean and error bars represent the standard deviation. 
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8 DISCUSSION AND CONCLUSIONS 
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8.1 Summary and Discussion 
8.1.1 Chapter Four 
Single nucleotide polymorphisms in genes that affect warfarin metabolism (cytochrome 
P450 2C9 gene, CYP2C9) and response (vitamin K epoxide reductase complex 1 gene, 
VKORC1) have an important influence on warfarin therapy, particularly during initiation; 
however, there is a lack of consensus regarding the optimal pharmacogenetics-based 
initiation strategy. The aim of Chapter Four was to develop a novel pharmacogenetics-
based initiation protocol that incorporates loading and maintenance doses calculated 
based on individual patient genetics, clinical variables, and anticoagulation response 
(WRAPID). Subsequently, the clinical utility of this initiation protocol was evaluated in 
atrial fibrillation (AF) and venous thromboembolism (VTE) patients. We hypothesized 
that the use of a pharmacogenetics-based dosing algorithm for initiating patients 
requiring new anticoagulation therapy should effectively eliminate genotype-driven 
differences in anticoagulation response to provide a safe, rapid, and uniform 
anticoagulation response in patients. Indeed, application of the WRAPID algorithm 
resulted in a negligible influence of genetic variation in VKORC1 or CYP2C9 on time to 
achievement of therapeutic response and risk of overanticoagulation. After adjustment for 
covariates, time to stable anticoagulation was not influenced by VKORC1 or CYP2C9 
genotype. Importantly, time spent within or above the therapeutic range did not differ 
among VKORC1 and CYP2C9 genotype groups. Moreover, the overall time course of the 
anticoagulation response among the genotype groups was similar and predictable. 
Collectively, these findings demonstrate the clinical utility of genetics-guided warfarin 
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initiation with the WRAPID protocol to eliminate genotype-driven differences in 
anticoagulation response, in turn providing safe and optimal anticoagulation therapy for 
patients with AF or VTE. 
 
8.1.2 Chapter Five 
While the influence of factors affecting S-warfarin PK parameters have been identified 
(ie, age, drug interactions, and CYP2C9 genotype), the influence of genetics and clinical 
parameters on S-warfarin PD variability is less clear. We hypothesized that genetic 
variations in CYP2C9 and VKORC1, as well as clinical variables contributes to 
interindividual variation in S-warfarin PK and PD parameters. Indeed, regression analysis 
demonstrated that CYP2C9 genotype, kidney function, and gender were independent 
determinants of S-warfarin clearance. The values for Imax were dependent on VKORC1 
and CYP4F2 genotypes, vitamin K status (as measured by plasma concentrations of 
proteins induced by vitamin K absence, PIVKA-II), and weight. Importantly, indication 
for warfarin was a major independent determinant of Imax during initiation, where PD 
sensitivity was greater in AF than VTE. To demonstrate the utility of the global PK-PD 
model, we compared the predicted initial anticoagulation responses with previously 
established warfarin dosing algorithms. These insights and modeling approaches support 
our hypothesis and have important implications for personalized warfarin therapy. 
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8.1.3 Chapter Six 
Rivaroxaban is a new oral anticoagulant (factor Xa inhibitor), where 30-40% of the 
administered drug is excreted unchanged through the kidney via a combination of 
glomerular filtration and active tubular secretion. As such, we hypothesized that the 
efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) 
contributes to the overall disposition of rivaroxaban. The ability of MDR1 and BCRP 
efflux transporters to mediate rivaroxaban transport in vitro was demonstrated in that 
significantly greater vectorial transport of rivaroxaban was observed in the basal to apical 
direction in Caco-2 cells, which was attenuated in the presence of the selective inhibitors. 
Thus, rivaroxaban is a shared substrate of MDR1 and BCRP. Following oral 
administration of 2 mg/kg rivaroxaban, plasma concentrations did not significantly differ 
between wild-type and Mdr1adef or Bcrp-/- mice (n = 6 per group). However, rivaroxaban 
clearance was significantly reduced in the triple knockout mice, Mdr1a/Mdr1b-/-/Bcrp-/-. 
Interestingly, rivaroxaban brain to plasma ratio did not differ in mice lacking only Mdr1a 
or Bcrp, but more than two times higher in the Mdr1a/Mdr1b-/-/Bcrp-/- mice. Overall, 
supportive of our hypothesis, MDR and BCRP likely function synergistically to modulate 
rivaroxaban disposition in vivo and appear to be particularly relevant to limiting its 
central nervous system entry. These data have important implications for safety and 
efficacy of anticoagulation therapy with rivaroxaban as many drugs in clinical use are 
known MDR1 inhibitors and loss-of-function polymorphisms in BCRP are common.  
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8.1.4 Chapter Seven 
It is thought that clopidogrel bioactivation and antiplatelet response are related to 
cytochrome P450 2C19 (CYP2C19). However, a recent study challenged this notion by 
proposing CYP2C19 as wholly irrelevant, while identifying paraoxonase-1 (PON1) and 
its Q192R polymorphism as the major driver of clopidogrel bioactivation and efficacy. 
The aim of Chapter Seven was to systematically elucidate the mechanism and relative 
contribution of PON1 in comparison to CYP2C19 to clopidogrel bioactivation and 
antiplatelet response. Indeed, we found a remarkably good correlation between 
clopidogrel active metabolite (H4) area under the plasma concentration curve (AUC0 - 8 
hours) and antiplatelet response (r2 = 0.78). Interestingly, CYP2C19 but not PON1 
genotype was predictive of H4 levels and antiplatelet response. Furthermore, there was 
no correlation between plasma paraoxonase activity and H4 levels. Metabolic profiling of 
clopidogrel in vitro confirmed the role of CYP2C19 in bioactivating clopidogrel to H4. 
However, heterologous expression of PON1 in cell-based systems revealed that PON1 
cannot generate the H4 active metabolite from its parent compound, but mediates the 
formation of another thiol metabolite, termed Endo. Importantly, Endo plasma levels in 
humans are nearly 20-fold lower than H4 and were not associated with any antiplatelet 
response. Our results demonstrate that PON1 does not mediate clopidogrel active 
metabolite formation or antiplatelet action, while CYP2C19 activity and genotype 
remains a predictor of clopidogrel pharmacokinetics and antiplatelet response. 
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8.2 Therapeutic Implications 
The occurrence of adverse drug reactions (ADRs) is a prominent matter of concern in 
medicine and drug therapy today (1). In many cases ADRs are caused by inappropriately 
or often inadvertently high doses of prescribed drugs, particularly worrisome for drugs 
with narrow therapeutic window and large interindividual variability in response. Indeed, 
interindividual variation in drug exposure and efficacy has meant that subsets of patients 
experience drug-related toxicities and inadequate therapeutic benefit. The one-dose-fits-
all paradigm for drug therapy is increasingly recognized as inappropriate for many drugs 
in clinical use. Alternative dosing models should be considered to provide and ensure 
therapeutic benefit for the vast majority of patients while reducing ADRs. In the past 
decade, a substantial amount of pharmacogenomics research has unraveled many genetic 
variants affecting cardiovascular treatment response. Accordingly, personalized medicine 
represents an exciting emerging field that integrates genetic makeup with environmental 
influences and disease states to determine a precise individualized dose regimen. 
  
To the best of our knowledge, the WRAPID nomogram represents the first warfarin 
initiation algorithm that incorporates both VKORC1 and CYP2C9 genotype-determined 
loading doses, which differs from the typical doubling of the maintenance dose. We 
demonstrated that the use of such an algorithm for warfarin initiation is not only practical 
in the ambulatory setting, but also effectively minimized interindividual variation in 
anticoagulation response to provide similar efficacy in a cohort of genotype-defined 
patients. A better understanding of pharmacogenomics and in vivo mechanisms 
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responsible for the observed variation in combination with a priori predictive modeling 
constitute the foundation for evaluating optimal pharmacogenetics-based dosing 
algorithms.  
 
One of the limitations of the study outlined in Chapter Four is that we did not evaluate 
the use of pharmacogenetics-based warfarin dosing in the randomized clinical trial (RCT) 
setting. However, the recent COUMAGEN-II RCT showed the superiority of 
pharmacogenetics-based warfarin dosing over standard care with respective to greater 
time spent in therapeutic range and reduced occurrence of ADRs (2). Moreover, a recent 
study in real-world patients found that genotyping during warfarin therapy reduced the 
hospitalization rate for bleeding or thromboembolic event by 30% compared to a 
historical control group (3). These results are well aligned with our findings. Indeed, we 
expect that personalized warfarin therapy will ultimately result in a more cost-effective, 
safer, and faster treatment outcome to maximize anticoagulation efficacy while 
minimizing life-threatening bleeding events. A number of additional RCTs involving 
larger sample sizes are currently underway to confirm these encouraging results.  
 
Although cost-effective analysis for use of warfarin pharmacogenetics has been 
controversial, there is consensus in that genotyping for CYP2C9 and VKORC1 for 
patients with higher risk of thromboembolic events or bleeding will be cost-effective 
resulting in increased quality-adjusted life years (QALYs) (4, 5). Indeed, additional cost-
effective analysis will be required as more convincing data from RCTs become available. 
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Nevertheless, given the richness of evidence for warfarin, it will likely be the first widely 
adopted pharmacogenetic application in cardiovascular medicine.  
 
The limitations of warfarin therapy have prompted the clinical development of novel oral 
anticoagulants that have more predictable response. The factor Xa inhibitor rivaroxaban 
is a new oral anticoagulant with direct mechanism of action by inhibiting the clotting 
cascade. It is known that rivaroxaban depends on the kidney for excretion of unchanged 
drug as well as its metabolites. Not surprisingly, elevated bleeding risk in patients with 
renal impairment is of particular concern with rivaroxaban therapy. In the past decade, 
remarkable progress has been made in the field of drug transporters in elucidating their 
importance in determining the disposition and efficacy of many drugs in clinical use. 
Indeed, we demonstrate in Chapter Six that the new oral anticoagulant rivaroxaban is a 
shared substrate of the efflux transporters MDR1 and BCRP.  As functional 
polymorphisms exist in both MDR1 and BCRP genes, in addition to the wide array of 
MDR1 drug inhibitors in clinical use, genetic variations as well as drug interactions will 
likely play an important role in modulating rivaroxaban exposure and thus efficacy. 
While the clinical experience with rivaroxaban is currently very limited, the full spectrum 
of factors determining efficacy and safety within the context of pharmacogenetics, 
demographics, concomitant medications, and comorbidities should be evaluated as it is 
used more frequently in real-world patients. 
 
The antiplatelet drug clopidogrel is used to treat patients with acute coronary syndrome, 
particularly for prevention of stent thrombosis in those undergoing percutaneous coronary 
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intervention. Similar to warfarin, pharmacogenetic studies have demonstrated clinically 
relevant implications on clopidogrel antiplatelet response and thrombosis event rates. A 
layer of complexity in defining optimal genetic markers for predicting clopidogrel 
response is that the mechanistic enzymes potentially involved in bioactivating inactive 
clopidogrel to its active metabolite has been under scrutiny. In Chapter Seven, we 
conducted a proof-of-principle healthy volunteer study powered sufficiently to delineate 
the effect of PON1 genetic variation in comparison to CYP2C19 polymorphisms on 
clopidogrel bioactivation and antiplatelet response. There was a lack of correlation 
between either PON1 genotypes or paraoxinase activity to clopidogrel active metabolite 
formation or antiplatelet effect. Rather, we observed an excellent correlation in 
antiplatelet effect with CYP2C19 polymorphisms, the enzyme that has been long 
appreciated as the key player for clopidogrel bioactivation. Subsequently, systematic in 
vitro metabolism studies confirmed that PON1 does not generate the active metabolite 
while CYP2C19 does, providing the mechanistic basis for the clinical significance of 
CYP2C19 polymorphisms. PON1, on the other hand, generates an inactive metabolite 
that likely does not confer any measureable antiplatelet effect in vivo. This data is in line 
with analysis of clinical trials data demonstrating the lack of association of PON1 genetic 
variation with clopidogrel antiplatelet response or risk of stent thrombosis (6-8). Overall, 
Chapter Seven highlights the importance of elucidating underlying molecular 
mechanisms of drug metabolism, disposition, and response for accurate interpretation of 
the clinical significance of candidate genetic markers. Indeed, recent RCT using point-of-
care CYP2C19*2 genotyping showed that guidance using genetic information led to 
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better antiplatelet response, setting the stage for personalized clopidogrel therapy to 
improve efficacy (9). 
 
8.3 Future Directions 
Warfarin has been the mainstay oral anticoagulant (OAC) prescribed for stroke 
prevention in AF patients. However, warfarin therapy is challenging due to marked 
interindividual variability in dose and response, requiring frequent monitoring and dose 
titration. These limitations have prompted the clinical development of new OACs 
(NOACs) that directly target the coagulation cascade with rapid onset/offset of action, 
lower risk for drug-drug interactions, and more predictable response. Recently, NOACs 
dabigatran (direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors) 
have gained regulatory approval as alternative therapies to warfarin. While the 
anticoagulation efficacy of these NOACs has been characterized, differences in their 
pharmacokinetic and pharmacodynamic profiles have become a significant consideration 
in terms of drug selection and dosing. Moreover, interindividual variability in plasma 
exposure/response of NOACs and bleeding risk associated with anticoagulation therapy 
remains a pertinent question. Indeed, even in a clinical trial setting with stringent 
enrollment criteria, the one-dose-fits-all dosing regimen strategy did not appear 
successful for NOACs, likely due to the various clinical covariates that significantly 
affected extent of drug exposure and response. It is evident that variability in NOAC 
plasma exposure will have significant impact on anticoagulation efficacy given the direct 
PK-PD relationship and its association with clinical outcomes. Thus, quantifying NOAC 
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plasma concentration is likely the most reliable assessment of response and bleeding risk. 
Collectively, studies in real-world patients treated with NOACs are required to better 
understand the effect of variables such as age, renal/hepatic function, dosing interval, as 
well as drug metabolism and transport pharmacogenetics and interactions on the 
variability in NOAC drug exposure. These proposed studies would allow for prediction 
of patients at risk for sub- and supra-therapeutic anticoagulation response and 
individualize OAC selection and dosing. Appendix C highlights in greater detail the 
clinical implications of the availability of NOACs in treating AF patients.  
 
Antiplatelet therapy with clopidogrel has emerged as a major success in the treatment of 
cardiovascular disease, particularly in reducing the risk for myocardial infarctions 
associated with coronary artery disease. Despite the well-known clinical benefit of 
clopidogrel in prevention of coronary ischemic events and stent thrombosis, the large 
interindividual variability observed with clopidogrel antiplatelet response results in 
therapy complexity. According to a recent genome-wide association (GWAS) study, 
CYP2C19 genotype only explains 12% of the variation in response (10). Thus, further 
delineation of additional genetic and nongenetic markers is required to better explain and 
predict response variation, which may in turn define optimal individualized doses for 
patients.  In addition, the first evidence of a therapeutic window range for clopidogrel 
antiplatelet efficacy has recently been proposed to classify responders and non-
responders, and more importantly, early identification of patients not achieving optimal 
platelet inhibition (11). Consensus on defining the optimal clopidogrel therapeutic 
window has been challenging due to the lack of a standardized platelet-function assay. 
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The point-of-care VerifyNow P2Y12 assay has recently been used as a feasible and 
reliable method of measuring antiplatelet response (12). However, VerifyNow is not as 
direct a measure of platelet P2Y12 signalling activity as the vasodilator-stimulated 
phosphoprotein (VASP) assay or even direct receptor occupancy assays using 33P-2MeS-
ADP (13). Although some studies show high correlation between VASP and VerifyNow 
measured antiplatelet response, others did not (14). Thus, the relationship between the 
gold-standard VASP assay and VerifyNow point-of-care assay in relation to optimal 
therapeutic response remains to be evaluated and defined. Furthermore, the stent 
thrombosis risk has been demonstrated to be the highest during initiation of clopidogrel 
therapy (15). Accordingly, the intra-individual variability in platelet response during this 
critical period is another area to be assessed to evaluate consistency of the responder and 
non-responder phenotypes. Moreover, quantification of active metabolite H4 plasma 
levels will aid in defining the relationship between the proposed therapeutic response 
window and a ‘therapeutic H4 concentration window’.  
 
As with warfarin, new antiplatelet agents (prasugrel, ticagrelor) are now available as 
alternative agents to clopidogrel. Both prasugrel and ticagrelor do not require extensive 
bioactivation by CYP2C19. However, CYP3A4 and CYP2B6 are responsible for 
bioactivation of prasugrel to its active metabolite and the influence of polymorphisms in 
these enzymes to prasugrel platelet efficacy remains to be delineated. Similarly, 
ticagrelor is a substrate of MDR1 and the influence of drug interactions as well as ABCB1 
polymorphisms remain to be addressed.  
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8.4 Conclusions 
Physicians have long sought over the phenomenon that patients respond variably to the 
same standard drug treatment. Over half a century ago, Dr Werner Kalow of University 
of Toronto (1917-2008) was one of the pioneering physicians to recognize interpatient 
variability in drug responsiveness following standard therapeutic doses (16). Werner 
Kalow’s work along with others set precedence for studying the link between genetic 
variations and pharmacology. Subsequently, the term pharmacogenetics was coined for 
describing this phenomenon. In fact, the first monograph of pharmacogenetics was by 
Werner Kalow in 1962 entitled “Pharmacogenetics: Heredity and Response to Drugs”, 
highlighting his work on the relationship between genetic polymorphisms of 
butyrylcholinesterase and the risk of prolonged apnea to standard doses of 
succinylcholine due to differential ability to hydrolyze succinylcholine (17).  
 
The field of pharmacogenetics has evolved significantly since the initial observations; 
however, the fundamental principles remain the same and that is to delineate the genetic 
basis of interindividual variation in drug pharmacokinetics, pharmacodynamics and 
ADRs. Indeed, remarkable process has been made in the past decade using a variety of 
study designs to unveil the genetic contribution to variable drug responsiveness for a 
variety of medications. Moreover, pharmacogenetic studies form the foundation and 
evidence needed to implement personalized medicine, an emerging drug treatment 
paradigm utilizing individual genetic makeup to guide the appropriate drug therapy and 
dosages. This in turn will allow for the greatest therapeutic benefit to be seen while 
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reducing risk for toxicity. Many classes of cardiovascular drugs exemplify how heritable 
genetic variations influence its efficacy.  
 
The first section of the thesis focused on the development of a novel pharmacogenetics-
based initiation protocol for warfarin therapy. We demonstrated its clinical utility in 
eliminating genotype-driven variability in anticoagulation response during the critical 
initiation phase, as well as sustaining optimal efficacy throughout maintenance therapy 
for AF and VTE patients. Additionally, we defined the genetic and non-genetic 
determinants of warfarin PK and PD parameters by use of mathematical PK-PD modeling 
to estimate individual clearance and anticoagulation responsiveness. The integration of 
elucidated variables contributing to PK and PD variability with modeling techniques 
represents a powerful tool for a priori prediction of anticoagulation outcomes in a variety 
of clinical scenarios. The availability of NOACs has meant that clinicians now have 
alternatives to warfarin; however, interindividual variation in anticoagulation efficacy 
remains a concern for NOACs. We determined that both efflux drug transporters MDR1 
and BCRP are involved in rivaroxaban active renal secretion, which likely play a 
synergistic role in modulating rivaroxaban accumulation and elimination in humans. The 
last part of the thesis involved elucidating the metabolic enzymes involved in clopidogrel 
bioactivation. We evaluated the impact of relevant genetic variations on the observed 
active metabolite plasma concentration and antiplatelet response in a healthy volunteer 
setting. Indeed, individuals harbouring reduced function CYP2C19 polymorphism have a 
reduced capacity to generate clopidogrel active metabolite and lower antiplatelet 
response.   
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It is evident that many factors contribute to variability in drug responsiveness, including 
renal and hepatic function, underlying disease mechanisms, drug interactions, and 
pharmacogenomics. Improvement in our understanding of interindividual variation in 
drug responsiveness allows for better prediction of patients at risk for lack of therapeutic 
efficacy or adverse event, setting the stage for personalized therapy. One of the major 
barriers to the widespread clinical implementation of personalized therapy is the 
requirement from trialists to demonstrate outcome and safety benefit of 
pharmacogenetics-directed therapy in randomized clinical trials (RCTs). However, these 
RCTs are too expensive, not feasible, and unethical in many clinical scenarios. Thus, it is 
necessary to resort to pragmatic trials and prospective cohort studies where early adopters 
of pharmacogenetics are needed to develop evidence for better efficacy and safety. As 
results from pharmacogenetic studies emerge, pharmacoeconomics should be 
continuously conducted to evaluate the health-economic benefit and cost-effectiveness of 
adopting pharmacogenetics into standard patient care.  
 
The studies presented herein demonstrate pragmatic translational medicine by bridging 
the necessary interplay between understanding molecular mechanisms and evaluating 
their impact on clinically important endpoints in the real-world setting. It is important to 
note that as we recognize that an individual patient’s drug response phenotype is the 
ultimate clinical endpoint, the use of pharmacogenomics should be integrated in context 
with other patient-specific parameters such as drug exposure, biomarkers, and other 
measures of response and toxicity, in the practice of personalized medicine. Overall, our 
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studies support the use of pharmacogenetics-guided care for delivery of personalized 
medicine to maximize efficacy while reducing toxicity by selecting the right drug at the 
right dose for the right patient. 
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Appendix C: Future of oral anticoagulation therapy: 
Importance of pharmacokinetic profile and variability 
as determinants of dose and response to dabigatran, 
rivaroxaban, and apixaban6
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Introduction 
Atrial fibrillation (AF) is associated with a fivefold increase in risk of disabling stroke 
(1). Therefore, antithrombotic therapy is required for stroke and systemic embolism 
(SSE) prophylaxis. Until recently, the vitamin-K antagonist warfarin was the primary 
treatment choice for long-term oral anticoagulation (OAC) as stroke risk is reduced by 
60% in nonvalvular AF patients (1). However, warfarin has a number of limitations 
including delayed onset of action, large interindividual variability in response, 
unpredictable pharmacokinetics (PK), drug-drug interactions, and genetic polymorphisms 
in genes affecting metabolism and pharmacodynamics (PD). Intensive monitoring using 
international normalized ratio (INR) and frequent dose adjustments are necessary to 
provide adequate anticoagulation within warfarin’s narrow therapeutic window.  
 
Significant effort has been made to develop new OACs (NOACs) with direct mechanisms 
of action with a sufficiently wide therapeutic window to allow for fixed dose 
administrations without the need for routine response monitoring. NOACs directly inhibit 
the coagulation pathway, either factor Xa or thrombin, for rapid onset of antithrombotic 
effects. The PK and pharmacology of these NOACs are distinct from that of warfarin 
(Table C.1, Figure C.1). In the present review, we will highlight the PK and PD features 
of the three NOACs that have recently been approved for stroke prevention in AF 
patients and provide NOAC selection and dosing recommendations based on their PK-PD 
profiles. 
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Table C.1 Comparison of pharmacokinetic features of warfarin, dabigatran, 
rivaroxaban and apixaban. 
Parameter Warfarin Dabigatran  Rivaroxaban Apixaban 
Mechanism of 
action 
Inhibition of 
VKOR 
Direct 
thrombin 
inhibitor (free 
or bound), 
reversible 
Factor Xa 
inhibitor (free 
or bound), 
reversible 
Factor Xa 
inhibitor (free 
or bound), 
reversible 
Onset of action 
Slow, indirect 
inhibition of 
clotting factor 
synthesis 
Fast Fast Fast 
Offset of action Long Short Short Short 
Absorption Rapid 
Rapid, acid 
dependent 
Rapid Rapid 
Bioavailability (%) 100 6.5 80a 50 
tmax (hr) 2.0 – 4.0 1.0 - 3.0 2.5 - 4.0 1.0 - 3.0 
Vd (L) 10 60 - 70 50 - 55 21 
Protein Binding 
(%) 
99 35 95 87 
t1/2β (hr) 40 12 - 17 9 - 13 8 - 15 
Renal excretion  None 80 33 25 
Fecal excretion None 20 28 50 - 70 
CL/F (L/hr) 0.35 70 - 140 10 5 
Accumulation in 
plasma 
Dependent on 
CYP2C9 
metabolic 
efficiency 
None None 1.3 - 1.9 
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Food effect None 
Delayed 
absorption 
with food with 
no influence 
on 
bioavailability 
Delayed 
absorption 
with food 
with 
increased 
bioavailabilit
y 
None 
Age  
Yes, lower CL/F 
as age increases 
Yes, lower 
CL/F as age 
increases 
None 
Yes, lower 
CL/F as age 
increases 
Bodyweight  
Yes, higher dose 
for increased 
weight 
None None 
Yes, higher 
exposure with 
increased 
weight 
Gender  
Yes, lower CL/F 
in females 
Yes, lower 
CL/F in 
females 
None 
Yes, higher 
exposure in 
females 
Ethnicity 
Lower dose in 
Asians; Higher 
dose in African-
Americans 
None 
Lower dose 
in Japanese 
patients 
None 
Drug transporter None P-gp P-gp, BCRP P-gp, BCRP 
CYP-mediated 
metabolism 
CYP2C9, 
CYP3A4, 
CYP2C19, 
CYP1A2 
None 
CYP3A4/5, 
CYP2J2 
(equal) 
CYP3A4/5, 
CYP2J2 
(minor), 
CYP1A2 
(minor) 
Drug-drug 
interactions 
Many; affecting 
metabolism 
Potent P-gp 
inhibitors; 
affecting 
absorption 
Potent 
CYP3A4 and 
P-gp 
inhibitors; 
Potent 
CYP3A4 and 
P-gp 
inhibitors; 
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affecting 
absorption, 
metabolism, 
and excretion 
affecting 
absorption, 
metabolism, 
and excretion 
Dosing for AF 
Variable 
(0.5 – 16 mg 
OD) 
150, 110 mg 
BID 
20, 15 mg 
OD 
5, 2.5 mg BID 
Coagulation 
measurement  
INR 
TT > 
Hemoclot > 
ECT > aPTT 
anti-FXa > 
PT 
anti-FXa  
AF, atrial fibrillation; aPTT, activated partial thromboplastin test; BCRP, breast cancer 
resistance protein; BID, twice daily; CL/F, apparent clearance; CYP, cytochrom P450 
isozymes; ECT, ecarin clotting time; OD, once daily; P-gp, P-glycoprotein; PD, 
pharmacodynamics; PT, prothrombin time; tmax, time to maximum plasma concentration; 
t1/2β, terminal half-life; TT, thrombin time; Vd, volume of distribution; VKOR, vitamin K 
epoxide reductase enzyme. 
a
 Bioavailability is dependent on dose (over 10 mg) and food intake. Thus, rivaroxaban 
doses over 10 mg OD should be administered with food. However, 10 mg rivaroxaban is 
only licensed for prophylaxis of thromboembolism following elective hip or knee 
surgery.     
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Figure C.1 Summary of absorption, metabolism, and excretion of dabigatran, 
rivaroxaban, and apixaban. 
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Clinical outcomes data comparing NOACs to warfarin 
Dabigatran etexilate is the first oral direct thrombin inhibitors (DTIs) to be approved for 
its clinical use in AF patients (2). In the RE-LY trial (open-label; n = 18,133), 150 mg 
dabigatran twice daily (BID) was associated with lower rates of stroke/SSE, achieving 
superiority, but a similar rate of major bleeding while 110 mg BID was associated with 
similar rates of stroke/SSE but fewer bleeds compared to warfarin (3). Rivaroxaban and 
apixaban are the first and second oral direct factor Xa (FXa) inhibitors approved for AF 
(4). In the ROCKET-AF trial (double-blinded, n = 14,264), rivaroxaban was noninferior 
to warfarin where 20 mg rivaroxaban once daily (OD) resulted in similar rates of 
stroke/SSE and major bleeding (5). In the ARISTOTLE trial (double-blinded; n = 18, 
201), the reduction in stroke/SSE by 5 mg BID apixaban was superior to warfarin (both 
ischemic and haemorrhagic, driven by haemorrhagic) (6). Interestingly, all three NOACs 
were associated with less intracranial bleeding compared to warfarin irrespective of time 
spent in therapeutic range (TTR) in the warfarin arm. However, more gastrointestinal 
(GI) bleeding was observed with dabigatran and rivaroxaban.    
 
Importance of renal function and NOAC clearance  
The extent of renal excretion is an important distinguishing feature of NOACs. Up to 
80% of circulating dabigatran is eliminated renally, whereas only 33% and 25% of 
unchanged rivaroxaban and apixaban is cleared by the kidney (7-9). Following 150 mg 
administration, total dabigatran AUC was increased by 1.5-, 3.1-, and 6.3-fold in 
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individuals with mild, moderate and severe renal impairment, respectively, compared to 
healthy individuals, leading to increased terminal half-life (t1/2β) to 15, 18, and 27 hours 
(10). For rivaroxaban, subjects with mild, moderate, and severe impairment exhibited an 
increase in AUC of 44, 52, and 65 %, respectively (11). The coagulation parameter 
prothrombin time (PT) was affected in a similar fashion. For apixaban, while no changes 
were observed in apixaban anti-FXa activity, overall AUC increased by 16, 29, and 44 % 
in individuals with mild, moderate and severe renal impairment compared to individuals 
with normal renal function (12).  
 
Importance of drug metabolism and transport processes for NOACs 
Dabigatran etexilate is the prodrug of dabigatran, and a substrate of efflux transporter P-
glycogprotein (P-gp, encoded by ABCB1), with an absolute bioavailability of only 6.5% 
(13, 14). Bioavailable dabigatran etexilate is converted entirely to dabigatran by 
nonspecific ubiquitously expressed carboxylesterases in the enterocytes, portal 
circulation, and hepatocytes (7, 13, 15). Very recently, a genome-wide subanalysis of the 
RE-LY trial demonstrated that a single nucleotide polymorphism (SNP) in the 
carboxyesterase 1 gene (CES1; rs2244613) attenuated dabigatran formation leading to 
lower trough concentrations while the ABCB1 SNP rs4148738 and CES1 SNP rs8192935 
were associated with higher and lower peak dabigatran concentrations, respectively (16). 
Rivaroxaban’s bioavailability is dose-dependent; the absolute bioavailability of 10 mg 
rivaroxaban ranged from 80 to 100 %, while bioavailability of 20 mg under fasting 
conditions was 66% (17). Coadministration of 15 or 20 mg rivaroxaban with food 
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increased the AUC by 39% (18). The low bioavailability in fasting conditions may result 
in risk of inadequate anticoagulation and thus, rivaroxaban should be administered with 
food. Apixaban’s absolute bioavailability is 50% and not affected by food intake (9).  
 
Dabigatran is not metabolized by the cytochrome P450 (CYP) isoenzymes; rather, it is 
conjugated to acylglucuronides (19). In patients with moderate hepatic impairment, the 
bioconversion from prodrug to dabigatran was slightly slower when compared to healthy 
subjects although the AUC and extent of dabigatran glucuronidation was unchanged (20). 
Conversely, rivaroxaban and apixaban are both subject to CYP-mediated metabolism 
whereby CYP3A4/5 and CYP2J2 accounts for clearance of two-thirds of rivaroxaban (8, 
21), and apixaban metabolism is predominantly driven by CYP3A4/5 (22). Patients with 
mild (Child-Pugh A) hepatic impairment showed no difference in rivaroxaban PK and PD 
(23). However, patients with moderate (Child-Pugh B) hepatic impairment exhibited 
reduced clearance of rivaroxaban. Therefore, rivaroxaban is not recommended in patients 
with moderate or severe (Child-Pugh C) hepatic impairment. The PK and anti-Fxa 
activity of 5 mg apixaban was not altered in subjects with either mild or moderate liver 
impairment when compared to healthy individuals (12).  
 
Both rivaroxaban and apixaban are substrates of efflux transporters P-gp and breast 
cancer resistance protein (BCRP, encoded by ABCG2); thus, active secretion likely 
contributes significantly to their renal elimination and systemic exposure (24-26). 
 
256 
 
 
 
NOAC drug-drug Interactions result from inhibitors or inducers of 
CYP3A4 and P-glycoprotein  
CYP3A4 located in the intestine and liver plays a pivotal role in governing metabolic 
pathways of 50% of all drugs (27). Similarly, many drugs are P-gp substrates, one of the 
most important efflux transporters in modulating drug disposition by preventing 
absorption and enhancing excretion into the bile and urine (28). Interestingly, there is a 
high degree of overlap in CYP3A4 and P-gp drug substrates (29), as the case for 
rivaroxaban and apixaban. In addition, the coexpression of these proteins in the gut, liver, 
and kidney means that CYP3A4 and P-gp play a concerted role in modulating excretion 
of NOACs.  
 
When dabigatran was coadministered with amiodarone or ketoconazole (P-gp and strong 
CYP3A4 inhibitor), AUC was increased by about 50% (30). Similarly, the potent P-gp 
inhibitor verapamil increased AUC by 2.4-fold when administered 1 hour before 
dabigatran while AUC increased by 71% when coadministered (31). Interestingly, 
patients of the RE-LY trial coadministered with amiodarone and verapamil only had a 
13% and 23% increased bioavailability, respectively (3). Coadministration of 
ketoconazole with rivaroxaban increased the AUC by 160% along with similar increases 
in coagulation measurements (26). The strong P-gp/CYP3A4 inhibitor ritonavir elevated 
rivaroxaban AUC by 150%. Coadministration of ketoconazole increased apixaban AUC 
by twofold (32). Overall, coadministration of rivaroxaban and apixaban with P-
gp/CYP3A4 inhibitors (namely azoles and protease inhibitors) should be avoided while 
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coadministration with moderate inhibitors (ie., erythromycin) should be exercised with 
caution (Table C.2).  
 
Inducers of CYP3A4/P-gp such as rifampin has been show to result in 65% reduction in 
dabigatran bioavailbility and 50% decrease in AUC and clotting parameters for 
rivaroxabin and apixaban (26, 32, 33). Thus, concomitant use of rivaroxaban/apxiaban 
with strong CYP3A4/P-gp inducers is contraindicated due to concern of reduced 
anticoagulation efficacy. 
 
We note that the clinical significance of concomitant use of multiple moderate inhibitors 
in the same patient, a particular concern in elderly AF patients where polypharmacy is 
common, remains to be established as it is unknown whether the effect on NOAC PK-PD 
would be equivalent to use of a single potent inhibitor. The full spectrum of these 
interactions remains to be addressed in the real-world population. Until then, dose 
lowering adjustments in conjunction with anticoagulation monitoring should be used to 
ensure efficacy and safety.   
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Table C.2 List of dual substrates, inhibitors, and inducers of CYP3A4 and P-
glycoprotein. 
Substrates Inhibitors Inducers 
Apixaban Amiodarone Carbamazepine 
Atorvastatin Cimetidine Phenobarbital 
Celiprolol Clarithromycin Rifampicin 
Cyclosporine Erythromycin St. John's wort 
Docetaxel Fluconazole  
Paclitaxel Ketoconazole  
Rivaroxaban Itraconazole  
Tacrolimus Nifedipine  
 Nelfinavir  
 Ritonavir  
 Saquinavir  
 Verapamil  
 Voriconazole  
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Why understanding the pharmacokinetic profile of NOACs is essential 
for predicting anticoagulation efficacy 
The predictable PK/PD of NOACs does not necessitate routine monitoring; however, the 
ability to accurately measure their efficacy is highly desirable in a variety of scenarios 
including assessment of compliance, and identifying patients at risk for over-
anticoagulation/bleeding or lack of efficacy. Although standardized coagulation assays 
are unavailable, several assays have been evaluated to determine their validity as a 
surrogate marker of NOAC plasma exposure and anticoagulation response. Generally, a 
parallel relationship exists between NOACs plasma exposure and anticoagulation effects 
in a concentration-dependent manner (13, 17, 34-37).  
 
The anticoagulant effect of dabigatran can be measured by activated partial 
thromboplastin time (aPTT), PT, thrombin time (TT), ecarin clotting time (ECT), and the 
diluted version of TT (Hemoclot). The TT, Hemoclot and ECT are most sensitive and 
precise for measuring dabigatran anticoagulation. However, TT is likely too sensitive for 
dabigatran efficacy and Hemoclot is currently considered more suitable to quantitate 
dabigatran concentrations (38). Unfortunately, these assays are not widely available and 
in emergency situations, aPTT may be most accessible for measuring anticoagulation. 
The clinical relevance of plasma concentrations was demonstrated in the RE-LY trial 
where dabigatran trough plasma concentrations were significantly associated with risk of 
stroke/SSE (30). Patients with lower trough plasma levels had substantially greater 
probability of ischemic stroke/SSE (<50 ng/mL) (39). Similarly, strong association was 
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found between increased dabigatran trough concentrations and bleeding risk. The mean 
dabigatran exposure in patients with major or minor bleeding was 50% and 20% greater 
than patients without. Bleeding risk was also dependent on age and renal impairment 
owing to modulation of dabigatran PK.  
 
For rivaroxaban and apxiaban, the anti-FXa activity assay is a direct measure of 
anticoagulation intensity, and thus, the most sensitive and consistent assay for 
quantitating plasma concentrations (40, 41). The PT and HepTest also demonstrated 
sensitivity for rivaroxaban response and may be used as a more readily available measure 
of response (17). Apixaban concentrations was correlated with INR, PT, and aPTT with 
less sensitivity (36). A dedicated study of 161 patients embedded into the ROCKET-AF 
trial confirmed the linear relationship between PT and anti-FXa activity to rivaroxaban 
plasma exposure (42). However, PT did not predict the occurrence of ischemic strokes in 
the ROCKET-AF trial (42). Conversely, a linear relationship was demonstrated between 
PT prolongation and risk of major bleeding (42). The linear relationship between 
apixaban plasma concentrations and anti-FXa activity was confirmed in elective hip/knee 
replacement patients (12).  
 
It is important to keep in mind that the sensitivity and precision of different reagents and 
instruments used for these coagulation assays is yet to be established. Further validation 
of these coagulation assays in measuring NOAC anticoagulation response is required in 
the real-world clinical setting. Moreover, is it evident that variability in NOAC plasma 
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exposure will have significant impact on anticoagulation efficacy given the direct PK-PD 
relationship and its association with clinical outcomes; thus, quantifying NOAC plasma 
concentration is likely the most reliable assessment of response and bleeding risk.  
 
Selecting the right OAC  
Although the NOACs have shown similar or greater efficacy to warfarin, it is unlikely 
that they will fully replace warfarin. The interindividual variability in exposure/response 
of NOACs and bleeding risk associated with anticoagulation therapy remains a pertinent 
issue. Indeed, even in a clinical trial setting with stringent enrollment criteria, the one-
dose-fits-all dosing regimen strategy did not appear successful for NOACs, likely due to 
the various clinical covariates that significantly affected extent of drug exposure and 
response (Figure C.2) (41, 43-46). Moreover, dabigatran and rivaroxaban use outside of 
the clinical trial setting has recently been noted to exhibit large interindividual variability 
in concentration and response (43, 47). The same trend is likely to be observed with 
apixaban as its clinical use increases.  
 
Nevertheless, the emergence of multiple NOACs has meant greater therapeutic options 
for treating physicians. However, we are now starting to face the question of how to 
select the most appropriate NOAC for individual patients. Factors to be assessed for 
deciding the right anticoagulant include patient bleeding risk (HAS-BLED) and benefit 
(CHADS2) as recommended by the Canadian Cardiovascular Society (48), lack of an 
antidote for NOACs, GI bleeding, renal/hepatic function, age, and concomitant 
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medications, relevant genetic variations, of which all have been demonstrated to 
influence the PK and PD of OACs. 
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Figure C.2 Plasma concentration profiles of dabigatran, rivaroxaban, and apixaban in 
atrial fibrillation patients. (A) Mean steady-state dabigatran plasma concentrations 
following 150 mg twice-daily administration is represented by the dashed black line 
(digitized from Dansirikul et al.) (49). Colored solid lines represent the predicted effect 
of various clinical variables and a genetic variation in the carboxylesterase 1 (CES1) gene 
on dabigatran concentration based on known area under the concentration curve (AUC) 
change (45). The shaded area represents Ctrough dabigatran concentrations associated with 
increased antithrombotic efficacy and decreased major bleeding risk according to 
population pharmacokinetics modeling of the RE-LY trial data. (B) Mean steady-state 
rivaroxaban plasma concentrations following 20 mg once daily administration is 
represented by the dashed black line (digitized from Mueck et al.) (44). Colored solid 
lines represent the predicted effect of various clinical variables on rivaroxaban 
concentration based on known AUC change (44). Although the optimal plasma Ctrough of 
rivaroxaban has not been well-defined as of yet, the shaded area represents the 5% - 95% 
confidence interval (CI) of Ctrough observed in the ROCKET-AF trial and the dashed line 
represents the average Ctrough. (C) Predicted mean steady-state apixaban plasma 
concentrations following 5 mg twice-daily administration is represented by the dashed 
black line (digitized from Leil et al.) (46). Colored solid lines represent the predicted 
effect of various clinical variables on apixaban concentration based on known AUC 
change (12). The shaded area represents the population pharmacokinetics model 
predicted 5% - 95% CI of Ctrough in atrial fibrillation patients. AF, atrial fibrillation; CrCl, 
creatinine clearance; P-gp, P-glycoprotein.  
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Figure C.2 Plasma concentration profiles of dabigatran, rivaroxaban, and apixaban 
in atrial fibrillation patients. 
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A potential decision tree for selecting the right oral anticoagulant based on individual 
patient characteristics (summarized in Figure C.3): The first question to address is 
whether the patient is a better candidate for NOAC or warfarin. For patients requiring 
new OAC therapy , the factors to consider in this regard include high cost of NOACs 
(dependent on patient insurance policy), convenient and accessibility of INR response 
monitoring, renal function, and potential drug-drug interactions (Table C.3). Patients who 
are already stably anticoagulated on warfarin achieving optimal TTR need not to be 
switched, given the familiarity of its use and ability to monitor anticoagulation efficacy. 
Indeed, the benefits of NOACs over warfarin are less impressive for patients achieving 
well-controlled TTR (> 65%) as evident in the finding that 150 mg BID dabigatran was 
no longer superior to warfarin for prevention with stroke (50). However, we note that no 
significant interaction was found between TTR and stroke/SSE rates in sub-analysis of 
the RE-LY, ROCKET-AF, and ARISTOTLE trial.  
 
In suspected noncompliant patients, warfarin will likely be the better choice because 
missed doses of NOACs with short half-lives will be more detrimental to efficacy than 
missed doses of warfarin. Moreover, adherence to drug therapy decreases by 10% when 
comparing OD to BID dosing, leading to unknowable consequences, especially without 
active monitoring of efficacy. Of the NOACs, rivaroxaban is the only one with OD 
dosing, preferred for suspected noncompliant patients. We note however, based on the 
t1/2β of rivaroxaban (Figure C.2), when strictly considering optimal dosing interval, 
splitting the total daily dose to BID dosing interval would be predicted to result in a more 
consistent exposure and response.  
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Since NOACs are dependent on renal excretion at varying extents, estimated CrCl 
(creatinine clearance) should be determined in all patients prior to initiating NOACs. 
Moreover, risk of bleeding associated with use of the new agents is compounded by poor 
renal function; more than 50% of AF patients over the age of 80 have moderate renal 
impairment (51). Although dosing adjustments in renal insufficiency has been 
recommended, a recent report indicated that the dose reduction did not obviate elevated 
bleeding risk completely (52). Thus, patients with CrCl below 30 mL/min are not suitable 
for NOACs; however, if NOAC in patients with renal impairment is preferred, apixaban 
is more appropriate than rivaroxaban and dabigatran, otherwise, warfarin should be used. 
Elderly patients and those with renal impairment should be assessed regularly for renal 
function throughout treatment to ensure that CrCl remains greater than 30 mL/min. 
 
Elevated GI bleeding risk is an important concern for dabigatran and rivaroxaban, and 
apixaban is a better choice in patients with a recent and/or recurrent history of GI bleed as 
well as patients with disease condition(s) predisposing higher risk of GI bleed (active 
peptic ulcer disease, recent biopsy or trauma, gastritis). However, in the case that the site 
of GI bleed is identified and the underlying condition adequately treated without 
suspected recurrence, any OAC may be considered for therapy if the patient is otherwise 
deemed suitable. Dose reduction is required for patients > 75 years old on dabigatran due 
to increased bleeding risk with age. The stability of dabigatran may be compromised 
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when stored in humid conditions, and once the bottle is opened the tablets should be used 
within 4 months. Patient education in this regard may be important.  
 
Since all NOACs depend on the liver for hepatic metabolism to some degree, patients 
with hepatic dysfunction are not candidates for NOACs. Moreover, both rivaoxaban and 
apixaban are substrates of CYP3A4, rendering these NOACs susceptible to drug-drug 
interactions whereby dose reduction is required in presence of strong inhibitors. Lastly, 
for AF patients with recent acute coronary syndrome or percutaneous coronary 
intervention requiring triple therapy with antiplatelets and OAC (warfarin or NOACs), 
caution is warranted as the benefit in terms of decreased stroke and myocardial infarction 
risk with triple therapy may be offset by the near two-fold increase in bleeding risk (53). 
Warfarin may be the better choice for these patients owing to the ability to conduct 
routine INR monitoring as well as tailoring dose to a lower anticoagulant intensity (lower 
INR target) to reduce bleeding risk.      
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Figure C.3 Guide for choosing an oral anticoagulation based on influence of patient 
characteristics on drug pharmacokinetics. API, apixaban; DAB, dabigatran; RIV, 
rivaroxaban. BID, twice daily dosing, OD, once daily dosing. CrCl, creatinine clearance; 
ERSD, end-stage renal disease; DDI, drug-drug interaction; GI, gastrointestinal; mod, 
moderate; NOAC, new oral anticoagulant. Renal function classification based on 
estimated CrCl is in accordance with the product monographs for dabigatran, 
rivaroxaban, and apixaban.(12, 54, 55) †Moderate renal impairment is defined as CrCl 30 
– 50 mL/min for dabigatran and apixaban, while moderate renal impairment is defined as 
CrCl 30 – 49 mL/min for rivaroxaban. *History of GI bleed refers to recent and/or 
recurrent GI bleeding events. Disease condition(s) predisposing higher risk of GI bleed 
include but not exclusive to active peptic ulcer disease, ulcerative gastrointestinal disease, 
recent biopsy or trauma, and gastritis.  
Disclaimer: The information presented herein represents the opinion of the authors based 
on currently available data and should not serve as substitute for clinical judgment.  
  
269 
 
 
 
 
Figure C.3 Guide for choosing an oral anticoagulation based on influence of patient 
characteristics on drug pharmacokinetics. 
A 
B 
C 
Selection of warfarin vs new oral anticoagulant (NOAC) for AF patients 
Selection of appropriate NOAC for AF patients 
Selection of appropriate NOAC continued 
history or higher  
risk of GI bleed*  
Yes No 
5 mg  
BID API 
age > 80 
weight ≤ 60 kg 
2.5 mg 
BID API 
mod hepatic 
impairment or 
CYP3A4 DDI  
Poor liver 
function 
warfarin Yes No 
150 mg  
BID DAB 
age > 75 
110 mg 
BID DAB 
20 mg 
OD RIV 
5 mg  
BID API 
poor 
compliance 
20 mg 
OD RIV 
2.5 mg 
BID API 
age>80 
weight≤60 kg 
already on 
warfarin? 
No Yes 
poor 
compliance? 
well 
managed? 
Yes No warfarin 
warfarin NOACs 
Initial Factors to be Considered 
• Cost of OAC/Insurance policy 
• Access to INR monitoring 
• Patient preference 
* refer to Table 3 for detailed criteria 
NOACs warfarin or 
NOACs 
renal 
impairment 
Mild 
(CrCl 51 – 80 mL/min) 
Moderate 
(CrCl 30 – 50 mL/min†) 
Severe 
(CrCl 15 – 29 mL/min) 
ESRD 
(CrCl < 15 mL/min) 
warfarin warfarin 
2.5 mg 
BID API 
Poor liver function  
or CYP3A4 DDI  
warfarin 
150 mg 
BID DAB 
20 mg 
OD RIV 
5 mg  
BID API 
110 mg 
BID DAB 
15 mg 
OD RIV 
5 mg  
BID API 
15 mg 
OD RIV 
2.5 mg 
BID API 
age>75 
110 mg 
BID DAB 
age>80 
weight≤60 kg 
2.5 mg 
BID API 
age>80 
weight≤60 kg 
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Table C.3 Summary of patient criteria for selecting warfarin vs new oral 
anticoagulants (NOACs). 
Select warfarin Select NOACs 
stable and well controlled INR previously on warfarin with poor INR 
control 
CrCl < 30 mL/min normal renal function or mild renal 
dysfunction 
low cost to patient/lack of insurance 
coverage 
high cost of drug affordable  
good compliance inadequate access to routine INR 
monitoring 
history of gastrointestinal bleeding require rapid onset of action 
require rapid reversal (antidote) harboring multiple variant alleles in 
CYP2C9 and VKORC1 known to confer 
warfarin sensitivity * 
concomitant use of P-gp/CYP3A4 
inhibitor or inducer 
patient preference 
CrCl, creatinine clearance; CYP, cytochrome P450; INR, international normalized ratio; 
P-gp, P-glycoprotein; VKORC1, vitamin K epoxide reductase enzyme subunit 1. 
* particularly CYP2C9 poor metabolizer genotype combined with VKORC1 sensitive 
genotype. 
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Dosing adjustments   
Dosing adjustments are summarized in Figure C.3 and Table C.4. As noted earlier, 
kidney is the predominant pathway of excretion for dabigatran while to a lesser extent for 
rivaroxaban and apixaban. Renal function is an important variable that must be 
considered carefully in AF patients, particularly because age-related decline in renal 
function and variation introduced by comorbidities has been well-characterized. The 
impact of renal function and demographics has been evaluated in RE-LY AF patients. 
The median CrCl of the trial was 69 mL/min; patients with CrCl of 30 and 50 mL/min 
had a 1.8- and 1.2- fold increase in dabigatran AUC, respectively (45). Not surprisingly, 
age reduced apparent clearance (CL/F) by 0.41% per year from median age of 72. Based 
on these data, age and renal function warrants dose adjustment. The standard dabigatran 
dose for AF patients with normal renal function is 150 mg BID while approved doses for 
patients with CrCl < 30 mL/min differs between countries. In the United States, a dose of 
75 mg is approved for patients with CrCl 15 - 29 mL/min. However, these 
recommendations were approved on the basis of PK modeling studies and clinical data 
supporting this is lacking, limiting the creditability of its use in real-world patients (45).  
In other countries including Canada, dabigatran use is contraindicated in patients with 
CrCl < 30 mL/min. For patients over 75 years old at increased bleeding risk, previous 
history of GI/intracerebral bleeding, or receiving concomitant antiplatelet or P-gp potent 
inhibitor, 110 mg BID should be used (a dose not available in the United States).  
 
The typical rivaroxaban dose for most AF patients is 20 mg OD. Based on PK modeling, 
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15 mg OD of rivaroxaban in individuals with moderate or severe renal impairment would 
have similar plasma levels as individuals with normal renal function taking 20 mg (42, 
44). In the ROCKET-AF trial, safety and efficacy of this dosing regimen in patients with 
moderate renal impairment was demonstrated in the comparable stroke and bleeding rates 
irrespective of renal impairment (56). Similar to dabigatran, approved doses of 
rivaroxaban is country-specific. In United States, 20 mg rivaroxaban is approved for 
patients with CrCl > 50 mL/min while 15 mg is approved for patients with CrCl 15 – 49 
mL/min. In all other countries, 15 mg is approved only for those with CrCl 30 – 49 
mL/min and contraindicated in those with severe impairment. Unlike dabigatran, patient 
age doesn’t appear to elevate bleeding risk and no dosing adjustments is suggested.  
Lower dose of 15 mg should be used with coadministration of a strong CYP3A4/P-gp 
inhibitor or multiple moderate inhibitors.  
 
The dose of apixaban to be administered to the average patient is 5 mg BID. In patients 
with mild or moderate renal impairment, no dose adjustment is necessary. Patients with 
severe renal impairment (CrCl 15 - 29 mL/min) require 2.5 mg BID and use in patients 
with CrCl < 15 mL/min is contraindicated. While no dose adjustment is required in 
patients with mild or moderate hepatic impairment, apixaban use should be used with 
caution in such patients. Individuals with body weight < 50 Kg had 30% greater exposure 
than individuals weighing 65 to 85 kg, whom had 30% lower exposure compared to 
individuals weighing > 120 kg (12). Elderly patients above 65 years-of-age exhibited 
32% greater AUC than younger patients (12). Accordingly, dose reduction to 2.5 mg BID 
is warranted for patients concomitantly taking CYP3A4/P-gp inhibitors or meeting at 
273 
 
 
 
least two of the following criteria: > 80 years old, body weight ≤ 60 kg, and creatinine > 
133 µmol/L.  
 
Ethnic differences in dosing requirement have only been found for rivaroxaban. The J-
ROCKET trial was conducted to evaluate rivaroxaban use in Japanese patients (57). This 
was due to the observation that healthy Japanese subjects had a 20-40% increase in 
rivaroxaban exposure compared to Caucasian subjects (57). Thus, 15 mg rivaroxaban in 
J-ROCKET patients resulted in similar efficacy and exposures as that observed in non-
Japanese patients. Similar reductions in rivaroxaban dose should be considered for 
patients of Asian ancestry, and not limited to those of Japanese ancestry.  
 
Notably, we are starting to realize the role of genetic variation to interindividual 
variability of NOAC exposure and clinical outcomes. The CES1 rs2244613 SNP was not 
only associated with lower dabigatran exposure but also with reduced bleeding risk, 
indicating the potential for pharmacogenetics-based dosing adjustments using this 
intronic SNP (16). As clinically relevant polymorphisms also exist in CYP3A4/5, P-gp, 
and BCRP, these genetic variations may also play an important role in determining 
NOAC exposure. Overall, the full spectrum of NOAC efficacy and safety within the 
context of pharmacogenetics, demographics, concomitant medications, and comorbidities 
should be characterized as the use of these new agents increase in AF patients outside of 
the clinical trial setting.  
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Table C.4 Dosing adjustments based on pharmacokinetic considerations. 
  Dabigatran  
(mg BID) 
Rivaroxaban 
(mg OD)  
Apixaban  
(mg BID) 
Renal impairment 
 Mild (CrCl 51 – 80 mL/min) 150 20 5 
 Moderate (CrCl 30 – 50 
mL/min)  
110 15 5 
 Severe (CrCl < 30 mL/min) n.r. 15 2.5 
Hepatic impairment 
 Mild (Child-Pugh A) 150 20 5 
 Moderate (Child-Pugh B) 150 n.r. 5 
 Severe (Child-Pugh C) n.r. n.r. n.r. 
 Hepatic dysfunction n.r. n.r. n.r. 
Demographic variables 
 Ethnicity, Asian 150 15 5 
 Age, > 75 - 80 yr 110 20 2.5 
 Weight, < 50 kg 150 20 2.5 
Drug-drug interactions 
 P-gp inhibitor 110 15 2.5 
 CYP3A4 inhibitor 150 15 2.5 
 P-gp/CYP3A4 inducer  n.r. * n.r. n.r. 
n.r., not recommended. CYP, cytochrome P450; P-gp, P-glycoprotein.  
* CYP3A4 and P-gp are both transcriptionally regulated by xenobiotic sensing nuclear 
receptors such as Pregnane X Receptor (PXR) and Constitutive Androstane Receptor 
(CAR) (58). Therefore, inducers listed in Table C.2 would lower the plasma level of all 
the NOACs outlined in this review. 
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Limitations of NOACs 
A major limitation of NOAC use is the lack of standardized coagulation tests for 
monitoring anticoagulation response. The need for monitoring has been heavily debated 
and regulators recently stated that monitoring is necessary in specific clinical 
circumstances: renal/liver dysfunction, overdose, prior to invasive surgery, non-
compliance, bleeding or thrombosis/stroke, drug-drug interaction and suspected variation 
in drug exposure (59). Although some assays have been suggested as surrogate markers 
of exposure, limitations in their use include accuracy and clinical experience/availability. 
More importantly, meaningful interpretation of the results is difficult owing to lack of 
guidance on extrapolating coagulation results to bleeding and thrombosis risk. 
Accordingly, directly measuring plasma NOAC drug concentrations may be more 
desirable and more accurate for monitoring anticoagulation. An important consideration 
for measuring either coagulation or NOAC drug exposure is the standardization of 
sampling time from the last dose. The Ctrough level is preferred over the Cmax, avoiding 
misinterpretation of results due to variability in absorption phase.   
 
The second limitation is the lack of a validated antidote for rapidly reversing NOACs’ 
effects. Hemodialysis of dabigatran may be an option given its relatively low protein 
binding, but not for rivaroxaban and apixaban which have high protein binding. Potential 
reversal agents that have shown promise for reversing NOAC anticoagulation include 
prothrombin complex concentrate and recombinant factor VIIa (60, 61). Until better 
guidelines are available, NOACs should be used with caution, particularly in patients 
with elevated bleeding risk.  
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Switching from warfarin to NOAC and vice versa 
Patients without adequate INR control will likely benefit from transitioning from 
warfarin to one of the NOACs for enhanced efficacy and reduced risk of intracranial 
bleeding. It has been recommended that NOAC should be started after INR decreases to 
< 2.3 following warfarin discontinuation (62). For patients unable to continue NOAC 
therapy and require transitioning to warfarin, it is necessary to consider the delayed onset 
of warfarin and allow attainment of therapeutic INR prior to discontinuation of NOAC.  
 
Conclusions 
NOACs are promising alternatives to warfarin, demonstrating at least similar 
antithrombotic efficacy and decreased rate of intracranial hemorrhage. However, the 
availability of multiple NOACs has introduced difficulty in deciding the best agent since 
head-to-head trials are unavailable and unlikely to be performed. Rather, clinicians are 
required to make informed decisions in selecting the appropriate agent based on 
characteristics of the patient and OAC pharmacology. As the clinical use of NOACs 
increases, surveillance using therapeutic monitoring (measurement of plasma drug 
concentration or anticoagulation response) throughout the treatment period may be 
valuable in minimizing risk of bleeding and lack of efficacy. Finally, due to the extent of 
interindividual variation in the metabolism and clearance of NOACs, it is likely a greater 
range of NOAC doses will be needed to more precisely treat our patients. 
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Western Ontario 
Presentation Award 
2010 
International Society for the Study of Xenobiotics 
Presentation Award 
2009 
Schulich Margaret Moffat Research Day, The University of Western Ontario 
Presentation Award 
2009 
J. Allyn Taylor Prize in Medicine Symposium, The University of Western Ontario 
Presentation Award 
2009 
21st Charles W. Gowdey Lecture, The University of Western Ontario 
Presentation Award 
2009 
 
Extra-curricular Activities: Related Work Experience 
 
Research Intern, Department of Clinical Pharmacology 
Genentech Inc, South San Francisco, California 
Analysis and mathematical modeling of data collected from human trials for proprietary 
drugs, analysis of drug-drug interaction potential of proprietary compounds in 
preparation for submission to the FDA, conducted a department seminar, attendance of 
weekly seminars, interaction and exchange of ideas with world-renowned scientists, 
drafting of a manuscript. 
Sept-Dec 2011 
 
Systematic Review Data Extractor, Department of Epidemiology and Biostatistics 
McMaster University, Hamilton, Ontario  
Reviewed literature in PubMed, screening of appropriate articles for a systematic review. 
2011 
 
Extra-curricular Activities: Teaching Experience 
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Teaching Assistant, Department of Physiology and Pharmacology    
Pharmacology 2060: Introduction to Pharmacology and Therapeutics 
Organized and delivered brief lectures covering basic areas of pharmacology and 
therapeutics, proctoring exams, addressing questions raised by students on the discussion 
board.    
2008-2012 
 
Teaching Assistant, Department of Physiology and Pharmacology    
Pharmacology 4350: Clinical Pharmacology 
Organized student presentations, held office hours, marking exams, proctoring exams, 
addressing questions raised by students on the discussion board.   
2012-2013 
 
Undergraduate Thesis Project Supervisor, Division of Clinical Pharmacology    
  
Responsible for teaching experimental design and techniques, critical thinking, and 
written and oral communication skills to a 4th year Honours student.    
2010-2011 
 
International Collaborations 
 
Vanderbilt University 
Collaborated with Dan Roden, MD, and C Michael Stein, MD, at Vanderbilt University 
Medical Centre (Tennessee), to interpret and analyze data from their database of atrial 
fibrillation and venous thromboembolism patients prescribed with warfarin.  
 
Genentech Inc 
Collaborated with Edna Choo, PhD, at Genentech Inc. to design and analyze data 
obtained from pharmacological efficacy studies of endoxifen in preclinical animal 
models. Subsequently, the collaboration extended to translating the preclinical data to 
that observed in the patient clinical setting to predict efficacy.   
 
National Collaborations 
 
Ottawa Hospital Research Institute  
Collaborated with Philip Wells, MD, at the Thrombosis Clinic to initiate patients with 
new diagnosis of deep vein thrombosis or pulmonary embolism using warfarin based on 
individual genetic make-up.  
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Publications 
 
Published 
 
Reviews 
 
Gong IY, Kim RB. (2013) Importance of pharmacokinetic profile and variability as 
determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Canadian 
Journal of Cardiology, Jul;29(7 Suppl):S24-33. 
 
Gong IY, Kim RB. (2013) Pharmacogenetic advances in cardiovascular medicine: 
Relevance to personalized medicine. Current Genetic Medicine Reports, in press. 
 
Gong IY, Kim RB. (2012) Impact of genetic variation in OATP transporters to drug 
disposition and response. Drug Metab Pharmacokinet, E-pub Oct 9, 2012. 
 
Original Articles 
 
Gong IY, Teft WA, Ly J, Chen Y, Alicke B, Kim RB, Choo EF. (2013) Determination of 
clinically therapeutic endoxifen concentrations efficacy from human MCF7 breast cancer 
xenografts. Breast Cancer Res Treat, doi10.1007/s10549-013-2530-1. 
 
Gong IY, Mansell SE, Kim RB. (2013) Absence of both MDR1 (ABCB1) and BCRP 
(ABCG2) transporters significantly alter rivaroxaban disposition and CNS entry. Basic 
Clin Pharmacol Toxicol, 112(3):164-70. 
 
Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, 
DeGorter MK, Woolsey S, Tirona RG, Kim RB. (2012) Clarifying the importance of 
CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo 
antiplatelet response. Eur Heart J, 33(22):2856-2464a. 
 
Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Wells PS, Kim RB, 
Tirona RG. (2011) Clinical and genetic determinants of warfarin pharmacokinetics and 
pharmacodynamics during treatment initiation. PloS One, 6(11): e27808. 
 
Gong IY, Tirona RG, Schwarz UI, Crown N, LaRue S, Langlois N, Dresser GK, Lazo-
Langner A, Zou GY, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB. (2011) 
Pharmacogenetics-guided warfarin loading and maintenance dosing regimen eliminates 
VKORC1 and CYP2C9 associated variation in anticoagulation response. Blood, 
118(11):3163-71. 
 
Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, 
Perera FE, Choi Y, Zou G, Legan RM, Tirona RG, Kim RB. (2013) CYP3A4 and 
seasonal variation in vitamin D status contribute to therapeutic endoxifen level during 
tamoxifen therapy. Breast Cancer Res Treat, doi10.1007/s10549-013-2511-4. 
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Clark J, Cutler M, Gong IY, Schwarz UI, Freeman D, Dasgupta M. (2011) Cytochrome 
P450 2D6 phenotyping in an elderly demented population and response to galantamine in 
dementia. Am J Geriatr Psychiatry, Aug;9(4):224-33. 
 
Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross C, Sistonen J, 
Carleton BC, Hayden MR, Lauwers AE, Koren G. (2010) Fetal hydrocodone overdose in 
a child: pharmacogenetics and drug interactions. Pediatrics, Oct;126(4):e986-9. 
 
Publications, in preparation for submission 
 
Jin JY, Gong IY, Chen Y, Salphati L, Budha N, West DA, Mukadam S, Holden S, 
Dresser MJ, Ware JA. Prediction of CYP3A4 mediated drug-drug interaction potential 
between PI3K inhibitor GDC-0941 and ketoconazole through physiologically based 
pharmacokinetics modeling using Simcyp.  
 
Richardson B, Gong IY, Tirona RG, Huang SS, Ledingham D. Case Report: Dabigatran 
toxicity and clearance with hemodialysis.  
 
Published Abstracts 
 
Involvement of efflux transporters MDR1 (ABCB1) and BCRP (ABCG2) in rivaroxaban 
disposition. (2012) Gong IY, Mansell SE, Kim RB. Drug Metab Rev.  
 
Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel 
bioactivation and in vivo antiplatelet response. (2012) Gong IY, Crown N, Suen CM, 
Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona 
RG, Kim RB. Journal of Population Therapeutics and Clinical Pharmacology. 
 
Regulation of Cytochrome P450 3A4 in Non-Alcoholic Fatty Liver Disease by Fibroblast 
Growth Factor 21. (2012) Woolsey SJ, Gong IY, Stein S, Kim RB, Levstik M, Beaton 
MD, Tirona RG. Hepatology. 
 
Pharmacokinetic-Pharmacodynamic Modeling Reveals Novel Determinants of Warfarin 
Response During Initiation of Therapy. (2011) Gong IY, Schwarz UI, Tirona RG, Crown 
N, Dresser GK, Roden DM, Stein CM, Lazo-Langner A, Zou GY, LaRue S, Langlose N, 
Wells P, Kim RB. Clin Pharmacol Thera.  
 
Molecular Determinants of Warfarin Pharmacokinetics and Pharmacological Response. 
(2010) Gong IY, Schwarz UI, Tirona RG, Crown N, Dresser GK, Lazo-Langner A, Zou 
GY, LaRue S, Langlose N, Wells P, Kim RB. Can J Clin Pharmacol.  
 
Pharmacokinetic and pharmacodynamic determinants of warfarin anticoagulation 
response. (2009) Gong IY, Schwarz UI, Tirona RG, Crown N, Dresser GK, Lazo-
Langner A, Zou GY, LaRue S, Langlose N, Wells P, Kim RB. Drug Metab Rev.  
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Warfarin oral anticoagulation therapy: R/S-warfarin and vitamin K levels as determinants 
of maintenance dose. (2009) Gong IY, Schwarz UI, Tirona RG, Kim RB. Can J Clin 
Pharmacol. 
 
Projects in Progress 
 
Antiplatelet therapy: 
Role: Lead; recruit patients already on prescribed with clopidogrel 
Objectives:  
Evaluate the role of genetics in explaining the interpatient variability in pharmacokinetics 
and antiplatelet response to clopidogrel therapy. 
Elucidate the PK-PD relationship of clopidogrel active metabolite to platelet reactivity. 
 
Antiplatelet therapy: (in collaboration with cardiologists) 
Role: Lead; enrollment of patients on clopidogrel and new antiplatelet agent ticagrelor 
Objective:  
Evaluate the interpatient variability in pharmacokinetics of patients on clopidogrel and 
ticagrelor, as well as delineating biomarkers of drug-related side effects.  
Assessment and compare endothelial function in patients treated with clopidogrel and 
ticagrelor.  
 
Immunosuppressant therapy: (in collaboration with nephrologists) 
Role: Lead; enrollment of patients on tacrolimus following organ transplantation 
Objective:  
Assessment of genetic markers of tacrolimus response, pharmacokinetics, and toxicities 
to design a precise protocol for individualized loading and maintenance tacrolimus 
dosing regimen.  
 
 
Invited Oral Presentations 
 
“Genetic and clinical determinants of CYP3A4 activity in patients using 4β-
hydroxycholesterol as an in vivo probe” Gong IY, DeGorter MK, Schwarz UI, Choi YH, 
Yin P, Tirona RG, Kim RB. American Society of Pharmacology and Experimental 
Therapeutics 2013, Boston, Massachusetts, April 2013. 
 
“Pharmacogenetics of oral anticoagulants and antiplatelets: implications on clinical 
practice” Gong IY. Department of Physiology and Pharmacology Seminar Series, the 
University of Western Ontario, London, Ontario, January 2013.  
 
“Learn and confirm: Evaluation of CYP3A4 Mediated Drug-Drug Interaction Potential 
Between PI3K Inhibitor GDC-0941 and Ketoconazole Using Simcyp” Gong IY. 
Department of Clinical Pharmacology Seminar Series, Genentech, South San Francisco, 
California, December 2011.  
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“Role of Efflux Transporters MDR1 and BCRP to Rivaroxaban Disposition” Gong IY, 
Kim RB. Canadian Society of Pharmacology and Therapeutics Meeting 2011, Montreal, 
Quebec, May 2011. 
 
“Warfarin pharmacogenetics and better patient care: the importance of teamwork in 
patient oriented research” Gong IY, Crown N, Dresser GK, Schwarz UI, Tirona RG, Kim 
RB. Medical Grand Rounds, Department of Medicine, London Health Sciences Centre, 
London, Ontario, January - February 2011. 
 
“Molecular Determinants of Warfarin Pharmacokinetics and Pharmacological Response” 
Gong IY, Schwarz UI, Tirona RG, Crown N, LaRue S, Langlois N, Dresser G, Lazo-
Langner A, Zou GY, Wells P, Kim RB. Canadian Society of Pharmacology and 
Therapeutics Meeting 2010, Toronto, Ontario, June 2010. 
 
“Drug disposition and dosing strategies of old and new oral anticoagulants” Gong IY. 
Division of Clinical Pharmacology Grand Rounds, University Hospital, London, Ontario, 
January 2010. 
 
“Liquid chromatography mass spectrometry: Basic Principals and Application to Clinical 
Pharmacology” Gong IY, Urquhart BL. Academic Teaching for Post-Graduate Medical 
Residents, University Hospital, London, Ontario, September 2009. 
 
“Personalized Medicine and Warfarin Initiation: UWO Experience and Preliminary 
Data” Kim RB, Tirona RG, Schwarz UI, Gong IY. Pharmacogenetics Research Network 
Webinar, April 2009. 
 
External Poster Presentations 
 
“CYP3A4*22 single nucleotide polymorphism is an important determinant of endoxifen 
plasma concentration” Gong IY, Teft WA, Dingle B, Potvin K, Younus J, Vandenberg 
TA, Brackstone M, Perera FE, Choi Y, Zou G, Legan RM, Tirona RG, Kim RB. 
American Society of Clinical Pharmacology and Therapeutics Meeting 2013, 
Indianapolis, Indiana, March 2013. 
 
“Role of Efflux Transporters MDR1 and BCRP to Rivaroxaban Disposition” Gong IY, 
Kim RB. 19th International Symposium on Microsomes and Drug Oxidations and 12th 
European International Society for the Study of Xenobiotics Meeting, Noordwijk Aan 
Zee, Netherlands, June 2012.  
 
“CYP2C19, PON1, and the role of PPIs to clopidogrel bioactivation and in vivo 
antiplatelet response” Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer 
MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB. Canadian Society of 
Pharmacology and Therapeutics Meeting 2012, Toronto, Ontario, June 2012. 
 
“Pharmacokinetic-Pharmacodynamic Modeling Reveals Novel Determinants of Warfarin 
Response During Initiation of Therapy” Gong IY, Schwarz UI, Crown N, Dresser GK, 
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Lazo-Langner A, Zou G, Roden DM, Stein CM, Wells PS, Kim RB, Tirona RG. 
American Society of Clinical Pharmacology and Therapeutics Meeting 2011, Dallas, 
Texas, March 2011. 
 
“Molecular determinants of warfarin pharmacokinetics and response” Gong IY, Schwarz 
UI, Tirona RG, Crown N, LaRue S, Langlois N, Dresser G, Lazo-Langner A, Zou GY, 
Wells P, Kim RB. 16th World Congress of Basic and Clinical Pharmacology, 
Copenhagen, Denmark, July 2010. 
 
“Pharmacokinetic and Pharmacodynamic Determinants of Warfarin Anticoagulation 
Response” Gong IY, Schwarz UI, Tirona RG, Crown N, LaRue S, Langlois N, Dresser 
G, Lazo-Langner A, Zou GY, Wells P, Kim RB. 16th Annual Meeting of the International 
Society for the Study of Xenobiotics, Baltimore, Maryland, October 2009. 
 
“Warfarin oral anticoagulation therapy: R/S-warfarin and vitamin K levels as 
determinants of maintenance dose.” Gong IY, Schwarz UI, Tirona RG, Kim RB. 
Canadian Society of Pharmacology and Therapeutics Meeting 2009, Saskatoon, 
Saskatchewan, May 2009. 
 
“Prediction of CYP3A4 mediated drug-drug interaction potential between PI3K inhibitor 
GDC-0941 and ketoconazole through physiologically-based pharmacokinetics modeling” 
Jin JY, Gong IY, Chen Y, Salphati L, Budha N, West DA, Mukadam S, Holden S, Ware 
JA, Dresser MJ. American Society of Clinical Pharmacology and Therapeutics Meeting 
2012, Washington, Maryland, March 2012. 
 
“Regulation of Cytochrome P450 3A4 in Non-Alcoholic Fatty Liver Disease by 
Fibroblast Growth Factor 21” Woolsey SJ, Gong IY, Stein S, Kim RB, Levstik M, 
Beaton MD, Tirona RG. American Association for the Study of Liver Diseases Meeting 
2012, Boston, Massachusetts, November 2012. 
 
 
